Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
The Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway is an evolutionarily conserved mechanism of transmembrane signal transduction that enables cells to communicate with the exterior environment. Various cytokines, interferons, growth factors, and other specific...
Uloženo v:
| Vydáno v: | Signal transduction and targeted therapy Ročník 8; číslo 1; s. 204 - 24 |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
Nature Publishing Group UK
19.05.2023
Nature Publishing Group |
| Témata: | |
| ISSN: | 2059-3635, 2095-9907, 2059-3635 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway is an evolutionarily conserved mechanism of transmembrane signal transduction that enables cells to communicate with the exterior environment. Various cytokines, interferons, growth factors, and other specific molecules activate JAK-STAT signaling to drive a series of physiological and pathological processes, including proliferation, metabolism, immune response, inflammation, and malignancy. Dysregulated JAK-STAT signaling and related genetic mutations are strongly associated with immune activation and cancer progression. Insights into the structures and functions of the JAK-STAT pathway have led to the development and approval of diverse drugs for the clinical treatment of diseases. Currently, drugs have been developed to mainly target the JAK-STAT pathway and are commonly divided into three subtypes: cytokine or receptor antibodies, JAK inhibitors, and STAT inhibitors. And novel agents also continue to be developed and tested in preclinical and clinical studies. The effectiveness and safety of each kind of drug also warrant further scientific trials before put into being clinical applications. Here, we review the current understanding of the fundamental composition and function of the JAK-STAT signaling pathway. We also discuss advancements in the understanding of JAK-STAT–related pathogenic mechanisms; targeted JAK-STAT therapies for various diseases, especially immune disorders, and cancers; newly developed JAK inhibitors; and current challenges and directions in the field. |
|---|---|
| AbstractList | The Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway is an evolutionarily conserved mechanism of transmembrane signal transduction that enables cells to communicate with the exterior environment. Various cytokines, interferons, growth factors, and other specific molecules activate JAK-STAT signaling to drive a series of physiological and pathological processes, including proliferation, metabolism, immune response, inflammation, and malignancy. Dysregulated JAK-STAT signaling and related genetic mutations are strongly associated with immune activation and cancer progression. Insights into the structures and functions of the JAK-STAT pathway have led to the development and approval of diverse drugs for the clinical treatment of diseases. Currently, drugs have been developed to mainly target the JAK-STAT pathway and are commonly divided into three subtypes: cytokine or receptor antibodies, JAK inhibitors, and STAT inhibitors. And novel agents also continue to be developed and tested in preclinical and clinical studies. The effectiveness and safety of each kind of drug also warrant further scientific trials before put into being clinical applications. Here, we review the current understanding of the fundamental composition and function of the JAK-STAT signaling pathway. We also discuss advancements in the understanding of JAK-STAT–related pathogenic mechanisms; targeted JAK-STAT therapies for various diseases, especially immune disorders, and cancers; newly developed JAK inhibitors; and current challenges and directions in the field. The Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway is an evolutionarily conserved mechanism of transmembrane signal transduction that enables cells to communicate with the exterior environment. Various cytokines, interferons, growth factors, and other specific molecules activate JAK-STAT signaling to drive a series of physiological and pathological processes, including proliferation, metabolism, immune response, inflammation, and malignancy. Dysregulated JAK-STAT signaling and related genetic mutations are strongly associated with immune activation and cancer progression. Insights into the structures and functions of the JAK-STAT pathway have led to the development and approval of diverse drugs for the clinical treatment of diseases. Currently, drugs have been developed to mainly target the JAK-STAT pathway and are commonly divided into three subtypes: cytokine or receptor antibodies, JAK inhibitors, and STAT inhibitors. And novel agents also continue to be developed and tested in preclinical and clinical studies. The effectiveness and safety of each kind of drug also warrant further scientific trials before put into being clinical applications. Here, we review the current understanding of the fundamental composition and function of the JAK-STAT signaling pathway. We also discuss advancements in the understanding of JAK-STAT-related pathogenic mechanisms; targeted JAK-STAT therapies for various diseases, especially immune disorders, and cancers; newly developed JAK inhibitors; and current challenges and directions in the field.The Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway is an evolutionarily conserved mechanism of transmembrane signal transduction that enables cells to communicate with the exterior environment. Various cytokines, interferons, growth factors, and other specific molecules activate JAK-STAT signaling to drive a series of physiological and pathological processes, including proliferation, metabolism, immune response, inflammation, and malignancy. Dysregulated JAK-STAT signaling and related genetic mutations are strongly associated with immune activation and cancer progression. Insights into the structures and functions of the JAK-STAT pathway have led to the development and approval of diverse drugs for the clinical treatment of diseases. Currently, drugs have been developed to mainly target the JAK-STAT pathway and are commonly divided into three subtypes: cytokine or receptor antibodies, JAK inhibitors, and STAT inhibitors. And novel agents also continue to be developed and tested in preclinical and clinical studies. The effectiveness and safety of each kind of drug also warrant further scientific trials before put into being clinical applications. Here, we review the current understanding of the fundamental composition and function of the JAK-STAT signaling pathway. We also discuss advancements in the understanding of JAK-STAT-related pathogenic mechanisms; targeted JAK-STAT therapies for various diseases, especially immune disorders, and cancers; newly developed JAK inhibitors; and current challenges and directions in the field. Abstract The Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway is an evolutionarily conserved mechanism of transmembrane signal transduction that enables cells to communicate with the exterior environment. Various cytokines, interferons, growth factors, and other specific molecules activate JAK-STAT signaling to drive a series of physiological and pathological processes, including proliferation, metabolism, immune response, inflammation, and malignancy. Dysregulated JAK-STAT signaling and related genetic mutations are strongly associated with immune activation and cancer progression. Insights into the structures and functions of the JAK-STAT pathway have led to the development and approval of diverse drugs for the clinical treatment of diseases. Currently, drugs have been developed to mainly target the JAK-STAT pathway and are commonly divided into three subtypes: cytokine or receptor antibodies, JAK inhibitors, and STAT inhibitors. And novel agents also continue to be developed and tested in preclinical and clinical studies. The effectiveness and safety of each kind of drug also warrant further scientific trials before put into being clinical applications. Here, we review the current understanding of the fundamental composition and function of the JAK-STAT signaling pathway. We also discuss advancements in the understanding of JAK-STAT–related pathogenic mechanisms; targeted JAK-STAT therapies for various diseases, especially immune disorders, and cancers; newly developed JAK inhibitors; and current challenges and directions in the field. |
| ArticleNumber | 204 |
| Author | Shi, Qingmiao Yuan, Xin Chu, Qingfei Xue, Chen Yao, Qinfan Lu, Juan Gu, Xinyu Bao, Zhengyi Li, Lanjuan |
| Author_xml | – sequence: 1 givenname: Chen surname: Xue fullname: Xue, Chen organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 2 givenname: Qinfan surname: Yao fullname: Yao, Qinfan organization: Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou – sequence: 3 givenname: Xinyu surname: Gu fullname: Gu, Xinyu organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 4 givenname: Qingmiao surname: Shi fullname: Shi, Qingmiao organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 5 givenname: Xin surname: Yuan fullname: Yuan, Xin organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 6 givenname: Qingfei surname: Chu fullname: Chu, Qingfei organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 7 givenname: Zhengyi surname: Bao fullname: Bao, Zhengyi organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 8 givenname: Juan surname: Lu fullname: Lu, Juan email: lujuanzju@zju.edu.cn organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 9 givenname: Lanjuan surname: Li fullname: Li, Lanjuan email: ljli@zju.edu.cn organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37208335$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kstu1DAYhSNUREvpC7BAkdh0E_DdDhs0qgoUKrFgurYcXzIeZezBTgb17fFMWmi76MKyZZ_z6cj_eV0dhRhsVb2F4AMEWHzMBOIWNQDhBkDCRMNfVCcI0LbBDNOjB-fj6iznNQAAMsw5Ja-qY8wREBjTk-rmcheHnQ99rWMf_OhjqKOrx5Wtvy9-NL-Wi2WdfR_UsNds1bj6o24_1Woao99spmBr43NMxqZcq2BqrYK26U310qkh27O7_bS6-XK5vPjWXP_8enWxuG40A3xsaKuh0IAyaxXhnSaKgJYRQ4wgUDHDHTbWWEIABZaDlkCkHbG0LGCIg_i0upq5Jqq13Ca_UelWRuXl4SKmXqo0ej1YaRiDqjBdRxVxBnSuNVxgTpzoOg50YX2eWdup21ijbRiTGh5BH78Ev5J93EkIYMsw4oVwfkdI8fdk8yg3Pms7DCrYOGWJBGScIXKQvn8iXccplV8-qKhgCBBcVO8eRvqX5X58RSBmgU4x52Sd1H5U-yGWhH4o0eS-LHIuiyxlkYeyyH0C9MR6T3_WhGdTLuLQ2_Q_9jOuv69W0SI |
| CitedBy_id | crossref_primary_10_1016_j_bbadis_2025_167973 crossref_primary_10_1038_s41392_024_01934_w crossref_primary_10_1016_j_ajpath_2025_01_013 crossref_primary_10_1038_s41388_024_03184_0 crossref_primary_10_1080_21541264_2023_2294623 crossref_primary_10_1016_j_ard_2025_05_014 crossref_primary_10_3389_fonc_2025_1555274 crossref_primary_10_1002_anie_202421497 crossref_primary_10_3390_ijms25168563 crossref_primary_10_1039_D5FO01278C crossref_primary_10_1007_s00284_024_03901_8 crossref_primary_10_1038_s41598_025_17930_1 crossref_primary_10_1016_j_cellsig_2024_111562 crossref_primary_10_1080_17568919_2025_2507564 crossref_primary_10_1186_s40478_025_02046_4 crossref_primary_10_1002_advs_202500612 crossref_primary_10_53941_ijddp_2024_100007 crossref_primary_10_1111_cns_14881 crossref_primary_10_1093_nar_gkaf545 crossref_primary_10_1016_j_ijbiomac_2025_144621 crossref_primary_10_3389_fimmu_2025_1615091 crossref_primary_10_1016_j_phrs_2024_107499 crossref_primary_10_1038_s41392_024_02072_z crossref_primary_10_3389_fimmu_2025_1509805 crossref_primary_10_1007_s11033_025_10843_2 crossref_primary_10_1016_j_neuro_2024_08_004 crossref_primary_10_1515_tjb_2025_0030 crossref_primary_10_1007_s10753_025_02306_4 crossref_primary_10_1007_s11010_024_04983_5 crossref_primary_10_1186_s13020_025_01176_0 crossref_primary_10_1016_j_jaut_2025_103358 crossref_primary_10_1002_cam4_70283 crossref_primary_10_3390_medicina61010054 crossref_primary_10_1007_s00210_024_03196_3 crossref_primary_10_1007_s00044_025_03434_0 crossref_primary_10_1016_j_jep_2025_120387 crossref_primary_10_1097_gscm_0000000000000021 crossref_primary_10_1016_j_drup_2024_101176 crossref_primary_10_3892_or_2025_8873 crossref_primary_10_1016_j_ejmech_2024_117114 crossref_primary_10_3390_pathogens14040324 crossref_primary_10_3389_fphar_2024_1384189 crossref_primary_10_1016_j_isci_2025_112339 crossref_primary_10_1016_j_isci_2025_113307 crossref_primary_10_1016_j_omton_2025_201008 crossref_primary_10_1016_j_intimp_2024_113715 crossref_primary_10_1177_03946320251327620 crossref_primary_10_1097_ICO_0000000000003942 crossref_primary_10_3389_fonc_2025_1444670 crossref_primary_10_1080_1744666X_2025_2543475 crossref_primary_10_1186_s13578_025_01374_1 crossref_primary_10_1007_s11033_025_10769_9 crossref_primary_10_3389_fimmu_2025_1609740 crossref_primary_10_3390_genes16030270 crossref_primary_10_1016_j_jare_2024_11_001 crossref_primary_10_1016_j_imbio_2024_152801 crossref_primary_10_1038_s41388_024_03140_y crossref_primary_10_3390_ijms25010029 crossref_primary_10_1016_j_cej_2024_156423 crossref_primary_10_1111_cpr_70008 crossref_primary_10_1016_j_ejcb_2025_151512 crossref_primary_10_1080_07853890_2024_2442067 crossref_primary_10_3390_ani15101365 crossref_primary_10_1080_0886022X_2025_2504633 crossref_primary_10_1007_s00432_025_06109_w crossref_primary_10_1016_j_phrs_2025_107776 crossref_primary_10_31718_2077_1096_25_2_310 crossref_primary_10_3390_foods13182991 crossref_primary_10_1007_s11030_025_11329_w crossref_primary_10_12677_TCM_2023_1210472 crossref_primary_10_1016_j_jep_2023_117641 crossref_primary_10_1002_advs_202413091 crossref_primary_10_1016_j_clim_2025_110595 crossref_primary_10_2500_aap_2025_46_240113 crossref_primary_10_1016_j_biopha_2024_117483 crossref_primary_10_1002_fsn3_70936 crossref_primary_10_1002_tox_24005 crossref_primary_10_1016_j_intimp_2024_113267 crossref_primary_10_3389_fimmu_2025_1630015 crossref_primary_10_3390_ph18091266 crossref_primary_10_3390_ijms252413589 crossref_primary_10_3897_pharmacia_72_e146995 crossref_primary_10_1016_j_bbrc_2024_150584 crossref_primary_10_3390_nu16223830 crossref_primary_10_2147_JEP_S528132 crossref_primary_10_3390_ph18040557 crossref_primary_10_1038_s41392_024_01851_y crossref_primary_10_3389_fcell_2024_1442193 crossref_primary_10_1016_j_cellsig_2024_111535 crossref_primary_10_1016_j_fbio_2025_106769 crossref_primary_10_1080_10428194_2025_2549519 crossref_primary_10_1016_j_xcrm_2025_102357 crossref_primary_10_1038_s41598_023_50257_3 crossref_primary_10_1016_j_intimp_2023_111238 crossref_primary_10_3389_fnagi_2025_1558078 crossref_primary_10_1016_j_lfs_2025_123936 crossref_primary_10_3390_jcm14051780 crossref_primary_10_3390_molecules30102183 crossref_primary_10_3390_biom15040487 crossref_primary_10_1002_advs_202416958 crossref_primary_10_1007_s00277_024_05703_1 crossref_primary_10_2147_JIR_S506050 crossref_primary_10_3390_ijms25158163 crossref_primary_10_1016_j_prenap_2025_100375 crossref_primary_10_1186_s12951_025_03316_y crossref_primary_10_1016_j_metabol_2025_156390 crossref_primary_10_1007_s40883_025_00447_4 crossref_primary_10_1021_acsomega_5c05364 crossref_primary_10_3389_fphar_2025_1571554 crossref_primary_10_1002_cac2_12597 crossref_primary_10_1186_s41065_025_00440_5 crossref_primary_10_3390_ph18060912 crossref_primary_10_1016_j_fsi_2025_110492 crossref_primary_10_1007_s10787_025_01796_w crossref_primary_10_3390_ijtm5030043 crossref_primary_10_1007_s11030_025_11268_6 crossref_primary_10_1016_j_bbamcr_2025_119962 crossref_primary_10_3390_ijms26031291 crossref_primary_10_3390_biom14020200 crossref_primary_10_1007_s00403_025_04004_5 crossref_primary_10_1126_sciadv_adt7450 crossref_primary_10_1186_s12943_023_01929_1 crossref_primary_10_3389_fimmu_2025_1538302 crossref_primary_10_1142_S2737416524500662 crossref_primary_10_1007_s12016_025_09068_9 crossref_primary_10_3390_jcm13030766 crossref_primary_10_3390_cimb46080542 crossref_primary_10_1002_pro_70022 crossref_primary_10_1016_j_ijbiomac_2025_146457 crossref_primary_10_3390_ani15030450 crossref_primary_10_1038_s41571_025_01059_1 crossref_primary_10_1186_s12935_025_03889_6 crossref_primary_10_3390_ijms25021009 crossref_primary_10_1016_j_ab_2024_115747 crossref_primary_10_1177_1934578X241293922 crossref_primary_10_2147_CCID_S525787 crossref_primary_10_1016_j_gene_2024_148719 crossref_primary_10_1016_j_retram_2024_103474 crossref_primary_10_1016_j_jep_2024_119097 crossref_primary_10_1038_s41398_025_03300_y crossref_primary_10_1111_ddg_15726_g crossref_primary_10_1186_s12935_025_03941_5 crossref_primary_10_1093_jleuko_qiae095 crossref_primary_10_1186_s12964_023_01421_9 crossref_primary_10_1093_rheumatology_keaf286 crossref_primary_10_3390_antiox14080990 crossref_primary_10_12998_wjcc_v12_i16_2704 crossref_primary_10_1016_j_jddst_2024_106513 crossref_primary_10_3390_biom14030342 crossref_primary_10_3390_cancers17091493 crossref_primary_10_3390_life15081316 crossref_primary_10_1111_jocd_70143 crossref_primary_10_1016_j_jid_2025_05_023 crossref_primary_10_1097_IMNA_D_22_00016 crossref_primary_10_1002_ijc_35459 crossref_primary_10_1038_s41581_025_00958_x crossref_primary_10_1080_14712598_2024_2389987 crossref_primary_10_18632_aging_206304 crossref_primary_10_3390_nu16223864 crossref_primary_10_1038_s41598_025_10196_7 crossref_primary_10_1002_mog2_69 crossref_primary_10_1016_j_bcp_2025_116774 crossref_primary_10_3389_fonc_2025_1564572 crossref_primary_10_1007_s11010_024_05057_2 crossref_primary_10_1111_ajco_14204 crossref_primary_10_1016_j_apsb_2025_08_010 crossref_primary_10_1186_s13287_025_04495_z crossref_primary_10_1111_1756_185X_70130 crossref_primary_10_1002_advs_202417374 crossref_primary_10_1111_ddg_15726 crossref_primary_10_1186_s12967_025_06635_8 crossref_primary_10_1016_j_clim_2024_110383 crossref_primary_10_1186_s12964_025_02313_w crossref_primary_10_1016_j_heliyon_2024_e39176 crossref_primary_10_3389_fimmu_2024_1443648 crossref_primary_10_26538_tjnpr_v9i8_9 crossref_primary_10_1007_s12672_025_02817_4 crossref_primary_10_3389_fcell_2024_1447939 crossref_primary_10_1016_j_mcp_2023_101938 crossref_primary_10_1186_s12964_024_01709_4 crossref_primary_10_3389_fimmu_2024_1441908 crossref_primary_10_3390_cancers16234048 crossref_primary_10_3389_fimmu_2025_1585624 crossref_primary_10_3389_fgene_2023_1238248 crossref_primary_10_1038_s41398_025_03469_2 crossref_primary_10_1080_15592294_2025_2477903 crossref_primary_10_1016_j_brainresbull_2025_111410 crossref_primary_10_1007_s00438_025_02227_9 crossref_primary_10_1016_j_intimp_2025_115369 crossref_primary_10_62425_rtpharma_1755193 crossref_primary_10_1016_j_tips_2024_02_002 crossref_primary_10_1097_ot9_0000000000000102 crossref_primary_10_3390_ijms26094000 crossref_primary_10_1002_adhm_202401512 crossref_primary_10_3390_cimb47090695 crossref_primary_10_1016_j_taap_2024_117077 crossref_primary_10_1136_bcr_2023_258133 crossref_primary_10_1016_j_genrep_2025_102243 crossref_primary_10_3389_fimmu_2023_1271102 crossref_primary_10_1038_s41419_025_07375_9 crossref_primary_10_1186_s12943_025_02294_x crossref_primary_10_1007_s43538_025_00448_5 crossref_primary_10_3389_fimmu_2025_1566794 crossref_primary_10_1186_s42358_024_00427_2 crossref_primary_10_3390_ijms25105489 crossref_primary_10_1038_s41598_025_92428_4 crossref_primary_10_3389_or_2025_1482866 crossref_primary_10_3389_fimmu_2025_1571247 crossref_primary_10_1016_j_ccr_2025_216494 crossref_primary_10_1080_14737140_2025_2483855 crossref_primary_10_1093_qjmed_hcae149 crossref_primary_10_3389_fimmu_2023_1331964 crossref_primary_10_1007_s12012_024_09860_7 crossref_primary_10_1186_s12967_024_05455_6 crossref_primary_10_3390_cancers16233974 crossref_primary_10_1016_j_jmgm_2024_108913 crossref_primary_10_1038_s41598_025_15658_6 crossref_primary_10_3389_fcell_2024_1507621 crossref_primary_10_3390_molecules28248064 crossref_primary_10_1002_ardp_202400621 crossref_primary_10_1016_j_intimp_2024_111487 crossref_primary_10_1016_j_ejmech_2025_117904 crossref_primary_10_3389_fphar_2023_1326281 crossref_primary_10_1001_jamadermatol_2024_0344 crossref_primary_10_3389_fimmu_2025_1539260 crossref_primary_10_1016_j_biotechadv_2025_108568 crossref_primary_10_1016_j_cub_2025_05_068 crossref_primary_10_1016_j_intimp_2025_114499 crossref_primary_10_1002_ange_202421497 crossref_primary_10_1038_s41419_024_06897_y crossref_primary_10_1186_s12943_024_02089_6 crossref_primary_10_1002_VIW_20250007 crossref_primary_10_1016_j_critrevonc_2025_104712 crossref_primary_10_1186_s12876_025_03920_0 crossref_primary_10_1186_s12943_024_02213_6 crossref_primary_10_1007_s10753_024_01970_2 crossref_primary_10_1016_j_cellsig_2025_111798 crossref_primary_10_1016_j_jdcr_2024_11_002 crossref_primary_10_1016_j_rechem_2025_102296 crossref_primary_10_3390_pathogens13121117 crossref_primary_10_1007_s00449_025_03204_7 crossref_primary_10_1016_j_ijbiomac_2023_127937 crossref_primary_10_1016_j_canlet_2025_217933 crossref_primary_10_1136_jitc_2024_009416 crossref_primary_10_3389_fimmu_2025_1596686 crossref_primary_10_1016_j_intimp_2023_110660 crossref_primary_10_3390_ijms25115708 crossref_primary_10_1007_s12032_025_02813_2 crossref_primary_10_1111_gtc_13188 crossref_primary_10_1016_j_bbrc_2025_151647 crossref_primary_10_1016_j_ejps_2025_107051 crossref_primary_10_1016_j_jtho_2025_02_029 crossref_primary_10_3389_fonc_2025_1499283 crossref_primary_10_3390_cimb47080586 crossref_primary_10_1038_s41392_025_02178_y crossref_primary_10_1016_j_aquaculture_2025_743046 crossref_primary_10_1093_hmg_ddae194 crossref_primary_10_3390_ijms25158327 crossref_primary_10_3390_chemistry7030077 crossref_primary_10_1080_17474086_2025_2528886 crossref_primary_10_1177_2050313X251341558 crossref_primary_10_1016_j_jtemb_2024_127517 crossref_primary_10_3389_fimmu_2025_1527817 crossref_primary_10_1093_ecco_jcc_jjaf087 crossref_primary_10_1038_s41419_025_07772_0 crossref_primary_10_1142_S0192415X25500417 crossref_primary_10_1016_j_bioorg_2023_107095 crossref_primary_10_3389_fgene_2025_1620723 crossref_primary_10_1007_s12016_025_09041_6 crossref_primary_10_1016_j_ijbiomac_2025_140639 crossref_primary_10_3390_ijms26083727 crossref_primary_10_1007_s10787_024_01453_8 crossref_primary_10_1039_D5CC02925B crossref_primary_10_2147_ITT_S485670 crossref_primary_10_3390_cells13221838 crossref_primary_10_1016_j_exer_2023_109748 crossref_primary_10_1007_s40610_025_00167_2 crossref_primary_10_1002_mco2_70152 crossref_primary_10_1016_j_intimp_2024_112821 crossref_primary_10_1016_j_phrs_2024_107381 crossref_primary_10_1038_s41598_024_73951_2 crossref_primary_10_1016_j_phymed_2025_156644 crossref_primary_10_1093_ced_llaf336 crossref_primary_10_1016_j_intimp_2025_115135 crossref_primary_10_1292_jvms_24_0432 crossref_primary_10_2485_jhtb_34_149 crossref_primary_10_1007_s10495_024_01970_5 crossref_primary_10_1016_j_critrevonc_2025_104860 crossref_primary_10_1016_j_abst_2025_07_002 crossref_primary_10_1177_20503121251348420 crossref_primary_10_1016_j_ejmech_2024_116571 crossref_primary_10_1097_MD_0000000000034464 crossref_primary_10_1186_s12890_025_03847_y crossref_primary_10_3389_fphar_2023_1302059 crossref_primary_10_1007_s12035_025_04834_4 crossref_primary_10_1038_s41392_024_02075_w crossref_primary_10_1038_s41419_024_06993_z crossref_primary_10_1007_s12672_025_02267_y crossref_primary_10_1016_j_intimp_2025_114731 crossref_primary_10_1186_s12951_024_02929_z crossref_primary_10_1080_07853890_2025_2455536 crossref_primary_10_1016_j_celrep_2025_116155 crossref_primary_10_1038_s41598_025_06017_6 crossref_primary_10_1016_j_addr_2023_115024 crossref_primary_10_3390_biomedicines12081816 crossref_primary_10_3389_fphar_2025_1548073 crossref_primary_10_1186_s12951_025_03321_1 crossref_primary_10_1007_s11255_025_04651_7 crossref_primary_10_1186_s13045_024_01621_x crossref_primary_10_1186_s13578_024_01277_7 crossref_primary_10_3390_cells13181531 |
| Cites_doi | 10.2174/1389203043379378 10.1182/blood.V87.11.4544.bloodjournal87114544 10.1186/s13045-017-0527-7 10.1158/2159-8290.CD-20-0026 10.1038/s43018-022-00431-9 10.1126/science.7973659 10.1038/nrc906 10.1038/leu.2010.69 10.1056/NEJMra0902908 10.1016/j.jinf.2020.04.017 10.1136/annrheumdis-2020-219601 10.1007/s10753-022-01644-x 10.1016/S0140-6736(20)30609-7 10.1016/j.antiviral.2017.10.003 10.1136/annrheumdis-2019-215163 10.1084/jem.181.1.399 10.1016/j.ijbiomac.2022.03.137 10.1038/s41598-017-17600-x 10.1016/j.immuni.2006.10.007 10.1016/S2468-1253(18)30009-8 10.1016/j.tibs.2007.12.002 10.1200/JCO.2015.61.4578 10.1186/s13045-017-0417-z 10.1016/j.jaad.2022.06.012 10.1016/j.canlet.2013.02.010 10.1016/j.cgh.2018.11.035 10.3390/ijms232415646 10.1016/j.jaad.2021.04.085 10.1038/s41467-022-30615-x 10.1016/S1473-3099(20)30132-8 10.1093/hmg/11.6.613 10.1016/j.canlet.2018.04.008 10.1200/JCO.2010.32.8021 10.1093/jnci/dji064 10.1007/s00018-009-0061-z 10.1016/j.jaci.2019.11.025 10.1182/blood-2012-06-435297 10.1097/CAD.0000000000000783 10.1001/jamadermatol.2019.2855 10.1038/s41375-022-01637-7 10.1016/j.jaad.2021.02.028 10.1016/j.jaad.2021.05.050 10.1016/S0140-6736(18)31115-2 10.1016/j.jaci.2019.11.047 10.1016/j.jhep.2019.12.009 10.1016/j.celrep.2023.112061 10.1016/j.semcancer.2019.10.002 10.1126/science.8197455 10.31138/mjr.31.1.100 10.1093/rheumatology/key339 10.1016/j.phrs.2022.106359 10.1038/onc.2010.605 10.1016/j.jep.2022.115507 10.1016/j.phrs.2022.106347 10.1016/j.immuni.2012.01.010 10.1136/annrheumdis-2014-207178 10.1038/s41556-019-0359-5 10.1097/01.tp.0000184634.25042.ea 10.1093/ecco-jcc/jjaa018 10.1038/sj.onc.1203523 10.1016/S0140-6736(22)00581-5 10.1136/annrheumdis-2021-221276 10.1128/MCB.20.19.7132-7139.2000 10.1038/leu.2016.215 10.1186/s13046-020-01769-7 10.1016/S2213-2600(21)00331-3 10.2169/internalmedicine.3528-19 10.1016/j.phrs.2022.106357 10.1007/s40265-020-01291-2 10.1002/ajh.26712 10.1007/s40265-013-0065-8 10.3390/cancers11111701 10.1056/NEJMoa1312542 10.1158/0008-5472.CAN-17-1510 10.1093/intimm/dxr077 10.1056/NEJMra1904794 10.3389/fphar.2021.651415 10.1016/j.jaad.2022.08.061 10.1002/art.42391 10.1016/j.jaci.2015.12.1318 10.1182/blood.2022017442 10.1016/j.clim.2016.09.014 10.1002/med.21850 10.1111/bjd.13745 10.1186/s12943-021-01377-9 10.1158/2159-8290.CD-22-0475 10.1016/j.kint.2021.01.024 10.1182/blood.V85.11.3101.bloodjournal85113101 10.1016/j.cmet.2017.11.001 10.1158/2159-8290.CD-21-1059 10.1074/jbc.M115.691170 10.1136/annrheumdis-2019-215764 10.1053/j.gastro.2020.02.030 10.1016/j.celrep.2013.07.012 10.5582/bst.2020.03106 10.1111/bjd.18898 10.1073/pnas.1301138111 10.1038/s41467-022-32928-3 10.1002/art.41384 10.1016/j.kint.2016.10.039 10.1136/ard.2003.013276 10.1073/pnas.92.8.3234 10.1007/s40261-019-00863-9 10.1093/ecco-jcc/jjz206 10.1016/j.phrs.2022.106362 10.1093/annonc/mdv026 10.1038/ki.2010.154 10.1016/j.jaip.2019.02.018 10.1007/s40265-022-01722-2 10.3322/caac.21551 10.1021/jm200720n 10.1074/jbc.R700016200 10.1007/s40265-017-0701-9 10.1084/jem.185.2.351 10.1016/j.cgh.2014.01.029 10.1016/j.molonc.2014.07.025 10.1002/pros.22741 10.1002/art.40798 10.1186/gb-2004-5-12-253 10.1186/s13045-018-0585-5 10.1155/2022/7838583 10.1016/j.jhep.2021.04.055 10.1126/science.1087061 10.1073/pnas.1401180111 10.1002/art.24567 10.1158/1535-7163.MCT-09-0461 10.1038/nrclinonc.2018.8 10.1038/nsmb.3378 10.1158/2159-8290.CD-15-1434 10.1182/blood.2020004823 10.1186/s12885-020-07285-3 10.1146/annurev.immunol.16.1.293 10.1126/science.abn8933 10.1093/eurheartj/ehab447 10.1200/JCO.2017.73.4418 10.1056/NEJMoa1409002 10.1136/annrheumdis-2019-215164 10.1001/jamaoncol.2015.1590 10.1016/j.cytogfr.2017.07.005 10.1016/S0140-6736(19)30419-2 10.1038/s42003-021-01846-3 10.1056/NEJMra1713263 10.1111/bjd.14871 10.1038/emboj.2010.4 10.1007/s40265-019-01211-z 10.1182/blood-2014-05-577635 10.1093/ecco-jcc/jjaa109 10.1056/NEJMoa1110557 10.1016/j.jaad.2017.12.019 10.1016/j.cgh.2021.07.040 10.1016/j.jaip.2022.08.042 10.1002/ajh.26709 10.1111/j.1365-2141.2006.06348.x 10.1126/sciadv.aat3834 10.1371/journal.pone.0008100 10.1126/science.277.5332.1630 10.1158/1078-0432.CCR-16-2253 10.3389/fimmu.2021.738481 10.1038/nature01661 10.1056/NEJMoa1112072 10.7326/J22-0073 10.1016/S1074-7613(00)80505-1 10.1016/j.tcb.2020.07.003 10.1016/S0140-6736(21)00588-2 10.1002/eji.201344369 10.1038/s41375-021-01231-3 10.1038/nature08448 10.1016/j.bcp.2021.114760 10.1093/rheumatology/kex347 10.1056/NEJMoa2109927 10.1016/j.jbspin.2015.09.002 10.1074/jbc.273.20.12567 10.1136/annrheumdis-2022-222586 10.1016/j.immuni.2006.09.009 10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E 10.1186/bcr38 10.1016/j.tree.2019.02.010 10.1002/art.38949 10.1016/j.jhazmat.2022.130083 10.1038/43206 10.1016/j.ejphar.2021.174121 10.3389/fimmu.2022.932240 10.1158/1078-0432.CCR-12-2246 10.1016/S1074-7613(00)00054-6 10.1016/S0140-6736(20)30304-4 10.1007/s40265-017-0835-9 10.1101/gad.11.2.179 10.1002/j.1460-2075.1995.tb07064.x 10.1007/s40257-021-00618-3 10.1073/pnas.94.22.11839 10.1056/NEJMoa1608345 10.1038/s41388-018-0449-z 10.1182/blood-2013-11-536557 10.1038/bcj.2015.63 10.1136/annrheumdis-2016-210104 10.3389/fphar.2019.00212 10.3322/caac.21660 10.1056/NEJMoa1114885 10.1001/jama.2019.9055 10.1002/ajh.26714 10.1002/art.11096 10.1056/NEJMc1109555 10.1038/leu.2016.280 10.1016/j.phrs.2022.106630 10.1038/jid.2011.140 10.1038/s41467-018-04013-1 10.1186/s12964-017-0177-y 10.1056/NEJMoa1311347 10.1001/jamadermatol.2020.3260 10.1093/emboj/21.7.1754 10.2337/diabetes.51.12.3505 10.1093/rheumatology/keaa613 10.1126/science.7973658 10.1016/j.tips.2022.02.008 10.1016/j.jaad.2021.05.075 10.1038/nrm909 10.1016/j.smim.2014.01.009 10.3899/jrheum.130683 10.1126/science.8272873 10.1097/01.TP.0000157117.30290.6F 10.1016/j.jinf.2020.06.052 10.1016/j.ajhg.2012.02.020 10.1038/nsmb.2099 10.1182/blood.2022015677 10.1016/j.tcb.2008.08.008 10.3389/fimmu.2015.00183 10.1182/blood-2016-03-643544 10.1016/j.redox.2018.101076 10.3389/fimmu.2018.02504 10.3389/fphar.2020.604314 10.1136/ard-2022-222608 10.1016/j.ccell.2017.11.009 10.1016/j.jaut.2019.102400 10.1126/science.abn0478 10.1093/ecco-jcc/jjy085 10.1016/S0092-8674(02)00701-8 10.1002/art.39955 10.1158/0008-5472.CAN-20-2426 10.1093/ecco-jcc/jjab099 10.1016/j.jaad.2022.07.002 10.1056/NEJMoa2019380 10.1073/pnas.1816410116 10.1136/annrheumdis-2018-214529 10.1038/bjc.2015.233 10.1056/NEJMoa1310476 10.1016/j.alit.2021.10.004 10.1073/pnas.1615730114 10.1136/ard.2011.150326 10.1056/NEJMoa2101643 10.1158/1078-0432.CCR-18-4089 10.1002/ajh.24775 10.1038/nsmb.2348 10.1002/j.1460-2075.1995.tb07100.x 10.1016/j.phrs.2022.106419 10.1016/j.lfs.2022.120996 10.1056/NEJMoa1615977 10.1136/annrheumdis-2021-221915 10.1016/S0959-437X(98)80015-4 10.1002/jcp.28715 10.1016/j.kint.2018.05.022 10.1038/nrc3818 10.1038/s41598-022-10777-w 10.1016/j.nbd.2022.105964 10.1016/j.trsl.2015.08.013 10.1200/JCO.2008.20.7753 10.1056/NEJMoa2022516 10.1016/j.tips.2019.03.001 10.1038/nri2093 10.1038/s41418-022-01005-z 10.1158/0008-5472.CAN-10-3025 10.1126/sciadv.abo4363 10.1016/S0140-6736(20)31284-8 10.1073/pnas.122236099 10.1016/j.cell.2022.09.023 10.1177/1756284819853208 10.1086/428480 10.1084/jem.20170457 10.1016/j.pharmthera.2022.108118 10.1002/art.41906 10.1101/gad.262642.115 10.1136/annrheumdis-2020-218412 10.1016/j.jaad.2018.01.018 10.1146/annurev-med-051113-024537 10.1038/leu.2013.192 10.1016/j.jaut.2019.01.013 10.1002/pros.20072 10.1016/j.clim.2013.11.003 10.1016/S2352-3026(19)30207-8 10.1186/s40425-019-0733-7 10.1016/j.immuni.2008.08.017 10.1038/s41423-022-00904-y 10.1016/j.immuni.2017.01.004 10.1136/annrheumdis-2015-208279 10.1016/j.kint.2017.03.027 10.1016/j.biopha.2022.113618 10.1001/jamadermatol.2016.1978 10.1016/j.phrs.2019.104609 10.3899/jrheum.201183 10.1016/j.cgh.2021.02.043 10.1002/pros.23015 10.1002/art.39473 10.1016/j.humpath.2012.06.001 10.1158/0008-5472.CAN-08-2989 10.1002/j.1460-2075.1995.tb07126.x 10.1056/NEJMoa1606910 10.1186/s12943-022-01679-6 10.1016/j.omtn.2020.10.008 10.1200/JCO.2012.44.4489 10.1056/NEJMra1202117 10.1016/j.jaci.2020.11.041 10.1016/j.jaad.2017.08.002 10.1016/j.autrev.2019.05.007 10.1038/ncomms12258 10.1016/S0092-8674(00)81288-X 10.1007/s40265-022-01796-y 10.1111/1346-8138.15173 10.1186/s41232-022-00221-x 10.1016/j.jaci.2022.01.026 10.1111/bjh.18207 10.1002/hep.31812 10.1016/S1097-2765(01)00398-7 10.1038/s41467-019-08743-8 10.1016/j.jaci.2019.08.004 10.1016/j.drup.2022.100903 10.1111/cei.12248 10.1186/1756-8722-6-90 10.1200/JCO.21.02188 10.1002/ctm2.978 10.1002/hep.20933 10.1182/blood.V86.7.2516.2516 10.1002/cac2.12393 10.1016/j.bcp.2021.114688 10.1056/NEJMc1302135 10.1038/s41572-020-00240-3 10.1007/s40265-019-01205-x 10.1038/sj.cr.7290255 10.1074/jbc.271.22.13221 10.1136/ard.2005.037929 10.1007/s40257-018-0413-2 10.1038/s41568-022-00537-3 10.1056/NEJMoa1109071 10.1182/blood-2006-04-018879 10.1038/ng0501-4 10.1038/s41375-021-01266-6 10.1038/s41467-022-32927-4 10.1016/j.ydbio.2009.10.045 10.3389/fimmu.2022.1068260 10.1136/annrheumdis-2020-219214 10.1093/cid/ciab212 10.1016/j.jaad.2013.10.010 10.1016/j.intimp.2020.106497 10.1056/NEJMoa2033122 10.1016/S1470-2045(16)30558-7 10.1158/2159-8290.CD-16-1439 10.1016/j.jaci.2019.08.042 10.1016/j.drup.2010.04.001 10.1016/S2213-2600(22)00088-1 10.1016/S0140-6736(20)31286-1 10.1016/j.immuni.2012.03.014 10.1038/s41571-020-0340-z 10.1016/j.jaad.2021.06.014 10.1016/j.jaci.2022.04.011 10.1084/jem.20070401 10.1016/S2352-3026(21)00367-7 10.1038/leu.2014.3 10.1016/S0168-9525(97)01006-8 10.1200/JCO.19.00895 10.1016/j.cgh.2020.10.004 10.1186/s13045-021-01157-4 10.1152/ajprenal.00181.2005 10.1038/leu.2016.148 10.1056/NEJMoa051113 10.1016/j.xcrm.2021.100269 10.1016/S0140-6736(20)30732-7 10.1056/NEJMoa2031994 10.1126/sciadv.aay3245 10.1136/ard-2022-222605 10.1186/s13045-017-0425-z 10.1016/j.immuni.2008.03.002 10.1038/ki.1996.3 10.1007/s10549-013-2488-z 10.1038/s41590-019-0466-2 10.1016/S0140-6736(12)61424-X 10.1056/NEJMoa1110556 10.1007/s40265-019-01131-y 10.1136/annrheumdis-2020-219213 10.1016/j.hoc.2012.07.007 10.1016/S0140-6736(21)00036-2 10.1007/s12072-019-09944-5 10.1016/j.ejphar.2019.05.020 10.1136/annrheumdis-2020-218870 10.1016/S0140-6736(98)09148-X 10.1172/JCI126567 10.1136/jitc-2021-004384 10.1158/2159-8290.CD-21-0282 10.1021/acs.jmedchem.2c00283 10.1136/annrheumdis-2020-216983 10.1016/S0140-6736(18)31363-1 10.1124/jpet.114.221176 10.1016/S0140-6736(22)01212-0 10.1111/j.0105-2896.2004.00211.x 10.1016/j.tcb.2022.03.007 10.1093/ecco-jcc/jjx003 10.1016/S0079-6107(98)00051-0 10.1056/NEJMoa1013343 10.1016/j.virusres.2009.12.003 10.1111/jdv.18170 10.1038/s41467-022-33909-2 10.1016/j.jaad.2019.12.015 10.1016/j.bcp.2022.114940 10.1038/s41392-021-00791-1 10.1111/all.12220 10.1016/j.cgh.2021.05.045 10.1016/j.ccell.2015.06.006 10.1001/jamadermatol.2020.1406 10.1016/S0092-8674(00)81168-X 10.2147/DDDT.S240866 10.1038/ni.3691 10.1016/S2665-9913(22)00044-3 10.1016/S0140-6736(10)60826-4 10.1016/j.cgh.2020.10.038 10.1016/j.cyto.2015.11.011 10.1093/jnci/djm328 10.1182/blood-2013-12-544411 10.1038/nri1995 10.1002/art.40841 10.1111/bjd.18469 10.1136/annrheumdis-2012-202576 10.1038/nrrheum.2015.53 10.1016/S0140-6736(21)00589-4 10.1146/annurev-immunol-110416-120628 10.1016/j.heliyon.2022.e11782 10.1016/j.jaci.2004.06.042 10.1038/s41375-019-0379-y 10.1186/s12943-020-01258-7 10.1146/annurev.iy.13.040195.002101 10.1038/leu.2008.226 10.1038/cr.2014.154 10.1136/annrheumdis-2015-208901 10.1111/bjd.21037 10.1053/j.gastro.2022.08.007 10.4049/jimmunol.155.3.1079 10.1158/1078-0432.CCR-05-0148 10.1136/annrheumdis-2014-206028 10.1002/art.33383 10.1056/NEJMoa2110343 10.1002/cncr.24183 10.1182/blood-2011-11-392985 10.1007/s40265-021-01638-3 10.1056/NEJMra1004965 10.1007/s40262-016-0419-y 10.1016/j.autrev.2021.102750 10.1016/j.antiviral.2015.03.001 10.1016/S0168-9525(00)89000-9 10.3390/molecules27144660 10.1002/ajh.25777 10.1158/1078-0432.CCR-18-1277 10.1074/jbc.270.7.3327 10.1073/pnas.2114324119 10.1080/10408398.2021.1945531 10.1136/annrheumdis-2020-218510 10.3390/ijms24043391 10.1016/j.intimp.2020.106210 10.1001/jamadermatol.2021.2830 10.1016/j.phrs.2016.07.038 10.1158/0008-5472.CAN-13-0874 10.1002/jlb.66.4.588 10.1056/NEJMoa1002028 10.1177/09636897211033778 10.1038/nrrheum.2015.167 10.1182/blood-2014-04-566687 10.1038/s41467-021-26983-5 10.1016/S0960-9822(06)00208-9 10.1056/NEJMoa1507247 10.1016/j.jaad.2022.04.009 10.1002/art.42250 10.3390/jcm11237020 10.1016/j.cmet.2022.02.002 10.1056/NEJMoa1917635 10.1182/blood-2014-02-554634 10.1093/burnst/tkac023 10.7326/0003-4819-159-4-201308200-00006 10.1111/bjd.21630 10.1002/j.1460-2075.1995.tb07128.x 10.1074/jbc.270.20.12286 10.6004/jnccn.2022.0046 10.1056/NEJMoa2008250 10.1016/j.isci.2020.101822 10.1161/01.CIR.0000057545.82749.FF 10.1371/journal.pmed.0030270 10.1002/art.41911 10.1016/S2352-3026(17)30088-1 10.1007/s13555-021-00596-8 10.1056/NEJMoa1615975 10.1136/annrheumdis-2016-209821 10.1158/0008-5472.CAN-22-0736 10.1182/blood-2005-03-1320 10.1016/j.phrs.2023.106703 10.1016/j.cytogfr.2006.09.008 10.2215/CJN.11010919 10.1016/j.semcancer.2022.08.003 10.1038/s41598-019-41106-3 10.1038/s41375-020-0954-2 10.1126/science.270.5237.794 10.1016/0968-0004(94)90026-4 10.1002/art.37816 10.1007/s40257-021-00627-2 10.1016/j.tem.2017.11.001 10.1002/art.40186 10.1146/annurev.bi.64.070195.003201 10.1038/s41419-022-05477-2 10.1007/s00281-017-0619-z 10.1016/j.cytogfr.2016.05.001 10.1007/s40265-019-01169-y 10.1016/j.cell.2011.09.022 10.1016/j.blre.2018.09.001 10.1002/art.41032 10.1073/pnas.0308340100 10.1093/qjmed/hcs205 10.1182/blood-2008-01-134114 10.1111/bjd.16004 10.1080/10408398.2018.1552244 10.1016/j.canlet.2019.02.029 10.1007/s12016-016-8550-y 10.1016/j.jaci.2021.07.036 10.1136/gutjnl-2016-312735 10.1002/art.38305 10.1016/j.pharmthera.2021.107969 10.1016/S2213-2600(22)00006-6 10.1053/j.gastro.2020.01.047 10.1016/S0140-6736(21)00438-4 10.1074/jbc.M803125200 10.1136/annrheumdis-2016-210105 10.1016/S2352-3026(17)30237-5 10.1016/S1074-7613(00)80566-X 10.1056/NEJMoa1112168 10.1136/ard.2006.063412 10.1093/ndt/gfn314 10.1002/ajh.26751 10.3389/fendo.2017.00071 10.1002/art.40054 10.1093/ecco-jcc/jjac141 10.1016/j.jaad.2022.09.060 10.1172/JCI153247 10.1016/j.anai.2023.01.020 10.1016/j.annonc.2023.01.009 10.1021/acs.jmedchem.9b01392 10.2174/0929867330666230216123419 10.1136/ard-2022-223356corr1 10.1016/j.jhep.2011.12.001 10.1111/imm.13614 10.1172/JCI125986 10.1016/j.blre.2022.100992 10.3390/ijms24010781 10.3390/cancers11122002 10.1002/anie.202205231 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2023 2023. The Author(s). The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2023 – notice: 2023. The Author(s). – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU COVID DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1038/s41392-023-01468-7 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 2059-3635 |
| EndPage | 24 |
| ExternalDocumentID | oai_doaj_org_article_d661aa6dfb5a4fd0bf9d78374f8bb70c PMC10196327 37208335 10_1038_s41392_023_01468_7 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: This work was funded by the National Key Research and Development Program of China (2021YFC2301800), and the National Nature Science Foundation of China (82200673 and U20A20343) – fundername: National Natural Science Foundation of China (National Science Foundation of China) grantid: 82200673 and U20A20343 funderid: https://doi.org/10.13039/501100001809 – fundername: ; grantid: 82200673 and U20A20343 – fundername: ; |
| GroupedDBID | 0R~ 3V. 5VS 7X7 8FI 8FJ AAJSJ ABUWG ACGFS ACSMW ADBBV AFKRA AJTQC ALMA_UNASSIGNED_HOLDINGS AOIJS BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU EBLON EBS EJD EMOBN FYUFA GROUPED_DOAJ HCIFZ HMCUK HYE M7P NAO OK1 PIMPY PQQKQ PROAC RNT RPM SNYQT UKHRP AASML AAYXX AFFHD CITATION PHGZM PHGZT PQGLB CGR CUY CVF ECM EIF NPM 7T5 7XB 8FE 8FH 8FK AZQEC COVID DWQXO GNUQQ H94 K9. LK8 PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c607t-59c18c056eea47bc4a40964d4d841a6d7f3dede44050e709412cf4e5f4e0d4f13 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 376 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000992776400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2059-3635 2095-9907 |
| IngestDate | Tue Oct 14 19:06:09 EDT 2025 Tue Nov 04 02:07:41 EST 2025 Mon Sep 08 12:11:58 EDT 2025 Tue Oct 07 07:04:26 EDT 2025 Mon Jul 21 06:00:58 EDT 2025 Sat Nov 29 05:11:17 EST 2025 Tue Nov 18 22:33:28 EST 2025 Fri Feb 21 02:39:05 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c607t-59c18c056eea47bc4a40964d4d841a6d7f3dede44050e709412cf4e5f4e0d4f13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2815862043?pq-origsite=%requestingapplication% |
| PMID | 37208335 |
| PQID | 2815862043 |
| PQPubID | 2041911 |
| PageCount | 24 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d661aa6dfb5a4fd0bf9d78374f8bb70c pubmedcentral_primary_oai_pubmedcentral_nih_gov_10196327 proquest_miscellaneous_2816762427 proquest_journals_2815862043 pubmed_primary_37208335 crossref_citationtrail_10_1038_s41392_023_01468_7 crossref_primary_10_1038_s41392_023_01468_7 springer_journals_10_1038_s41392_023_01468_7 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-05-19 |
| PublicationDateYYYYMMDD | 2023-05-19 |
| PublicationDate_xml | – month: 05 year: 2023 text: 2023-05-19 day: 19 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Signal transduction and targeted therapy |
| PublicationTitleAbbrev | Sig Transduct Target Ther |
| PublicationTitleAlternate | Signal Transduct Target Ther |
| PublicationYear | 2023 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | Alexander (CR123) 1999; 66 Scherer, Häupl, Burmester (CR172) 2020; 110 Russell (CR49) 1994; 266 CR281 CR282 MacDonagh (CR375) 2018; 428 CR280 Pardanani (CR508) 2015; 1 Ihle, Kerr (CR17) 1995; 11 Pérez-Jeldres (CR555) 2019; 10 Bottos (CR332) 2016; 7 Jonker (CR378) 2018; 3 Gooderham (CR526) 2019; 155 Zeidan, Shallis, Wang, Davidoff, Ma (CR211) 2019; 34 Fleischmann (CR515) 2015; 67 Yin, Yang, Yang (CR46) 1995; 85 Choudhury, Marra, Kiyomoto, Abboud (CR47) 1996; 49 Genovese (CR475) 2016; 374 Park (CR147) 2014; 66 Costa-Pereira (CR139) 2002; 99 Finbloom, Winestock (CR64) 1995; 155 Roxburgh, McMillan (CR133) 2016; 167 Tzeng, Chyuan, Lai (CR28) 2021; 193 CR294 Liu (CR403) 2022; 154 Mui, Wakao, O’Farrell, Harada, Miyajima (CR365) 1995; 14 Bieber (CR284) 2021; 384 Harrison (CR417) 2017; 4 Miyawaki (CR472) 2020; 59 Liu (CR311) 2015; 75 Miyazaki (CR48) 1994; 266 Vanhoutte (CR197) 2017; 69 Dinakar (CR328) 2022; 309 Sun (CR396) 2022; 184 Rampal (CR223) 2014; 123 Schafer, Sorrell (CR296) 1999; 353 Tsoi (CR247) 2020; 145 Meyer (CR208) 2015; 28 Fleischmann (CR266) 2019; 71 Kleppe (CR558) 2018; 33 Tefferi, Vardiman (CR210) 2009; 361 Léger, Balaguer, Le Hégarat, Fessard (CR96) 2023; 442 Mesa (CR415) 2013; 31 Meraz (CR5) 1996; 84 Di, Zhang (CR387) 2019; 30 Papp (CR256) 2021; 85 Khosrow-Khavar, Kim, Lee, Lee, Desai (CR455) 2022; 81 Das Gupta (CR51) 2022; 29 CR257 Hou, Perrimon (CR3) 1997; 13 Brambilla, Lahiri, Cammer, Levy (CR380) 2020; 23 Marconi (CR490) 2021; 9 CR374 Sandborn (CR446) 2017; 376 Verstovsek (CR440) 2017; 10 McInnes (CR277) 2021; 384 Darnell (CR14) 2002; 2 Yoshimura, Naka, Kubo (CR120) 2007; 7 Chlebowski (CR317) 2005; 97 Drucker, Wang, Qureshi (CR244) 2016; 152 Mahata (CR399) 2022; 208 Duggan, Keam (CR521) 2019; 79 Rubbert-Roth (CR260) 2020; 383 Fragiadaki (CR345) 2017; 91 Pikman (CR231) 2006; 3 Schindler, Darnell (CR79) 1995; 64 Genini (CR382) 2017; 114 Dhillon (CR444) 2017; 77 Tanaka (CR477) 2019; 78 Schmieder (CR289) 2018; 179 Robek, Boyd, Wieland, Chisari (CR302) 2004; 101 Mease (CR466) 2017; 377 Changelian (CR350) 2003; 302 Panés (CR467) 2017; 66 Harrison (CR511) 2022; 198 Tao (CR334) 2018; 94 Lis (CR370) 2017; 7 Tefferi (CR215) 2010; 24 Nguyen (CR180) 2017; 46 Adachi (CR351) 2022; 82 Koike (CR336) 2014; 150 Wang, Zhao (CR191) 2020; 84 Wolfe (CR488) 2022; 10 McInnes, Schett (CR173) 2011; 365 Lupardus (CR60) 2014; 111 Goropevšek, Holcar, Avčin (CR146) 2017; 52 Nangalia (CR232) 2013; 369 Arber (CR228) 2016; 127 Zeiser (CR413) 2020; 382 Wong (CR383) 2015; 26 McLornan, Pope, Gotlib, Harrison (CR408) 2021; 398 Geyer, Mesa (CR222) 2014; 124 Lei (CR479) 2021; 99 Westhovens (CR198) 2021; 80 Kopalli, Annamneedi, Koppula (CR252) 2022; 27 Pieringer, Studnicka-Benke (CR175) 2013; 106 Deodhar (CR264) 2022; 74 King (CR487) 2022; 386 Hirpara (CR381) 2019; 25 Pike, Tremblay (CR130) 2018; 9 Tefferi, Gangat, Pardanani (CR544) 2022; 97 Thoidingjam (CR549) 2022; 61 Ständer (CR527) 2022; 36 Lasho (CR240) 2006; 135 Bandaranayake (CR61) 2012; 19 Zhang (CR562) 2008; 100 Shuai (CR106) 1999; 71 Krueger (CR457) 2016; 137 CR249 Genovese (CR177) 2019; 322 Sandborn (CR270) 2020; 158 Lee (CR497) 2020; 40 Nakashima, Yanagihara, Otsuka (CR251) 2022; 71 Liu, Kieltyka, Fleischmann, Gadina, O’Shea (CR409) 2021; 73 Hoey, Schindler (CR105) 1998; 8 Degryse (CR54) 2014; 124 Debili (CR236) 1995; 86 Liu (CR306) 2021; 20 O’Shea (CR38) 2015; 66 Villarino, Kanno, O’Shea (CR43) 2017; 18 Mullally, Lane, Brumme, Ebert (CR235) 2012; 26 Fleischmann (CR262) 2019; 78 Barcia Durán (CR55) 2021; 4 Burmester (CR520) 2018; 391 Marconi (CR442) 2022; 74 O’Shea, Holland, Staudt (CR138) 2013; 368 Panés, Vermeire (CR354) 2020; 14 Taylor (CR476) 2022; 81 Mahajan (CR514) 2015; 353 Thomas, Snowden, Zeidler, Danson (CR125) 2015; 113 Roskoski (CR418) 2020; 152 Burmester (CR30) 2013; 381 Shih (CR113) 2022; 234 CR104 Arakawa (CR347) 2008; 23 CR468 Takeuchi (CR187) 2016; 75 Hanahan (CR168) 2022; 12 Tefferi (CR230) 2014; 28 CR464 Kavanaugh (CR522) 2021; 48 Guenterberg (CR358) 2010; 9 Zhang (CR343) 2017; 92 Gracey (CR149) 2020; 130 Zhao (CR307) 2020; 39 Bieber (CR484) 2022; 187 Furqan (CR92) 2013; 6 Pei (CR393) 2019; 450 Cianciulli, Calvello, Porro, Trotta, Panaro (CR406) 2017; 37 Cantini (CR493) 2020; 81 Putz (CR142) 2013; 4 Li (CR107) 2008; 18 Chen (CR199) 2022; 8 Rodriguez-Barrueco (CR331) 2015; 29 Fisher (CR432) 2019; 33 Houthuys, Wilmer, Peetermans, Meersseman, Devos (CR436) 2022; 8 Pastore (CR559) 2020; 10 Liu (CR326) 2023; 66 Koeberlein (CR301) 2010; 148 Harrison (CR209) 2018; 5 CR316 Khosrow-Khavar, Desai, Lee, Lee, Kim (CR471) 2022; 74 Kaushansky (CR237) 1995; 92 Runtsch (CR404) 2022; 34 Wang (CR299) 2020; 72 Sandborn (CR447) 2012; 367 Wollenhaupt (CR449) 2014; 41 Markham, Keam (CR496) 2019; 79 Nakagawa (CR503) 2021; 85 Huang, Chung, Wu, Chen (CR248) 2022; 13 Weinstein (CR357) 2018; 215 Karpov (CR473) 2022; 23 Conigliaro (CR513) 2019; 18 Sun (CR541) 2021; 30 Casarella (CR344) 2022; 42 Forbes (CR269) 2022; 175 Coltro (CR434) 2017; 92 Bissonnette (CR459) 2016; 175 Tucci (CR34) 2022; 13 Zou (CR319) 2020; 19 Long, Chen, Wu, Zhao, Lu (CR131) 2019; 99 Lussana (CR239) 2017; 10 Richardson (CR492) 2020; 395 Pedroza (CR388) 2018; 57 Nakagawa (CR504) 2019; 144 Patterson, Nibbs, McInnes, Siebert (CR551) 2014; 176 Constantinescu, Girardot, Pecquet (CR21) 2008; 33 Etra (CR518) 2023; 141 Dorritie, McCubrey, Johnson (CR93) 2014; 28 Pardanani (CR510) 2015; 5 Wakao, Gouilleux, Groner (CR366) 1995; 14 Banerjee, Biehl, Gadina, Hasni, Schwartz (CR42) 2017; 77 Mendes-Bastos (CR263) 2022; 87 Pelham (CR100) 2022; 150 Beebe, Lee, Micchelli (CR163) 2010; 338 Fahmideh (CR40) 2022; 2022 Guschin (CR63) 1995; 14 Higgs (CR190) 2011; 70 Favoino (CR352) 2021; 20 Bitsch (CR377) 2022; 10 Vannucchi (CR419) 2015; 372 Baldini, Moriconi, Galimberti, Libby, De Caterina (CR108) 2021; 42 Reich (CR259) 2021; 397 Gao (CR303) 2015; 118 You (CR470) 2021; 60 Patel (CR400) 2020; 60 Barrat, Crow, Ivashkiv (CR4) 2019; 20 Jones (CR224) 2005; 106 Eichenfield (CR245) 2014; 70 Guttman-Yassky (CR279) 2021; 397 CR543 Eckert (CR243) 2018; 78 Zhang (CR546) 2022; 97 Thieu (CR356) 2008; 29 Mohamed (CR274) 2016; 55 Zeiser (CR428) 2021; 385 Lee (CR68) 2009; 115 Taylor (CR495) 2019; 71 Sigurdsson (CR150) 2005; 76 van der Pouw Kraan (CR183) 2003; 48 Verstovsek (CR35) 2017; 31 Refaeli, Van Parijs, London, Tschopp, Abbas (CR362) 1998; 8 Ku, Yonemura, Kaushansky, Ogawa (CR238) 1996; 87 Silverberg (CR267) 2022; 149 Chen, Daines (CR13) 2004; 114 Hoisnard (CR474) 2022; 12 Benucci (CR36) 2022; 183 Guttman-Yassky (CR268) 2020; 145 Casaca (CR152) 2013; 68 Tefferi (CR221) 2022; 97 Lee (CR205) 2014; 370 Thiele (CR219) 2023; 98 Al-Bawardy, Shivashankar, Proctor (CR564) 2021; 12 Klampfl (CR233) 2013; 369 Liau (CR84) 2019; 11 Baratchian (CR169) 2022; 119 Lauper (CR195) 2022; 81 Cohen (CR261) 2021; 80 Kasperkovitz (CR182) 2004; 63 Bromberg (CR320) 2000; 2 Zhao (CR542) 2021; 22 Pardanani (CR241) 2006; 108 Schindler, Levy, Decker (CR102) 2007; 282 Strober (CR537) 2023; 88 Fridman (CR563) 2011; 131 Cotter, Schairer, Eichenfield (CR250) 2018; 78 Bejar (CR214) 2011; 364 Chen (CR539) 2022; 163 Lee (CR160) 2022; 10 Stebbing (CR491) 2020; 20 Kollmann (CR229) 2017; 31 Starr (CR121) 1997; 387 Nakagawa (CR501) 2020; 47 Irey (CR333) 2019; 116 De Vries, Wildenberg, De Jonge, D’Haens (CR410) 2017; 11 Guan (CR405) 2023; 189 Han (CR431) 2022; 4 Sandborn (CR453) 2019; 17 Passamonti (CR421) 2017; 18 Genovese, van Vollenhoven, Pacheco-Tena, Zhang, Kinnman (CR516) 2016; 68 Genovese, Yang, Østergaard, Kinnman (CR517) 2016; 75 Dodington, Desai, Woo (CR77) 2018; 29 Passamonti (CR439) 2014; 123 Kralovics (CR226) 2005; 352 Chen (CR361) 2021; 2 Dao (CR423) 2020; 38 Yamaoka (CR6) 2004; 5 van der Pouw Kraan (CR189) 2007; 66 Lundgren (CR154) 2021; 35 Burkhardt (CR159) 2022; 12 Nakagawa (CR502) 2020; 82 Pohóczky (CR550) 2022; 182 Levy, Darnell (CR10) 2002; 3 Villanueva (CR290) 2019; 380 Mu, Ao, Li, Zhang, Duan (CR74) 2022; 296 Boyle (CR32) 2015; 74 Rytinki, Kaikkonen, Pehkonen, Jääskeläinen, Palvimo (CR128) 2009; 66 Verstovsek (CR441) 2017; 10 Han (CR300) 2017; 147 Lin, Leonard (CR364) 2000; 19 Hoy (CR535) 2022; 82 Harrison (CR422) 2022; 40 Takeuchi (CR186) 2019; 78 Bader-Meunier (CR430) 2022; 81 Kang, Biswas, Field, Snapper (CR141) 2019; 10 Deng (CR166) 2022; 3 Dethlefsen, Højfeldt, Hojman (CR330) 2013; 138 Jamieson, Wallace, Das, Bhattacharyya, Bishayee (CR395) 2023; 63 Mease (CR272) 2021; 80 Goult (CR59) 2010; 29 Stahl (CR87) 1994; 263 Onkar (CR313) 2023; 13 Cordell (CR145) 2021; 75 Verhoeven (CR91) 2020; 60 van Vollenhoven (CR265) 2020; 72 Lo (CR164) 2022; 12 Kvasnicka (CR427) 2018; 11 Cook, Hansen, Siu, Abdul Razak (CR554) 2015; 9 Chifotides, Bose, Verstovsek (CR220) 2022; 15 Garrido-Trigo, Salas (CR505) 2020; 14 Genovese (CR188) 2017; 69 Guha (CR392) 2019; 38 Tanaka (CR185) 2019; 78 Robinson (CR389) 2022; 11 Azam (CR367) 1995; 14 Sun (CR167) 2019; 21 Armstrong (CR536) 2023; 88 Mesa (CR206) 2017; 35 Ely (CR489) 2022; 10 Feng (CR315) 2023; 43 DeMichele (CR329) 2009; 69 Freitas, Gooderham, Torres (CR246) 2022; 82 Hu, Li, Fu, Zhao, Wang (CR76) 2021; 6 Mesa (CR207) 2022; 36 van Vollenhoven (CR202) 2012; 367 Taylor (CR485) 2017; 376 Yu, Kortylewski, Pardoll (CR372) 2007; 7 O’Shea (CR2) 1997; 7 Harrison (CR426) 2016; 30 Sandborn (CR458) 2014; 12 Lee (CR27) 2004; 60 Tian, Tian, Qiao, Li, Zhang (CR401) 2019; 234 Liao (CR52) 2014; 111 Uppal, Chat, Kearns, Wu (CR288) 2021; 397 Leonard, O’Shea (CR1) 1998; 16 Blair (CR560) 2019; 79 Rosmarin (CR412) 2020; 396 Singh, Chen, Hou (CR39) 2005; 15 Meng (CR547) 2020; 14 Koskela (CR19) 2012; 366 Liu (CR363) 1997; 11 Morand (CR538) 2023; 75 Kavanaugh (CR178) 2017; 76 Li (CR305) 2019; 13 Karaghiosoff (CR82) 2000; 13 Durham, Williams, Nasim, Palmer (CR117) 2019; 40 Meissl, Macho-Maschler, Müller, Strobl (CR24) 2017; 89 Guttman-Yassky (CR483) 2019; 80 Ytterberg (CR448) 2022; 386 Khan (CR304) 2020; 20 Borie (CR348) 2005; 80 Deodhar (CR456) 2021; 80 Wang (CR98) 2022; 140 Cazzola (CR213) 2020; 383 Darnell (CR11) 1997; 277 Gauzzi (CR85) 1997; 94 O’Shea, Plenge (CR134) 2012; 36 Harrison (CR424) 2012; 366 Jung (CR386) 2017; 23 Simpson (CR287) 2020; 396 Llovet (CR293) 2021; 7 Worm (CR499) 2022; 187 Deeks, Duggan (CR283) 2021; 81 Quintanal-Villalonga (CR161) 2020; 17 Firestein (CR170) 2003; 423 Caraglia (CR298) 2004; 5 Lai, Johnson (CR29) 2010; 13 Worm (CR500) 2020; 182 Dawson (CR218) 2009; 461 Rojas (CR26) VT Thieu (1468_CR356) 2008; 29 HM Kvasnicka (1468_CR427) 2018; 11 DA Arber (1468_CR228) 2016; 127 H Nakagawa (1468_CR502) 2020; 82 EL Simpson (1468_CR482) 2021; 85 S Banerjee (1468_CR42) 2017; 77 H Pieringer (1468_CR175) 2013; 106 B Chen (1468_CR539) 2022; 163 DM Schwartz (1468_CR137) 2016; 12 D Ungureanu (1468_CR225) 2011; 18 A Blauvelt (1468_CR285) 2022; 86 Y Zhang (1468_CR546) 2022; 97 J Stebbing (1468_CR491) 2020; 20 R Feng (1468_CR315) 2023; 43 M Cazzola (1468_CR213) 2020; 383 P Conigliaro (1468_CR513) 2019; 18 PC Taylor (1468_CR485) 2017; 376 WJ Sandborn (1468_CR447) 2012; 367 PC Taylor (1468_CR476) 2022; 81 X Sun (1468_CR541) 2021; 30 F Gothe (1468_CR111) 2022; 150 HN Nguyen (1468_CR180) 2017; 46 DC Thomis (1468_CR81) 1995; 270 DC Borie (1468_CR349) 2005; 79 L Gao (1468_CR310) 2005; 11 MGM Khan (1468_CR304) 2020; 20 S Bi (1468_CR376) 2019; 855 E Freitas (1468_CR246) 2022; 82 AP Costa-Pereira (1468_CR139) 2002; 99 WJ Sandborn (1468_CR453) 2019; 17 T Kishimoto (1468_CR124) 2001; 28 D Genini (1468_CR382) 2017; 114 T Wang (1468_CR323) 2018; 27 B Bakir (1468_CR158) 2020; 30 CN Harrison (1468_CR511) 2022; 198 GL Wong (1468_CR318) 2022; 86 JJ O’Shea (1468_CR134) 2012; 36 F Patera (1468_CR346) 2019; 9 A Deodhar (1468_CR456) 2021; 80 P Mendes-Bastos (1468_CR263) 2022; 87 S Dhillon (1468_CR498) 2020; 80 JS Weinstein (1468_CR357) 2018; 215 BD Page (1468_CR369) 2012; 55 K Reich (1468_CR532) 2022; 10 DF Schafer (1468_CR296) 1999; 353 Y Malka (1468_CR53) 2008; 283 DB Burkhardt (1468_CR159) 2022; 12 R Buettner (1468_CR368) 2002; 8 IB McInnes (1468_CR173) 2011; 365 A Tefferi (1468_CR544) 2022; 97 D Guschin (1468_CR63) 1995; 14 H Yu (1468_CR321) 2014; 14 D van der Heijde (1468_CR204) 2013; 65 C Lis (1468_CR370) 2017; 7 JS Smolen (1468_CR523) 2019; 393 A Kavanaugh (1468_CR178) 2017; 76 R Westhovens (1468_CR198) 2021; 80 J Tao (1468_CR334) 2018; 94 T Miyagi (1468_CR355) 2007; 204 P Robinson (1468_CR389) 2022; 11 WT Watford (1468_CR143) 2004; 202 B Woods (1468_CR227) 2019; 25 S Duggan (1468_CR521) 2019; 79 H Patterson (1468_CR551) 2014; 176 SO Lee (1468_CR27) 2004; 60 Y Minegishi (1468_CR9) 2006; 25 KT Dao (1468_CR423) 2020; 38 K Liu (1468_CR403) 2022; 154 P Richardson (1468_CR492) 2020; 395 T Hoey (1468_CR105) 1998; 8 CN Harrison (1468_CR426) 2016; 30 J Panés (1468_CR467) 2017; 66 RL Philips (1468_CR548) 2022; 185 A Chimalakonda (1468_CR534) 2021; 11 D Ellinghaus (1468_CR151) 2012; 90 Y Tanaka (1468_CR185) 2019; 78 DJ Wallace (1468_CR480) 2018; 392 H Fahmideh (1468_CR40) 2022; 2022 K Yamaoka (1468_CR6) 2004; 5 J Sabino (1468_CR556) 2019; 12 JE Boudreau (1468_CR144) 2011; 71 UG Lo (1468_CR164) 2022; 12 W Liao (1468_CR52) 2014; 111 EL Simpson (1468_CR533) 2021; 22 JS Fridman (1468_CR563) 2011; 131 A Mullally (1468_CR235) 2012; 26 R van Vollenhoven (1468_CR265) 2020; 72 JX Di (1468_CR387) 2019; 30 W Mu (1468_CR74) 2022; 296 D Chatterjee (1468_CR165) 2023; 42 J Krueger (1468_CR457) 2016; 137 VY Shi (1468_CR530) 2022; 87 A Goropevšek (1468_CR146) 2017; 52 T Yin (1468_CR46) 1995; 85 M Furqan (1468_CR92) 2013; 6 MC Genovese (1468_CR517) 2016; 75 JF Houthuys (1468_CR436) 2022; 8 HI Hurwitz (1468_CR414) 2015; 33 D Meraviglia-Crivelli (1468_CR327) 2022; 21 E Guttman-Yassky (1468_CR279) 2021; 397 RA Mesa (1468_CR415) 2013; 31 EB Lee (1468_CR205) 2014; 370 C Dethlefsen (1468_CR330) 2013; 138 DW Dodington (1468_CR77) 2018; 29 C Liu (1468_CR311) 2015; 75 Y Zhu (1468_CR325) 2022; 13 ME Liosi (1468_CR70) 2022; 65 H Guo (1468_CR308) 2022; 45 T Zhang (1468_CR94) 2000; 20 WJ Sandborn (1468_CR458) 2014; 12 JT Kwock (1468_CR95) 2020; 6 F Passamonti (1468_CR439) 2014; 123 WJ Sandborn (1468_CR451) 2022; 20 MT Spiotto (1468_CR25) 2000; 42 K Papp (1468_CR256) 2021; 85 H He (1468_CR273) 2019; 20 M Fragiadaki (1468_CR345) 2017; 91 CN Harrison (1468_CR417) 2017; 4 YJ Zhou (1468_CR58) 2001; 8 A Garrido-Trigo (1468_CR505) 2020; 14 MC Runtsch (1468_CR404) 2022; 34 P Xin (1468_CR109) 2020; 80 H Chen (1468_CR103) 2011; 147 H Li (1468_CR305) 2019; 13 RL Siegel (1468_CR314) 2019; 69 RT Chlebowski (1468_CR317) 2005; 97 DE Levy (1468_CR10) 2002; 3 JJ O’Shea (1468_CR16) 2002; 109 A Deodhar (1468_CR524) 2022; 400 RM Fleischmann (1468_CR262) 2019; 78 R Roskoski Jr (1468_CR69) 2022; 183 D Moreira (1468_CR394) 2018; 24 R Bissonnette (1468_CR459) 2016; 175 T Takeuchi (1468_CR187) 2016; 75 XS Hou (1468_CR3) 1997; 13 JJ O’Shea (1468_CR38) 2015; 66 D Gladman (1468_CR454) 2017; 377 C Ma (1468_CR460) 2019; 79 PJ Lupardus (1468_CR60) 2014; 111 F Pastore (1468_CR559) 2020; 10 JG Walker (1468_CR184) 2006; 65 CN Harrison (1468_CR209) 2018; 5 JI Silverberg (1468_CR528) 2020; 156 GM Forbes (1468_CR269) 2022; 175 S Dhillon (1468_CR444) 2017; 77 S Verstovsek (1468_CR441) 2017; 10 B Al-Bawardy (1468_CR564) 2021; 12 DG Cotter (1468_CR250) 2018; 78 M Worm (1468_CR499) 2022; 187 S Sigurdsson (1468_CR150) 2005; 76 F Barahmand-Pour (1468_CR62) 1998; 273 NPD Liau (1468_CR84) 2019; 11 AA Karpov (1468_CR473) 2022; 23 T Arakawa (1468_CR347) 2008; 23 A Rojas (1468_CR26) 2011; 30 W Sheng (1468_CR390) 2014; 24 CN Harrison (1468_CR509) 2020; 95 M Karaghiosoff (1468_CR82) 2000; 13 H Neubauer (1468_CR73) 1998; 93 MD Robek (1468_CR302) 2004; 101 ZK Liu (1468_CR306) 2021; 20 J Liu (1468_CR545) 2020; 11 P Mease (1468_CR466) 2017; 377 D Hanahan (1468_CR168) 2022; 12 SK Uppal (1468_CR288) 2021; 397 YH Kang (1468_CR141) 2019; 10 Y Adachi (1468_CR351) 2022; 82 H Nakagawa (1468_CR504) 2019; 144 S Ständer (1468_CR527) 2022; 36 KA Dorritie (1468_CR93) 2014; 28 SR Kopalli (1468_CR252) 2022; 27 WJ Sandborn (1468_CR452) 2022; 20 A Yoshimura (1468_CR115) 2012; 36 IB McInnes (1468_CR277) 2021; 384 SC Meyer (1468_CR208) 2015; 28 Z Zhao (1468_CR307) 2020; 39 R Rodriguez-Barrueco (1468_CR331) 2015; 29 LB Mora (1468_CR309) 2002; 62 R Rampal (1468_CR223) 2014; 123 LC Tsoi (1468_CR247) 2020; 145 A Tefferi (1468_CR221) 2022; 97 GR Burmester (1468_CR520) 2018; 391 TC van der Pouw Kraan (1468_CR189) 2007; 66 B King (1468_CR487) 2022; 386 R Fleischmann (1468_CR201) 2012; 64 E Rico-Bautista (1468_CR119) 2006; 17 LJ Scott (1468_CR443) 2013; 73 KD Guenterberg (1468_CR358) 2010; 9 P Guha (1468_CR392) 2019; 38 C Liu (1468_CR326) 2023; 66 AV Villarino (1468_CR43) 2017; 18 GR Burmester (1468_CR30) 2013; 381 YX Wang (1468_CR299) 2020; 72 A Marabelle (1468_CR155) 2017; 7 S Verstovsek (1468_CR440) 2017; 10 F Cantini (1468_CR493) 2020; 81 R Mesa (1468_CR207) 2022; 36 AM Drucker (1468_CR244) 2016; 152 SR Ytterberg (1468_CR448) 2022; 386 T Bieber (1468_CR284) 2021; 384 E Guttman-Yassky (1468_CR483) 2019; 80 K Papp (1468_CR193) 2015; 173 JF Colombel (1468_CR461) 2022; 20 J Panés (1468_CR354) 2020; 14 Y Zhao (1468_CR542) 2021; 22 Z Yan (1468_CR132) 2018; 189 R Kralovics (1468_CR226) 2005; 352 VC Marconi (1468_CR490) 2021; 9 JJ O’Shea (1468_CR2) 1997; 7 R Ferrao (1468_CR57) 2017; 8 M Han (1468_CR300) 2017; 147 GG Choudhury (1468_CR47) 1996; 49 H Yang (1468_CR65) 2022; 13 Y Liang (1468_CR122) 2014; 44 C Aul (1468_CR212) 1998; 83 A Casarella (1468_CR344) 2022; 42 TL Lasho (1468_CR240) 2006; 135 R Bitsch (1468_CR377) 2022; 10 SY Lai (1468_CR29) 2010; 13 AV Jones (1468_CR224) 2005; 106 X Hu (1468_CR76) 2021; 6 MB Marrero (1468_CR340) 2006; 290 X Meng (1468_CR547) 2020; 14 SS Onkar (1468_CR313) 2023; 13 K Koike (1468_CR336) 2014; 150 WJ Sandborn (1468_CR271) 2020; 158 TC van der Pouw Kraan (1468_CR183) 2003; 48 VC Marconi (1468_CR442) 2022; 74 M Pang (1468_CR335) 2010; 78 J Bromberg (1468_CR320) 2000; 2 WJ Leonard (1468_CR1) 1998; 16 MJ Kim (1468_CR379) 2013; 335 PC Taylor (1468_CR495) 2019; 71 X Wang (1468_CR339) 2002; 51 JN Ihle (1468_CR17) 1995; 11 B King (1468_CR481) 2021; 85 CM Ahmed (1468_CR407) 2015; 6 L MacDonagh (1468_CR375) 2018; 428 W Zhang (1468_CR562) 2008; 100 M Worm (1468_CR500) 2020; 182 Y Pikman (1468_CR231) 2006; 3 DJ Jonker (1468_CR378) 2018; 3 MJ Welham (1468_CR89) 1995; 270 SR Singh (1468_CR39) 2005; 15 HA Yu (1468_CR162) 2013; 19 JJ Kiladjian (1468_CR416) 2020; 7 EJ Hillmer (1468_CR373) 2016; 31 SM Langan (1468_CR242) 2020; 396 EK Podewski (1468_CR353) 2003; 107 N Stahl (1468_CR87) 1994; 263 Q Sun (1468_CR396) 2022; 184 F Khosrow-Khavar (1468_CR471) 2022; 74 JE Darnell Jr (1468_CR14) 2002; 2 A Rubbert-Roth (1468_CR260) 2020; 383 CM Lin (1468_CR553) 2020; 31 A Bottos (1468_CR332) 2016; 7 PS Changelian (1468_CR350) 2003; 302 C Charles-Schoeman (1468_CR200) 2016; 75 JM Llovet (1468_CR293) 2021; 7 AW Armstrong (1468_CR536) 2023; 88 C Nakashima (1468_CR251) 2022; 71 G Coltro (1468_CR434) 2017; 92 X Guan (1468_CR405) 2023; 189 H You (1468_CR470) 2021; 60 HT Chifotides (1468_CR220) 2022; 15 T Klampfl (1468_CR233) 2013; 369 H Ku (1468_CR238) 1996; 87 M Tian (1468_CR401) 2019; 234 A Yoshimura (1468_CR120) 2007; 7 S Ghosh (1468_CR278) 2021; 15 JN Ihle (1468_CR18) 1994; 19 C Chen (1468_CR199) 2022; 8 A Villanueva (1468_CR290) 2019; 380 A Tefferi (1468_CR210) 2009; 361 C Schindler (1468_CR79) 1995; 64 S Degryse (1468_CR54) 2014; 124 R Roskoski Jr. (1468_CR418) 2020; 152 JJ O’Shea (1468_CR140) 2013; 72 K Beebe (1468_CR163) 2010; 338 C Schindler (1468_CR102) 2007; 282 DE Johnson (1468_CR322) 2018; 15 JN Ihle (1468_CR80) 1995; 13 K Kollmann (1468_CR229) 2017; 31 L Sun (1468_CR167) 2019; 21 N Debili (1468_CR236) 1995; 86 WS Alexander (1468_CR123) 1999; 66 A Jerez (1468_CR20) 2012; 120 SF Altekruse (1468_CR292) 2009; 27 KI Arimoto (1468_CR12) 2017; 24 C Jehanno (1468_CR156) 2022; 32 B Strober (1468_CR537) 2023; 88 MC Gauzzi (1468_CR85) 1997; 94 DC Borie (1468_CR348) 2005; 80 C Liu (1468_CR409) 2021; 73 JS Smolen (1468_CR478) 2017; 76 EL Simpson (1468_CR287) 2020; 396 SS Patel (1468_CR400) 2020; 60 E Lubberts (1468_CR176) 2015; 11 A Cianciulli (1468_CR406) 2017; 37 EM Linossi (1468_CR116) 2021; 12 R Bejar (1468_CR214) 2011; 364 EM Putz (1468_CR142) 2013; 4 K Kaushansky (1468_CR237) 1995; 92 J Hong (1468_CR110) 2022; 82 K Reich (1468_CR254) 2020; 156 M Talpaz (1468_CR561) 2021; 35 Y Qin (1468_CR99) 2022; 81 CS Wu (1468_CR127) 2016; 291 J Wang (1468_CR191) 2020; 84 AC Kalil (1468_CR486) 2021; 384 MC Genovese (1468_CR516) 2016; 68 C Liu (1468_CR312) 2014; 74 JJ O’Shea (1468_CR138) 2013; 368 LF Eichenfield (1468_CR529) 2021; 157 M Palmroth (1468_CR33) 2021; 12 TA Waldmann (1468_CR44) 2017; 35 RM Fleischmann (1468_CR515) 2015; 67 HL Geyer (1468_CR222) 2014; 124 A Tefferi (1468_CR230) 2014; 28 PC Shih (1468_CR113) 2022; 234 U Sengupta (1468_CR341) 2009 |
| References_xml | – ident: CR282 – volume: 5 start-page: 475 year: 2004 end-page: 485 ident: CR298 article-title: Alpha-interferon and its effects on signalling pathways within cells publication-title: Curr. Protein Pept. Sci. doi: 10.2174/1389203043379378 – volume: 87 start-page: 4544 year: 1996 end-page: 4551 ident: CR238 article-title: Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice publication-title: Blood doi: 10.1182/blood.V87.11.4544.bloodjournal87114544 – volume: 10 start-page: 156 year: 2017 ident: CR440 article-title: Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-017-0527-7 – volume: 10 start-page: 1742 year: 2020 end-page: 1757 ident: CR559 article-title: PRMT5 inhibition modulates E2F1 methylation and gene-regulatory networks leading to therapeutic efficacy in JAK2(V617F)-mutant MPN publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-20-0026 – volume: 3 start-page: 1071 year: 2022 end-page: 1087 ident: CR166 article-title: Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance publication-title: Nat. Cancer doi: 10.1038/s43018-022-00431-9 – volume: 266 start-page: 1045 year: 1994 end-page: 1047 ident: CR48 article-title: Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits publication-title: Science doi: 10.1126/science.7973659 – volume: 2 start-page: 740 year: 2002 end-page: 749 ident: CR14 article-title: Transcription factors as targets for cancer therapy publication-title: Nat. Rev. Cancer doi: 10.1038/nrc906 – volume: 24 start-page: 1128 year: 2010 end-page: 1138 ident: CR215 article-title: Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 publication-title: Leukemia doi: 10.1038/leu.2010.69 – volume: 361 start-page: 1872 year: 2009 end-page: 1885 ident: CR210 article-title: Myelodysplastic syndromes publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra0902908 – volume: 81 start-page: 318 year: 2020 end-page: 356 ident: CR493 article-title: Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact publication-title: J. Infect. doi: 10.1016/j.jinf.2020.04.017 – volume: 80 start-page: 1004 year: 2021 end-page: 1013 ident: CR456 article-title: Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2020-219601 – volume: 45 start-page: 1585 year: 2022 end-page: 1599 ident: CR308 article-title: HHLA2 activates the JAK/STAT signaling pathway by binding to TMIGD2 in hepatocellular carcinoma cells publication-title: Inflammation doi: 10.1007/s10753-022-01644-x – volume: 396 start-page: 110 year: 2020 end-page: 120 ident: CR412 article-title: Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial publication-title: Lancet doi: 10.1016/S0140-6736(20)30609-7 – volume: 147 start-page: 75 year: 2017 end-page: 85 ident: CR300 article-title: Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2017.10.003 – volume: 78 start-page: 1320 year: 2019 end-page: 1332 ident: CR185 article-title: Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3) publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2019-215163 – volume: 181 start-page: 399 year: 1995 end-page: 404 ident: CR88 article-title: Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12 publication-title: J. Exp. Med. doi: 10.1084/jem.181.1.399 – volume: 208 start-page: 356 year: 2022 end-page: 366 ident: CR399 article-title: In-silico and in-vitro investigation of STAT3-PIM1 heterodimeric complex: Its mechanism and inhibition by curcumin for cancer therapeutics publication-title: Int. J. Biol. Macromol. doi: 10.1016/j.ijbiomac.2022.03.137 – volume: 7 year: 2017 ident: CR370 article-title: Development of Erasin: a chromone-based STAT3 inhibitor which induces apoptosis in Erlotinib-resistant lung cancer cells publication-title: Sci. Rep. doi: 10.1038/s41598-017-17600-x – volume: 25 start-page: 695 year: 2006 end-page: 697 ident: CR90 article-title: Human tyk2 kinase deficiency: another primary immunodeficiency syndrome publication-title: Immunity doi: 10.1016/j.immuni.2006.10.007 – volume: 3 start-page: 263 year: 2018 end-page: 270 ident: CR378 article-title: Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial publication-title: Lancet Gastroenterol. Hepatol. doi: 10.1016/S2468-1253(18)30009-8 – volume: 33 start-page: 122 year: 2008 end-page: 131 ident: CR21 article-title: Mining for JAK-STAT mutations in cancer publication-title: Trends Biochem. Sci. doi: 10.1016/j.tibs.2007.12.002 – ident: CR294 – volume: 33 start-page: 4039 year: 2015 end-page: 4047 ident: CR414 article-title: Randomized, double-blind, phase ii study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2015.61.4578 – volume: 10 start-page: 55 year: 2017 ident: CR441 article-title: Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-017-0417-z – volume: 87 start-page: 784 year: 2022 end-page: 791 ident: CR263 article-title: Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2022.06.012 – volume: 335 start-page: 145 year: 2013 end-page: 152 ident: CR379 article-title: OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells publication-title: Cancer Lett. doi: 10.1016/j.canlet.2013.02.010 – volume: 17 start-page: 1541 year: 2019 end-page: 1550 ident: CR453 article-title: Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials publication-title: Clin. Gastroenterol. Hepatol. doi: 10.1016/j.cgh.2018.11.035 – volume: 23 start-page: 15646 year: 2022 ident: CR473 article-title: Inhibition of JAK1,2 prevents fibrotic remodeling of pulmonary vascular bed and improves outcomes in the rat model of chronic thromboembolic pulmonary hypertension publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms232415646 – volume: 85 start-page: 863 year: 2021 end-page: 872 ident: CR256 article-title: Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2021.04.085 – volume: 9 start-page: 2415 year: 1994 end-page: 2423 ident: CR8 article-title: JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells publication-title: Oncogene – volume: 13 year: 2022 ident: CR469 article-title: Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis publication-title: Nat. Commun. doi: 10.1038/s41467-022-30615-x – volume: 20 start-page: 400 year: 2020 end-page: 402 ident: CR491 article-title: COVID-19: combining antiviral and anti-inflammatory treatments publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(20)30132-8 – volume: 11 start-page: 613 year: 2002 end-page: 621 ident: CR101 article-title: STAT6 as an asthma candidate gene: polymorphism-screening, association and haplotype analysis in a Caucasian sib-pair study publication-title: Hum. Mol. Genet. doi: 10.1093/hmg/11.6.613 – volume: 428 start-page: 117 year: 2018 end-page: 126 ident: CR375 article-title: BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC publication-title: Cancer Lett. doi: 10.1016/j.canlet.2018.04.008 – volume: 29 start-page: 789 year: 2011 end-page: 796 ident: CR507 article-title: Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.32.8021 – volume: 97 start-page: 439 year: 2005 end-page: 448 ident: CR317 article-title: Ethnicity and breast cancer: factors influencing differences in incidence and outcome publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/dji064 – volume: 66 start-page: 3029 year: 2009 end-page: 3041 ident: CR128 article-title: PIAS proteins: pleiotropic interactors associated with SUMO publication-title: Cell Mol. Life Sci. doi: 10.1007/s00018-009-0061-z – volume: 145 start-page: 877 year: 2020 end-page: 884 ident: CR268 article-title: Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2019.11.025 – volume: 120 start-page: 3048 year: 2012 end-page: 3057 ident: CR20 article-title: STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia publication-title: Blood doi: 10.1182/blood-2012-06-435297 – volume: 30 start-page: 846 year: 2019 end-page: 853 ident: CR387 article-title: C188-9, a small-molecule STAT3 inhibitor, exerts an antitumor effect on head and neck squamous cell carcinoma publication-title: Anticancer Drugs doi: 10.1097/CAD.0000000000000783 – volume: 155 start-page: 1371 year: 2019 end-page: 1379 ident: CR526 article-title: Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial publication-title: JAMA Dermatol. doi: 10.1001/jamadermatol.2019.2855 – volume: 36 start-page: 2261 year: 2022 end-page: 2268 ident: CR207 article-title: Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis publication-title: Leukemia doi: 10.1038/s41375-022-01637-7 – volume: 85 start-page: 62 year: 2021 end-page: 70 ident: CR482 article-title: Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5) publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2021.02.028 – volume: 85 start-page: 847 year: 2021 end-page: 853 ident: CR481 article-title: Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2021.05.050 – volume: 391 start-page: 2503 year: 2018 end-page: 2512 ident: CR520 article-title: Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(18)31115-2 – volume: 145 start-page: 1406 year: 2020 end-page: 1415 ident: CR247 article-title: Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2019.11.047 – volume: 72 start-page: 865 year: 2020 end-page: 876 ident: CR299 article-title: Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication publication-title: J. Hepatol. doi: 10.1016/j.jhep.2019.12.009 – volume: 42 start-page: 112061 year: 2023 ident: CR165 article-title: Cell polarity opposes Jak/STAT-mediated Escargot activation that drives intratumor heterogeneity in a Drosophila tumor model publication-title: Cell Rep. doi: 10.1016/j.celrep.2023.112061 – ident: CR281 – volume: 60 start-page: 41 year: 2020 end-page: 56 ident: CR91 article-title: The potential and controversy of targeting STAT family members in cancer publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2019.10.002 – volume: 264 start-page: 1415 year: 1994 end-page: 1421 ident: CR136 article-title: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins publication-title: Science doi: 10.1126/science.8197455 – volume: 31 start-page: 100 year: 2020 end-page: 104 ident: CR553 article-title: Basic mechanisms of JAK inhibition publication-title: Mediterr. J. Rheumatol. doi: 10.31138/mjr.31.1.100 – volume: 58 start-page: 953 year: 2019 end-page: 962 ident: CR552 article-title: Clinical significance of Janus Kinase inhibitor selectivity publication-title: Rheumatology doi: 10.1093/rheumatology/key339 – volume: 183 start-page: 106359 year: 2022 ident: CR36 article-title: Cardiovascular safety, cancer and Jak-inhibitors: differences to be highlighted publication-title: Pharm. Res. doi: 10.1016/j.phrs.2022.106359 – volume: 30 start-page: 2345 year: 2011 end-page: 2355 ident: CR26 article-title: IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR publication-title: Oncogene doi: 10.1038/onc.2010.605 – volume: 296 start-page: 115507 year: 2022 ident: CR74 article-title: Exploring the protective mechanisms of total tannins from Geum japonicum var. chinense F.Bolle in mice with hematopoietic dysfunction via the JAK2/STAT3/5 signaling pathway publication-title: J. Ethnopharmacol. doi: 10.1016/j.jep.2022.115507 – volume: 182 start-page: 106347 year: 2022 ident: CR550 article-title: Discovery of novel targets in a complex regional pain syndrome mouse model by transcriptomics: TNF and JAK-STAT pathways publication-title: Pharm. Res. doi: 10.1016/j.phrs.2022.106347 – volume: 36 start-page: 157 year: 2012 end-page: 159 ident: CR115 article-title: JAK’s SOCS: a mechanism of inhibition publication-title: Immunity doi: 10.1016/j.immuni.2012.01.010 – volume: 75 start-page: 1293 year: 2016 end-page: 1301 ident: CR200 article-title: Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2014-207178 – ident: CR374 – volume: 8 start-page: 945 year: 2002 end-page: 954 ident: CR368 article-title: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention publication-title: Clin. Cancer Res. – volume: 21 start-page: 1015 year: 2019 end-page: 1026 ident: CR167 article-title: Modelling liver cancer initiation with organoids derived from directly reprogrammed human hepatocytes publication-title: Nat. Cell Biol. doi: 10.1038/s41556-019-0359-5 – volume: 80 start-page: 1756 year: 2005 end-page: 1764 ident: CR348 article-title: Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates publication-title: Transplantation doi: 10.1097/01.tp.0000184634.25042.ea – volume: 14 start-page: 1026 year: 2020 end-page: 1028 ident: CR462 article-title: Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience publication-title: J. Crohns Colitis doi: 10.1093/ecco-jcc/jjaa018 – volume: 19 start-page: 2566 year: 2000 end-page: 2576 ident: CR364 article-title: The role of Stat5a and Stat5b in signaling by IL-2 family cytokines publication-title: Oncogene doi: 10.1038/sj.onc.1203523 – volume: 399 start-page: 2113 year: 2022 end-page: 2128 ident: CR525 article-title: Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials publication-title: Lancet doi: 10.1016/S0140-6736(22)00581-5 – volume: 81 start-page: 335 year: 2022 end-page: 343 ident: CR476 article-title: Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2021-221276 – volume: 20 start-page: 7132 year: 2000 end-page: 7139 ident: CR94 article-title: The coiled-coil domain of Stat3 is essential for its SH2 domain-mediated receptor binding and subsequent activation induced by epidermal growth factor and interleukin-6 publication-title: Mol. Cell Biol. doi: 10.1128/MCB.20.19.7132-7139.2000 – volume: 31 start-page: 393 year: 2017 end-page: 402 ident: CR35 article-title: A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis publication-title: Leukemia doi: 10.1038/leu.2016.215 – volume: 39 start-page: 259 year: 2020 ident: CR307 article-title: CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2/STAT3 signaling pathway publication-title: J. Exp. Clin. Cancer Res. doi: 10.1186/s13046-020-01769-7 – volume: 9 start-page: 1407 year: 2021 end-page: 1418 ident: CR490 article-title: Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(21)00331-3 – volume: 59 start-page: 229 year: 2020 end-page: 233 ident: CR472 article-title: Long-term effects of the janus kinase 1/2 inhibitor ruxolitinib on pulmonary hypertension and the cardiac function in a patient with myelofibrosis publication-title: Intern. Med. doi: 10.2169/internalmedicine.3528-19 – volume: 182 start-page: 106357 year: 2022 ident: CR398 article-title: Inhibiting STAT3 signaling pathway by natural products for cancer prevention and therapy: In vitro and in vivo activity and mechanisms of action publication-title: Pharm. Res. doi: 10.1016/j.phrs.2022.106357 – volume: 80 start-page: 609 year: 2020 end-page: 615 ident: CR498 article-title: Delgocitinib: first approval publication-title: Drugs doi: 10.1007/s40265-020-01291-2 – volume: 97 start-page: 1507 year: 2022 end-page: 1509 ident: CR544 article-title: Jaktinib (JAK1/2 inhibitor): a momelotinib derivative with similar activity and optimized dosing schedule publication-title: Am. J. Hematol. doi: 10.1002/ajh.26712 – volume: 73 start-page: 857 year: 2013 end-page: 874 ident: CR443 article-title: Tofacitinib: a review of its use in adult patients with rheumatoid arthritis publication-title: Drugs doi: 10.1007/s40265-013-0065-8 – volume: 11 start-page: 1701 year: 2019 ident: CR84 article-title: Enzymatic characterization of wild-type and mutant janus kinase 1 publication-title: Cancers (Basel) doi: 10.3390/cancers11111701 – volume: 369 start-page: 2391 year: 2013 end-page: 2405 ident: CR232 article-title: Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1312542 – volume: 77 start-page: 5701 year: 2017 end-page: 5705 ident: CR129 article-title: Therapeutic targeting of oncogenic tyrosine phosphatases publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-1510 – volume: 23 start-page: 701 year: 2011 end-page: 712 ident: CR181 article-title: IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis publication-title: Int. Immunol. doi: 10.1093/intimm/dxr077 – volume: 383 start-page: 1358 year: 2020 end-page: 1374 ident: CR213 article-title: Myelodysplastic syndromes publication-title: N. Engl. J. Med doi: 10.1056/NEJMra1904794 – volume: 12 start-page: 651415 year: 2021 ident: CR564 article-title: Novel and emerging therapies for inflammatory bowel disease publication-title: Front. Pharm. doi: 10.3389/fphar.2021.651415 – volume: 88 start-page: 40 year: 2023 end-page: 51 ident: CR537 article-title: Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2022.08.061 – volume: 75 start-page: 242 year: 2023 end-page: 252 ident: CR538 article-title: Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase ii, randomized, double-blind, placebo-controlled trial publication-title: Arthritis Rheumatol. doi: 10.1002/art.42391 – volume: 137 start-page: 1079 year: 2016 end-page: 1090 ident: CR457 article-title: Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2015.12.1318 – volume: 141 start-page: 481 year: 2023 end-page: 489 ident: CR518 article-title: Effective treatment of low-risk acute GVHD with itacitinib monotherapy publication-title: Blood doi: 10.1182/blood.2022017442 – volume: 189 start-page: 4 year: 2018 end-page: 13 ident: CR132 article-title: Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases publication-title: Clin. Immunol. doi: 10.1016/j.clim.2016.09.014 – volume: 42 start-page: 629 year: 2022 end-page: 640 ident: CR344 article-title: Autosomic dominant polycystic kidney disease and metformin: old knowledge and new insights on retarding progression of chronic kidney disease publication-title: Med. Res. Rev. doi: 10.1002/med.21850 – ident: CR464 – volume: 173 start-page: 767 year: 2015 end-page: 776 ident: CR193 article-title: A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis publication-title: Br. J. Dermatol. doi: 10.1111/bjd.13745 – volume: 20 year: 2021 ident: CR306 article-title: EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK/STAT signaling publication-title: Mol. Cancer doi: 10.1186/s12943-021-01377-9 – volume: 13 start-page: 23 year: 2023 end-page: 40 ident: CR313 article-title: The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-22-0475 – volume: 99 start-page: 1331 year: 2021 end-page: 1341 ident: CR479 article-title: A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Fas(lpr) mice with proliferative lupus nephritis predicts low effect size publication-title: Kidney Int. doi: 10.1016/j.kint.2021.01.024 – volume: 85 start-page: 3101 year: 1995 end-page: 3106 ident: CR46 article-title: Tyrosine phosphorylation and activation of JAK family tyrosine kinases by interleukin-9 in MO7E cells publication-title: Blood doi: 10.1182/blood.V85.11.3101.bloodjournal85113101 – volume: 27 start-page: 136 year: 2018 end-page: 150.e135 ident: CR323 article-title: JAK/STAT3-regulated fatty acid β-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance publication-title: Cell Metab. doi: 10.1016/j.cmet.2017.11.001 – volume: 12 start-page: 31 year: 2022 end-page: 46 ident: CR168 article-title: Hallmarks of cancer: new dimensions publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-21-1059 – volume: 291 start-page: 279 year: 2016 end-page: 290 ident: CR127 article-title: The SUMO (small ubiquitin-like modifier) ligase PIAS3 primes ATR for checkpoint activation publication-title: J. Biol. Chem. doi: 10.1074/jbc.M115.691170 – volume: 78 start-page: 1454 year: 2019 end-page: 1462 ident: CR262 article-title: Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2019-215764 – volume: 158 start-page: 2139 year: 2020 end-page: 2149.e2114 ident: CR270 article-title: Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis publication-title: Gastroenterology doi: 10.1053/j.gastro.2020.02.030 – volume: 4 start-page: 437 year: 2013 end-page: 444 ident: CR142 article-title: CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance publication-title: Cell Rep. doi: 10.1016/j.celrep.2013.07.012 – volume: 14 start-page: 161 year: 2020 end-page: 167 ident: CR547 article-title: Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19 publication-title: Biosci. Trends doi: 10.5582/bst.2020.03106 – volume: 183 start-page: 242 year: 2020 end-page: 255 ident: CR255 article-title: Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials publication-title: Br. J. Dermatol. doi: 10.1111/bjd.18898 – volume: 111 start-page: 3508 year: 2014 end-page: 3513 ident: CR52 article-title: Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1301138111 – volume: 13 year: 2022 ident: CR72 article-title: Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm publication-title: Nat. Commun. doi: 10.1038/s41467-022-32928-3 – volume: 72 start-page: 1607 year: 2020 end-page: 1620 ident: CR265 article-title: Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial publication-title: Arthritis Rheumatol. doi: 10.1002/art.41384 – volume: 91 start-page: 575 year: 2017 end-page: 586 ident: CR345 article-title: STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease publication-title: Kidney Int doi: 10.1016/j.kint.2016.10.039 – volume: 63 start-page: 233 year: 2004 end-page: 239 ident: CR182 article-title: Activation of the STAT1 pathway in rheumatoid arthritis publication-title: Ann. Rheum. Dis. doi: 10.1136/ard.2003.013276 – volume: 92 start-page: 3234 year: 1995 end-page: 3238 ident: CR237 article-title: Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.92.8.3234 – volume: 40 start-page: 65 year: 2020 end-page: 72 ident: CR497 article-title: Comparative efficacy and safety of peficitinib 25, 50, 100, and 150 mg in patients with active rheumatoid arthritis: a bayesian network meta-analysis of randomized controlled trials publication-title: Clin. Drug Investig. doi: 10.1007/s40261-019-00863-9 – volume: 14 start-page: S713 year: 2020 end-page: s724 ident: CR505 article-title: Molecular structure and function of janus kinases: implications for the development of inhibitors publication-title: J. Crohns Colitis doi: 10.1093/ecco-jcc/jjz206 – volume: 183 start-page: 106362 year: 2022 ident: CR69 article-title: Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders publication-title: Pharm. Res. doi: 10.1016/j.phrs.2022.106362 – volume: 26 start-page: 998 year: 2015 end-page: 1005 ident: CR383 article-title: Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies publication-title: Ann. Oncol. doi: 10.1093/annonc/mdv026 – volume: 78 start-page: 257 year: 2010 end-page: 268 ident: CR335 article-title: A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy publication-title: Kidney Int. doi: 10.1038/ki.2010.154 – volume: 7 start-page: 1958 year: 2019 end-page: 1969.e1959 ident: CR153 article-title: Clinical aspects of STAT3 gain-of-function germline mutations: a systematic review publication-title: J. Allergy Clin. Immunol. Pr. doi: 10.1016/j.jaip.2019.02.018 – volume: 82 start-page: 843 year: 2022 end-page: 853 ident: CR246 article-title: New topical therapies in development for atopic dermatitis publication-title: Drugs doi: 10.1007/s40265-022-01722-2 – volume: 69 start-page: 7 year: 2019 end-page: 34 ident: CR314 article-title: Cancer statistics, 2019 publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21551 – volume: 55 start-page: 1047 year: 2012 end-page: 1055 ident: CR369 article-title: Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity publication-title: J. Med Chem. doi: 10.1021/jm200720n – volume: 282 start-page: 20059 year: 2007 end-page: 20063 ident: CR102 article-title: JAK-STAT signaling: from interferons to cytokines publication-title: J. Biol. Chem. doi: 10.1074/jbc.R700016200 – volume: 77 start-page: 521 year: 2017 end-page: 546 ident: CR42 article-title: JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects publication-title: Drugs doi: 10.1007/s40265-017-0701-9 – volume: 185 start-page: 351 year: 1997 end-page: 356 ident: CR50 article-title: Crucial role of Jak3 in negative selection of self-reactive T cells publication-title: J. Exp. Med. doi: 10.1084/jem.185.2.351 – volume: 12 start-page: 1485 year: 2014 end-page: 1493.e1482 ident: CR458 article-title: A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease publication-title: Clin. Gastroenterol. Hepatol. doi: 10.1016/j.cgh.2014.01.029 – volume: 9 start-page: 997 year: 2015 end-page: 1007 ident: CR554 article-title: Early phase clinical trials to identify optimal dosing and safety publication-title: Mol. Oncol. doi: 10.1016/j.molonc.2014.07.025 – volume: 74 start-page: 201 year: 2014 end-page: 209 ident: CR312 article-title: Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells publication-title: Prostate doi: 10.1002/pros.22741 – volume: 71 start-page: 892 year: 2019 end-page: 900 ident: CR37 article-title: Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an observational cohort study publication-title: Arthritis Rheumatol. doi: 10.1002/art.40798 – volume: 5 year: 2004 ident: CR6 article-title: The Janus kinases (Jaks) publication-title: Genome Biol. doi: 10.1186/gb-2004-5-12-253 – volume: 11 start-page: 42 year: 2018 ident: CR427 article-title: Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-018-0585-5 – volume: 2022 start-page: 7838583 year: 2022 ident: CR40 article-title: The role of natural products as inhibitors of JAK/STAT signaling pathways in glioblastoma treatment publication-title: Oxid. Med Cell Longev. doi: 10.1155/2022/7838583 – volume: 75 start-page: 572 year: 2021 end-page: 581 ident: CR145 article-title: An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs publication-title: J. Hepatol. doi: 10.1016/j.jhep.2021.04.055 – volume: 302 start-page: 875 year: 2003 end-page: 878 ident: CR350 article-title: Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor publication-title: Science doi: 10.1126/science.1087061 – volume: 111 start-page: 8025 year: 2014 end-page: 8030 ident: CR60 article-title: Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1401180111 – volume: 60 start-page: 1895 year: 2009 end-page: 1905 ident: CR450 article-title: The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo publication-title: Arthritis Rheum. doi: 10.1002/art.24567 – volume: 9 start-page: 510 year: 2010 end-page: 520 ident: CR358 article-title: Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-09-0461 – volume: 15 start-page: 234 year: 2018 end-page: 248 ident: CR322 article-title: Targeting the IL-6/JAK/STAT3 signalling axis in cancer publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2018.8 – volume: 24 start-page: 279 year: 2017 end-page: 289 ident: CR12 article-title: STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling publication-title: Nat. Struct. Mol. Biol. doi: 10.1038/nsmb.3378 – volume: 6 start-page: 368 year: 2016 end-page: 381 ident: CR234 article-title: Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-15-1434 – volume: 135 start-page: 1739 year: 2020 end-page: 1749 ident: CR437 article-title: Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial publication-title: Blood doi: 10.1182/blood.2020004823 – volume: 20 year: 2020 ident: CR304 article-title: Prognostic significance of SOCS1 and SOCS3 tumor suppressors and oncogenic signaling pathway genes in hepatocellular carcinoma publication-title: BMC Cancer doi: 10.1186/s12885-020-07285-3 – volume: 16 start-page: 293 year: 1998 end-page: 322 ident: CR1 article-title: Jaks and STATs: biological implications publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev.immunol.16.1.293 – volume: 376 start-page: 163 year: 2022 end-page: 169 ident: CR56 article-title: Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation publication-title: Science doi: 10.1126/science.abn8933 – volume: 42 start-page: 4389 year: 2021 end-page: 4400 ident: CR108 article-title: The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehab447 – ident: CR468 – volume: 35 start-page: 3844 year: 2017 end-page: 3850 ident: CR206 article-title: SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naïve patients with myelofibrosis publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2017.73.4418 – volume: 372 start-page: 426 year: 2015 end-page: 435 ident: CR419 article-title: Ruxolitinib versus standard therapy for the treatment of polycythemia vera publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1409002 – volume: 78 start-page: 1305 year: 2019 end-page: 1319 ident: CR186 article-title: Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2019-215164 – volume: 1 start-page: 643 year: 2015 end-page: 651 ident: CR508 article-title: Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2015.1590 – volume: 37 start-page: 67 year: 2017 end-page: 79 ident: CR406 article-title: Understanding the role of SOCS signaling in neurodegenerative diseases: current and emerging concepts publication-title: Cytokine Growth Factor Rev. doi: 10.1016/j.cytogfr.2017.07.005 – volume: 393 start-page: 2303 year: 2019 end-page: 2311 ident: CR523 article-title: Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study publication-title: Lancet doi: 10.1016/S0140-6736(19)30419-2 – volume: 4 start-page: 406 year: 2021 ident: CR55 article-title: Endothelial Jak3 expression enhances pro-hematopoietic angiocrine function in mice publication-title: Commun. Biol. doi: 10.1038/s42003-021-01846-3 – volume: 380 start-page: 1450 year: 2019 end-page: 1462 ident: CR290 article-title: Hepatocellular carcinoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra1713263 – volume: 175 start-page: 902 year: 2016 end-page: 911 ident: CR459 article-title: Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial publication-title: Br. J. Dermatol. doi: 10.1111/bjd.14871 – volume: 29 start-page: 1069 year: 2010 end-page: 1080 ident: CR59 article-title: Structure of a double ubiquitin-like domain in the talin head: a role in integrin activation publication-title: EMBO J. doi: 10.1038/emboj.2010.4 – volume: 79 start-page: 1819 year: 2019 end-page: 1828 ident: CR521 article-title: Upadacitinib: first approval publication-title: Drugs doi: 10.1007/s40265-019-01211-z – volume: 124 start-page: 3529 year: 2014 end-page: 3537 ident: CR222 article-title: Therapy for myeloproliferative neoplasms: when, which agent, and how? publication-title: Blood doi: 10.1182/blood-2014-05-577635 – volume: 14 start-page: S711 year: 2020 end-page: s712 ident: CR354 article-title: JAK inhibitors: back to small molecules for the treatment of IBD publication-title: J. Crohns Colitis doi: 10.1093/ecco-jcc/jjaa109 – volume: 366 start-page: 799 year: 2012 end-page: 807 ident: CR420 article-title: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1110557 – volume: 78 start-page: S53 year: 2018 end-page: s62 ident: CR250 article-title: Emerging therapies for atopic dermatitis: JAK inhibitors publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2017.12.019 – volume: 20 start-page: 1408 year: 2022 end-page: 1410.e1402 ident: CR429 article-title: Ruxolitinib: targeted approach for treatment of autoinflammatory very early onset inflammatory bowel disease publication-title: Clin. Gastroenterol. Hepatol. doi: 10.1016/j.cgh.2021.07.040 – volume: 10 start-page: e3222 year: 2022 ident: CR532 article-title: Magnitude and time course of response to abrocitinib for moderate-to-severe atopic dermatitis publication-title: J. Allergy Clin. Immunol. Pract. doi: 10.1016/j.jaip.2022.08.042 – volume: 97 start-page: 1510 year: 2022 end-page: 1519 ident: CR546 article-title: Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: results of a phase II trial publication-title: Am. J. Hematol. doi: 10.1002/ajh.26709 – volume: 135 start-page: 683 year: 2006 end-page: 687 ident: CR240 article-title: Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time publication-title: Br. J. Haematol. doi: 10.1111/j.1365-2141.2006.06348.x – volume: 4 start-page: eaat3834 year: 2018 ident: CR435 article-title: Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis publication-title: Sci. Adv. doi: 10.1126/sciadv.aat3834 – volume: 4 start-page: e8100 year: 2009 ident: CR341 article-title: Expression-based network biology identifies alteration in key regulatory pathways of type 2 diabetes and associated risk/complications publication-title: PLoS One doi: 10.1371/journal.pone.0008100 – volume: 277 start-page: 1630 year: 1997 end-page: 1635 ident: CR11 article-title: STATs and gene regulation publication-title: Science doi: 10.1126/science.277.5332.1630 – volume: 23 start-page: 5537 year: 2017 end-page: 5546 ident: CR386 article-title: Multifunctional effects of a small-molecule STAT3 inhibitor on NASH and hepatocellular carcinoma in mice publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-2253 – volume: 12 start-page: 738481 year: 2021 ident: CR33 article-title: Tofacitinib suppresses several JAK-STAT pathways in rheumatoid arthritis in vivo and baseline signaling profile associates with treatment response publication-title: Front. Immunol. doi: 10.3389/fimmu.2021.738481 – volume: 423 start-page: 356 year: 2003 end-page: 361 ident: CR170 article-title: Evolving concepts of rheumatoid arthritis publication-title: Nature doi: 10.1038/nature01661 – volume: 367 start-page: 508 year: 2012 end-page: 519 ident: CR202 article-title: Tofacitinib or adalimumab versus placebo in rheumatoid arthritis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1112072 – volume: 175 start-page: Jc113 year: 2022 ident: CR269 article-title: In active UC, upadacitinib induced and maintained remission publication-title: Ann. Intern. Med. doi: 10.7326/J22-0073 – volume: 7 start-page: 1 year: 1997 end-page: 11 ident: CR2 article-title: Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? publication-title: Immunity doi: 10.1016/S1074-7613(00)80505-1 – volume: 30 start-page: 764 year: 2020 end-page: 776 ident: CR158 article-title: EMT, MET, plasticity, and tumor metastasis publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2020.07.003 – volume: 397 start-page: 2151 year: 2021 end-page: 2168 ident: CR279 article-title: Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials publication-title: Lancet doi: 10.1016/S0140-6736(21)00588-2 – volume: 44 start-page: 1265 year: 2014 end-page: 1275 ident: CR122 article-title: SOCS signaling in autoimmune diseases: molecular mechanisms and therapeutic implications publication-title: Eur. J. Immunol. doi: 10.1002/eji.201344369 – volume: 35 start-page: 1365 year: 2021 end-page: 1379 ident: CR154 article-title: Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia publication-title: Leukemia doi: 10.1038/s41375-021-01231-3 – volume: 461 start-page: 819 year: 2009 end-page: 822 ident: CR218 article-title: JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin publication-title: Nature doi: 10.1038/nature08448 – volume: 193 start-page: 114760 year: 2021 ident: CR28 article-title: Targeting the JAK-STAT pathway in autoimmune diseases and cancers: a focus on molecular mechanisms and therapeutic potential publication-title: Biochem. Pharm. doi: 10.1016/j.bcp.2021.114760 – volume: 57 start-page: 1838 year: 2018 end-page: 1850 ident: CR388 article-title: Role of STAT3 in skin fibrosis and transforming growth factor beta signalling publication-title: Rheumatology doi: 10.1093/rheumatology/kex347 – volume: 386 start-page: 316 year: 2022 end-page: 326 ident: CR448 article-title: Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2109927 – volume: 83 start-page: 525 year: 2016 end-page: 532 ident: CR540 article-title: JAK1-STAT3 blockade by JAK inhibitor SHR0302 attenuates inflammatory responses of adjuvant-induced arthritis rats and decreases Th17 and total B cells publication-title: Jt. Bone Spine doi: 10.1016/j.jbspin.2015.09.002 – volume: 273 start-page: 12567 year: 1998 end-page: 12575 ident: CR62 article-title: Jak2-Stat5 interactions analyzed in yeast publication-title: J. Biol. Chem. doi: 10.1074/jbc.273.20.12567 – volume: 81 start-page: 1358 year: 2022 end-page: 1366 ident: CR195 article-title: Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2022-222586 – volume: 25 start-page: 745 year: 2006 end-page: 755 ident: CR9 article-title: Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity publication-title: Immunity doi: 10.1016/j.immuni.2006.09.009 – volume: 42 start-page: 186 year: 2000 end-page: 195 ident: CR25 article-title: STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells publication-title: Prostate doi: 10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E – volume: 2 start-page: 86 year: 2000 end-page: 90 ident: CR320 article-title: Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development publication-title: Breast Cancer Res. doi: 10.1186/bcr38 – volume: 34 start-page: 555 year: 2019 end-page: 568 ident: CR157 article-title: Causes and consequences of phenotypic plasticity in complex environments publication-title: Trends Ecol. Evol. doi: 10.1016/j.tree.2019.02.010 – volume: 67 start-page: 334 year: 2015 end-page: 343 ident: CR515 article-title: A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis publication-title: Arthritis Rheumatol. doi: 10.1002/art.38949 – volume: 442 start-page: 130083 year: 2023 ident: CR96 article-title: Fate and PPARγ and STATs-driven effects of the mitochondrial complex I inhibitor tebufenpyrad in liver cells revealed with multi-omics publication-title: J. Hazard Mater. doi: 10.1016/j.jhazmat.2022.130083 – volume: 387 start-page: 917 year: 1997 end-page: 921 ident: CR121 article-title: A family of cytokine-inducible inhibitors of signalling publication-title: Nature doi: 10.1038/43206 – volume: 902 start-page: 174121 year: 2021 ident: CR342 article-title: JAK/STAT pathway promotes the progression of diabetic kidney disease via autophagy in podocytes publication-title: Eur. J. Pharm. doi: 10.1016/j.ejphar.2021.174121 – volume: 13 start-page: 932240 year: 2022 ident: CR34 article-title: Baricitinib therapy response in rheumatoid arthritis patients associates to STAT1 phosphorylation in monocytes publication-title: Front. Immunol. doi: 10.3389/fimmu.2022.932240 – volume: 19 start-page: 2240 year: 2013 end-page: 2247 ident: CR162 article-title: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-2246 – ident: CR257 – volume: 13 start-page: 549 year: 2000 end-page: 560 ident: CR82 article-title: Partial impairment of cytokine responses in Tyk2-deficient mice publication-title: Immunity doi: 10.1016/S1074-7613(00)00054-6 – volume: 395 start-page: e30 year: 2020 end-page: e31 ident: CR492 article-title: Baricitinib as potential treatment for 2019-nCoV acute respiratory disease publication-title: Lancet doi: 10.1016/S0140-6736(20)30304-4 – volume: 77 start-page: 1987 year: 2017 end-page: 2001 ident: CR444 article-title: Tofacitinib: a review in rheumatoid arthritis publication-title: Drugs doi: 10.1007/s40265-017-0835-9 – volume: 11 start-page: 179 year: 1997 end-page: 186 ident: CR363 article-title: Stat5a is mandatory for adult mammary gland development and lactogenesis publication-title: Genes Dev. doi: 10.1101/gad.11.2.179 – volume: 14 start-page: 854 year: 1995 end-page: 855 ident: CR366 article-title: Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response publication-title: EMBO J. doi: 10.1002/j.1460-2075.1995.tb07064.x – volume: 22 start-page: 693 year: 2021 end-page: 707 ident: CR533 article-title: Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program publication-title: Am. J. Clin. Dermatol. doi: 10.1007/s40257-021-00618-3 – volume: 94 start-page: 11839 year: 1997 end-page: 11844 ident: CR85 article-title: The amino-terminal region of Tyk2 sustains the level of interferon alpha receptor 1, a component of the interferon alpha/beta receptor publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.94.22.11839 – volume: 376 start-page: 652 year: 2017 end-page: 662 ident: CR485 article-title: Baricitinib versus placebo or adalimumab in rheumatoid arthritis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1608345 – volume: 38 start-page: 533 year: 2019 end-page: 548 ident: CR392 article-title: STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells publication-title: Oncogene doi: 10.1038/s41388-018-0449-z – volume: 123 start-page: 2157 year: 2014 end-page: 2160 ident: CR438 article-title: Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study publication-title: Blood doi: 10.1182/blood-2013-11-536557 – volume: 5 year: 2015 ident: CR510 article-title: A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis publication-title: Blood Cancer J. doi: 10.1038/bcj.2015.63 – volume: 76 start-page: 998 year: 2017 end-page: 1008 ident: CR196 article-title: Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1) publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2016-210104 – volume: 10 start-page: 212 year: 2019 ident: CR555 article-title: Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1PR agonists publication-title: Front. Pharm. doi: 10.3389/fphar.2019.00212 – volume: 71 start-page: 209 year: 2021 end-page: 249 ident: CR291 article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21660 – volume: 366 start-page: 1905 year: 2012 end-page: 1913 ident: CR19 article-title: Somatic STAT3 mutations in large granular lymphocytic leukemia publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1114885 – volume: 322 start-page: 315 year: 2019 end-page: 325 ident: CR177 article-title: Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial publication-title: Jama doi: 10.1001/jama.2019.9055 – volume: 97 start-page: E433 year: 2022 end-page: e435 ident: CR221 article-title: Momelotinib for myelofibrosis: 12-year survival data and retrospective comparison to ruxolitinib publication-title: Am. J. Hematol. doi: 10.1002/ajh.26714 – volume: 48 start-page: 2132 year: 2003 end-page: 2145 ident: CR183 article-title: Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues publication-title: Arthritis Rheum. doi: 10.1002/art.11096 – volume: 365 start-page: 1455 year: 2011 end-page: 1457 ident: CR425 article-title: Long-term outcome of treatment with ruxolitinib in myelofibrosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc1109555 – volume: 31 start-page: 934 year: 2017 end-page: 944 ident: CR229 article-title: A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation publication-title: Leukemia doi: 10.1038/leu.2016.280 – volume: 188 start-page: 106630 year: 2023 ident: CR397 article-title: Mangosteen for malignancy prevention and intervention: current evidence, molecular mechanisms, and future perspectives publication-title: Pharm. Res. doi: 10.1016/j.phrs.2022.106630 – volume: 131 start-page: 1838 year: 2011 end-page: 1844 ident: CR563 article-title: Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation publication-title: J. Invest. Dermatol. doi: 10.1038/jid.2011.140 – volume: 9 year: 2018 ident: CR118 article-title: The molecular basis of JAK/STAT inhibition by SOCS1 publication-title: Nat. Commun. doi: 10.1038/s41467-018-04013-1 – volume: 15 year: 2017 ident: CR126 article-title: The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells publication-title: Cell Commun. Signal. doi: 10.1186/s12964-017-0177-y – volume: 369 start-page: 2379 year: 2013 end-page: 2390 ident: CR233 article-title: Somatic mutations of calreticulin in myeloproliferative neoplasms publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1311347 – volume: 156 start-page: 1333 year: 2020 end-page: 1343 ident: CR254 article-title: Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial publication-title: JAMA Dermatol. doi: 10.1001/jamadermatol.2020.3260 – volume: 21 start-page: 1754 year: 2002 end-page: 1763 ident: CR15 article-title: Regulated nuclear import of the STAT1 transcription factor by direct binding of importin-alpha publication-title: EMBO J. doi: 10.1093/emboj/21.7.1754 – volume: 51 start-page: 3505 year: 2002 end-page: 3509 ident: CR339 article-title: Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronectin synthesis in mesangial cells publication-title: Diabetes doi: 10.2337/diabetes.51.12.3505 – volume: 60 start-page: 2472 year: 2021 end-page: 2477 ident: CR470 article-title: Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis publication-title: Rheumatology doi: 10.1093/rheumatology/keaa613 – volume: 266 start-page: 1042 year: 1994 end-page: 1045 ident: CR49 article-title: Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID publication-title: Science doi: 10.1126/science.7973658 – volume: 43 start-page: 424 year: 2022 end-page: 436 ident: CR506 article-title: Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease publication-title: Trends Pharm. Sci. doi: 10.1016/j.tips.2022.02.008 – volume: 86 start-page: 104 year: 2022 end-page: 112 ident: CR285 article-title: Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN phase 3 trial publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2021.05.075 – volume: 3 start-page: 651 year: 2002 end-page: 662 ident: CR10 article-title: Stats: transcriptional control and biological impact publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/nrm909 – volume: 26 start-page: 88 year: 2014 end-page: 96 ident: CR360 article-title: A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy publication-title: Semin. Immunol. doi: 10.1016/j.smim.2014.01.009 – volume: 41 start-page: 837 year: 2014 end-page: 852 ident: CR449 article-title: Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies publication-title: J. Rheumatol. doi: 10.3899/jrheum.130683 – ident: CR316 – volume: 263 start-page: 92 year: 1994 end-page: 95 ident: CR87 article-title: Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components publication-title: Science doi: 10.1126/science.8272873 – volume: 79 start-page: 791 year: 2005 end-page: 801 ident: CR349 article-title: Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates publication-title: Transplantation doi: 10.1097/01.TP.0000157117.30290.6F – volume: 81 start-page: 647 year: 2020 end-page: 679 ident: CR494 article-title: Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study publication-title: J. Infect. doi: 10.1016/j.jinf.2020.06.052 – volume: 90 start-page: 636 year: 2012 end-page: 647 ident: CR151 article-title: Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci publication-title: Am. J. Hum. Genet. doi: 10.1016/j.ajhg.2012.02.020 – volume: 18 start-page: 971 year: 2011 end-page: 976 ident: CR225 article-title: The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling publication-title: Nat. Struct. Mol. Biol. doi: 10.1038/nsmb.2099 – volume: 140 start-page: 2076 year: 2022 end-page: 2090 ident: CR98 article-title: Leukemia inhibitory factor protects against graft-versus-host disease while preserving graft-versus-leukemia activity publication-title: Blood doi: 10.1182/blood.2022015677 – volume: 18 start-page: 545 year: 2008 end-page: 551 ident: CR107 article-title: Canonical and non-canonical JAK-STAT signaling publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2008.08.008 – volume: 6 start-page: 183 year: 2015 ident: CR407 article-title: SOCS1 mimetics and antagonists: a complementary approach to positive and negative regulation of immune function publication-title: Front. Immunol. doi: 10.3389/fimmu.2015.00183 – volume: 127 start-page: 2391 year: 2016 end-page: 2405 ident: CR228 article-title: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia publication-title: Blood doi: 10.1182/blood-2016-03-643544 – ident: CR280 – volume: 25 start-page: 101076 year: 2019 ident: CR381 article-title: Metabolic reprogramming of oncogene-addicted cancer cells to OXPHOS as a mechanism of drug resistance publication-title: Redox Biol. doi: 10.1016/j.redox.2018.101076 – volume: 9 start-page: 2504 year: 2018 ident: CR130 article-title: Protein tyrosine phosphatases: regulators of CD4 T cells in inflammatory bowel disease publication-title: Front. Immunol. doi: 10.3389/fimmu.2018.02504 – volume: 11 start-page: 604314 year: 2020 ident: CR545 article-title: A phase i, randomized, double-blind, placebo-controlled, single ascending dose, multiple ascending dose and food effect study to evaluate the tolerance, pharmacokinetics of jaktinib, a new selective janus kinase inhibitor in healthy chinese volunteers publication-title: Front. Pharm. doi: 10.3389/fphar.2020.604314 – volume: 81 start-page: 1515 year: 2022 end-page: 1523 ident: CR275 article-title: Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial publication-title: Ann. Rheum. Dis. doi: 10.1136/ard-2022-222608 – volume: 33 start-page: 29 year: 2018 end-page: 43.e27 ident: CR558 article-title: Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms publication-title: Cancer Cell doi: 10.1016/j.ccell.2017.11.009 – volume: 110 start-page: 102400 year: 2020 ident: CR172 article-title: The etiology of rheumatoid arthritis publication-title: J. Autoimmun. doi: 10.1016/j.jaut.2019.102400 – ident: CR23 – volume: 377 start-page: 1180 year: 2022 end-page: 1191 ident: CR31 article-title: Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling publication-title: Science doi: 10.1126/science.abn0478 – volume: 12 start-page: 1158 year: 2018 end-page: 1169 ident: CR194 article-title: Peficitinib, an oral janus kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomised, phase 2 study publication-title: J. Crohns Colitis doi: 10.1093/ecco-jcc/jjy085 – volume: 109 start-page: S121 year: 2002 end-page: S131 ident: CR16 article-title: Cytokine signaling in 2002: new surprises in the Jak/Stat pathway publication-title: Cell doi: 10.1016/S0092-8674(02)00701-8 – volume: 69 start-page: 709 year: 2017 end-page: 719 ident: CR192 article-title: Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate publication-title: Arthritis Rheumatol. doi: 10.1002/art.39955 – volume: 82 start-page: 292 year: 2022 end-page: 306 ident: CR351 article-title: Inhibition of FGFR reactivates IFNγ signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-20-2426 – volume: 15 start-page: 2022 year: 2021 end-page: 2030 ident: CR278 article-title: Upadacitinib treatment improves symptoms of bowel urgency and abdominal pain, and correlates with quality of life improvements in patients with moderate to severe ulcerative colitis publication-title: J. Crohns Colitis doi: 10.1093/ecco-jcc/jjab099 – volume: 88 start-page: 29 year: 2023 end-page: 39 ident: CR536 article-title: Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2022.07.002 – volume: 384 start-page: 1101 year: 2021 end-page: 1112 ident: CR284 article-title: Abrocitinib versus placebo or dupilumab for atopic dermatitis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2019380 – volume: 116 start-page: 12442 year: 2019 end-page: 12451 ident: CR333 article-title: JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1816410116 – volume: 78 start-page: 890 year: 2019 end-page: 898 ident: CR477 article-title: Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2018-214529 – volume: 113 start-page: 365 year: 2015 end-page: 371 ident: CR125 article-title: The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours publication-title: Br. J. Cancer doi: 10.1038/bjc.2015.233 – volume: 370 start-page: 2377 year: 2014 end-page: 2386 ident: CR205 article-title: Tofacitinib versus methotrexate in rheumatoid arthritis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1310476 – volume: 71 start-page: 40 year: 2022 end-page: 46 ident: CR251 article-title: Innovation in the treatment of atopic dermatitis: emerging topical and oral Janus kinase inhibitors publication-title: Allergol. Int. doi: 10.1016/j.alit.2021.10.004 – volume: 114 start-page: E4924 year: 2017 end-page: e4933 ident: CR382 article-title: Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1615730114 – volume: 70 start-page: 2029 year: 2011 end-page: 2036 ident: CR190 article-title: Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway publication-title: Ann. Rheum. Dis. doi: 10.1136/ard.2011.150326 – volume: 385 start-page: 406 year: 2021 end-page: 415 ident: CR445 article-title: Tofacitinib in patients hospitalized with Covid-19 pneumonia publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2101643 – volume: 25 start-page: 5901 year: 2019 end-page: 5912 ident: CR227 article-title: Activation of JAK/STAT signaling in megakaryocytes sustains myeloproliferation in vivo publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-4089 – volume: 92 start-page: 833 year: 2017 end-page: 838 ident: CR434 article-title: A life-threatening ruxolitinib discontinuation syndrome publication-title: Am. J. Hematol. doi: 10.1002/ajh.24775 – volume: 19 start-page: 754 year: 2012 end-page: 759 ident: CR61 article-title: Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F publication-title: Nat. Struct. Mol. Biol. doi: 10.1038/nsmb.2348 – volume: 14 start-page: 1166 year: 1995 end-page: 1175 ident: CR365 article-title: Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs publication-title: EMBO J. doi: 10.1002/j.1460-2075.1995.tb07100.x – volume: 184 start-page: 106419 year: 2022 ident: CR396 article-title: Flavonoids regulate tumor-associated macrophages - from structure-activity relationship to clinical potential (Review) publication-title: Pharm. Res. doi: 10.1016/j.phrs.2022.106419 – volume: 309 start-page: 120996 year: 2022 ident: CR328 article-title: Role of STAT3 in the initiation, progression, proliferation and metastasis of breast cancer and strategies to deliver JAK and STAT3 inhibitors publication-title: Life Sci. doi: 10.1016/j.lfs.2022.120996 – volume: 377 start-page: 1525 year: 2017 end-page: 1536 ident: CR454 article-title: Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1615977 – volume: 81 start-page: 798 year: 2022 end-page: 804 ident: CR455 article-title: Tofacitinib and risk of cardiovascular outcomes: results from the safety of TofAcitinib in routine care patients with Rheumatoid Arthritis (STAR-RA) study publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2021-221915 – volume: 8 start-page: 582 year: 1998 end-page: 587 ident: CR105 article-title: STAT structure and function in signaling publication-title: Curr. Opin. Genet. Dev. doi: 10.1016/S0959-437X(98)80015-4 – volume: 234 start-page: 21126 year: 2019 end-page: 21134 ident: CR401 article-title: Modulation of Myb-induced NF-kB -STAT3 signaling and resulting cisplatin resistance in ovarian cancer by dietary factors publication-title: J. Cell Physiol. doi: 10.1002/jcp.28715 – ident: CR97 – volume: 94 start-page: 795 year: 2018 end-page: 808 ident: CR334 article-title: JAK-STAT signaling is activated in the kidney and peripheral blood cells of patients with focal segmental glomerulosclerosis publication-title: Kidney Int. doi: 10.1016/j.kint.2018.05.022 – volume: 14 start-page: 736 year: 2014 end-page: 746 ident: CR321 article-title: Revisiting STAT3 signalling in cancer: new and unexpected biological functions publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3818 – volume: 12 year: 2022 ident: CR474 article-title: Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database publication-title: Sci. Rep. doi: 10.1038/s41598-022-10777-w – volume: 176 start-page: 105964 year: 2023 ident: CR75 article-title: TNF and IL6/Jak2 signaling pathways are the main contributors of the glia-derived neuroinflammation present in Lafora disease, a fatal form of progressive myoclonus epilepsy publication-title: Neurobiol. Dis. doi: 10.1016/j.nbd.2022.105964 – volume: 167 start-page: 61 year: 2016 end-page: 66 ident: CR133 article-title: Therapeutics targeting innate immune/inflammatory responses through the interleukin-6/JAK/STAT signal transduction pathway in patients with cancer publication-title: Transl. Res. doi: 10.1016/j.trsl.2015.08.013 – volume: 27 start-page: 1485 year: 2009 end-page: 1491 ident: CR292 article-title: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2008.20.7753 – volume: 384 start-page: 1227 year: 2021 end-page: 1239 ident: CR277 article-title: Trial of upadacitinib and adalimumab for psoriatic arthritis publication-title: N. Engl. J. Med doi: 10.1056/NEJMoa2022516 – volume: 40 start-page: 298 year: 2019 end-page: 308 ident: CR117 article-title: Targeting SOCS proteins to control JAK-STAT signalling in disease publication-title: Trends Pharm. Sci. doi: 10.1016/j.tips.2019.03.001 – volume: 7 start-page: 454 year: 2007 end-page: 465 ident: CR120 article-title: SOCS proteins, cytokine signalling and immune regulation publication-title: Nat. Rev. Immunol. doi: 10.1038/nri2093 – volume: 29 start-page: 2163 year: 2022 end-page: 2176 ident: CR51 article-title: IRF4 deficiency vulnerates B-cell progeny for leukemogenesis via somatically acquired Jak3 mutations conferring IL-7 hypersensitivity publication-title: Cell Death Differ. doi: 10.1038/s41418-022-01005-z – volume: 71 start-page: 2497 year: 2011 end-page: 2506 ident: CR144 article-title: IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-10-3025 – volume: 8 start-page: eabo4363 year: 2022 ident: CR199 article-title: A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing γc cytokine-related JAK-STAT signal publication-title: Sci. Adv. doi: 10.1126/sciadv.abo4363 – volume: 396 start-page: 215 year: 2020 end-page: 217 ident: CR286 article-title: Abrocitinib for atopic dermatitis: a step forward publication-title: Lancet doi: 10.1016/S0140-6736(20)31284-8 – volume: 99 start-page: 8043 year: 2002 end-page: 8047 ident: CR139 article-title: Mutational switch of an IL-6 response to an interferon-gamma-like response publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.122236099 – volume: 185 start-page: 3857 year: 2022 end-page: 3876 ident: CR548 article-title: The JAK-STAT pathway at 30: much learned, much more to do publication-title: Cell doi: 10.1016/j.cell.2022.09.023 – volume: 12 start-page: 1756284819853208 year: 2019 ident: CR556 article-title: New biologics and small molecules in inflammatory bowel disease: an update publication-title: Ther. Adv. Gastroenterol. doi: 10.1177/1756284819853208 – volume: 76 start-page: 528 year: 2005 end-page: 537 ident: CR150 article-title: Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus publication-title: Am. J. Hum. Genet. doi: 10.1086/428480 – volume: 215 start-page: 337 year: 2018 end-page: 355 ident: CR357 article-title: STAT4 and T-bet control follicular helper T cell development in viral infections publication-title: J. Exp. Med. doi: 10.1084/jem.20170457 – volume: 234 start-page: 108118 year: 2022 ident: CR113 article-title: The role of the STAT3 signaling transduction pathways in radioresistance publication-title: Pharm. Ther. doi: 10.1016/j.pharmthera.2022.108118 – volume: 73 start-page: 2166 year: 2021 end-page: 2178 ident: CR409 article-title: A decade of JAK inhibitors: what have we learned and what may be the future? publication-title: Arthritis Rheumatol. doi: 10.1002/art.41906 – volume: 29 start-page: 1631 year: 2015 end-page: 1648 ident: CR331 article-title: Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers publication-title: Genes Dev. doi: 10.1101/gad.262642.115 – volume: 80 start-page: 432 year: 2021 end-page: 439 ident: CR276 article-title: Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2020-218412 – volume: 80 start-page: 913 year: 2019 end-page: 921.e919 ident: CR483 article-title: Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2018.01.018 – volume: 66 start-page: 311 year: 2015 end-page: 328 ident: CR38 article-title: The JAK-STAT pathway: impact on human disease and therapeutic intervention publication-title: Annu. Rev. Med. doi: 10.1146/annurev-med-051113-024537 – volume: 28 start-page: 248 year: 2014 end-page: 257 ident: CR93 article-title: STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention publication-title: Leukemia doi: 10.1038/leu.2013.192 – volume: 99 start-page: 1 year: 2019 end-page: 14 ident: CR131 article-title: Clinical significance and immunobiology of IL-21 in autoimmunity publication-title: J. Autoimmun. doi: 10.1016/j.jaut.2019.01.013 – volume: 60 start-page: 303 year: 2004 end-page: 309 ident: CR27 article-title: RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells publication-title: Prostate doi: 10.1002/pros.20072 – volume: 150 start-page: 78 year: 2014 end-page: 87 ident: CR336 article-title: Protective role of JAK/STAT signaling against renal fibrosis in mice with unilateral ureteral obstruction publication-title: Clin. Immunol. doi: 10.1016/j.clim.2013.11.003 – volume: 7 start-page: e226 year: 2020 end-page: e237 ident: CR416 article-title: Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study publication-title: Lancet Haematol. doi: 10.1016/S2352-3026(19)30207-8 – volume: 7 start-page: 245 year: 2019 ident: CR391 article-title: Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer publication-title: J. Immunother. Cancer doi: 10.1186/s40425-019-0733-7 – volume: 29 start-page: 679 year: 2008 end-page: 690 ident: CR356 article-title: Signal transducer and activator of transcription 4 is required for the transcription factor T-bet to promote T helper 1 cell-fate determination publication-title: Immunity doi: 10.1016/j.immuni.2008.08.017 – volume: 19 start-page: 1130 year: 2022 end-page: 1140 ident: CR66 article-title: Treatment with a JAK1/2 inhibitor ameliorates murine autoimmune cholangitis induced by IFN overexpression publication-title: Cell Mol. Immunol. doi: 10.1038/s41423-022-00904-y – volume: 46 start-page: 220 year: 2017 end-page: 232 ident: CR180 article-title: Autocrine loop involving IL-6 family member LIF, LIF Receptor, and STAT4 drives sustained fibroblast production of inflammatory mediators publication-title: Immunity doi: 10.1016/j.immuni.2017.01.004 – volume: 75 start-page: 1057 year: 2016 end-page: 1064 ident: CR187 article-title: Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2015-208279 – volume: 92 start-page: 909 year: 2017 end-page: 921 ident: CR343 article-title: Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice publication-title: Kidney Int. doi: 10.1016/j.kint.2017.03.027 – volume: 154 start-page: 113618 year: 2022 ident: CR403 article-title: Focus on immune checkpoint PD-1/PD-L1 pathway: new advances of polyphenol phytochemicals in tumor immunotherapy publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2022.113618 – volume: 152 start-page: 873 year: 2016 end-page: 874 ident: CR244 article-title: Research gaps in quality of life and economic burden of atopic dermatitis: the national eczema association burden of disease audit publication-title: JAMA Dermatol. doi: 10.1001/jamadermatol.2016.1978 – volume: 152 start-page: 104609 year: 2020 ident: CR418 article-title: Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update publication-title: Pharm. Res. doi: 10.1016/j.phrs.2019.104609 – volume: 48 start-page: 1230 year: 2021 end-page: 1238 ident: CR522 article-title: Safety and efficacy of filgotinib: up to 4-year results from an open-label extension study of phase II rheumatoid arthritis programs publication-title: J. Rheumatol. doi: 10.3899/jrheum.201183 – volume: 20 start-page: 591 year: 2022 end-page: 601.e598 ident: CR452 article-title: Efficacy and safety of tofacitinib in ulcerative colitis based on prior tumor necrosis factor inhibitor failure status publication-title: Clin. Gastroenterol. Hepatol. doi: 10.1016/j.cgh.2021.02.043 – volume: 75 start-page: 1341 year: 2015 end-page: 1353 ident: CR311 article-title: Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition publication-title: Prostate doi: 10.1002/pros.23015 – volume: 68 start-page: 46 year: 2016 end-page: 55 ident: CR516 article-title: VX-509 (decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis publication-title: Arthritis Rheumatol. doi: 10.1002/art.39473 – volume: 44 start-page: 310 year: 2013 end-page: 319 ident: CR22 article-title: Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy publication-title: Hum. Pathol. doi: 10.1016/j.humpath.2012.06.001 – volume: 69 start-page: 4184 year: 2009 end-page: 4191 ident: CR329 article-title: Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-08-2989 – volume: 14 start-page: 1402 year: 1995 end-page: 1411 ident: CR367 article-title: Interleukin-3 signals through multiple isoforms of Stat5 publication-title: EMBO J. doi: 10.1002/j.1460-2075.1995.tb07126.x – volume: 376 start-page: 1723 year: 2017 end-page: 1736 ident: CR446 article-title: Tofacitinib as induction and maintenance therapy for ulcerative colitis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1606910 – volume: 21 year: 2022 ident: CR327 article-title: IL-6/STAT3 signaling in tumor cells restricts the expression of frameshift-derived neoantigens by SMG1 induction publication-title: Mol. Cancer doi: 10.1186/s12943-022-01679-6 – volume: 22 start-page: 871 year: 2020 end-page: 884 ident: CR337 article-title: miR-150-based RNA interference attenuates tubulointerstitial fibrosis through the SOCS1/JAK/STAT pathway in vivo and in vitro publication-title: Mol. Ther. Nucleic Acids doi: 10.1016/j.omtn.2020.10.008 – volume: 31 start-page: 1285 year: 2013 end-page: 1292 ident: CR415 article-title: Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2012.44.4489 – volume: 368 start-page: 161 year: 2013 end-page: 170 ident: CR138 article-title: JAKs and STATs in immunity, immunodeficiency, and cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra1202117 – volume: 147 start-page: 2202 year: 2021 end-page: 2212.e2208 ident: CR253 article-title: JAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2020.11.041 – volume: 78 start-page: 54 year: 2018 end-page: 61.e51 ident: CR243 article-title: The burden of atopic dermatitis in US adults: health care resource utilization data from the 2013 National Health and Wellness Survey publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2017.08.002 – volume: 18 start-page: 706 year: 2019 end-page: 713 ident: CR513 article-title: Challenges in the treatment of rheumatoid arthritis publication-title: Autoimmun. Rev. doi: 10.1016/j.autrev.2019.05.007 – volume: 7 year: 2016 ident: CR332 article-title: Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models publication-title: Nat. Commun. doi: 10.1038/ncomms12258 – volume: 62 start-page: 6659 year: 2002 end-page: 6666 ident: CR309 article-title: Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells publication-title: Cancer Res. – volume: 84 start-page: 431 year: 1996 end-page: 442 ident: CR5 article-title: Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway publication-title: Cell doi: 10.1016/S0092-8674(00)81288-X – volume: 82 start-page: 1671 year: 2022 end-page: 1679 ident: CR535 article-title: Deucravacitinib: first approval publication-title: Drugs doi: 10.1007/s40265-022-01796-y – volume: 47 start-page: 114 year: 2020 end-page: 120 ident: CR501 article-title: Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis publication-title: J. Dermatol. doi: 10.1111/1346-8138.15173 – volume: 42 start-page: 35 year: 2022 ident: CR463 article-title: Cytokines and cytokine receptors as targets of immune-mediated inflammatory diseases-RA as a role model publication-title: Inflamm. Regen. doi: 10.1186/s41232-022-00221-x – volume: 150 start-page: 955 year: 2022 end-page: 964.e916 ident: CR111 article-title: Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2022.01.026 – volume: 198 start-page: 317 year: 2022 end-page: 327 ident: CR511 article-title: Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts publication-title: Br. J. Haematol. doi: 10.1111/bjh.18207 – volume: 74 start-page: 1395 year: 2021 end-page: 1410 ident: CR385 article-title: Analysis and validation of human targets and treatments using a hepatocellular carcinoma-immune humanized mouse model publication-title: Hepatology doi: 10.1002/hep.31812 – volume: 8 start-page: 959 year: 2001 end-page: 969 ident: CR58 article-title: Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases publication-title: Mol. Cell doi: 10.1016/S1097-2765(01)00398-7 – volume: 10 year: 2019 ident: CR141 article-title: STAT1 signaling shields T cells from NK cell-mediated cytotoxicity publication-title: Nat. Commun. doi: 10.1038/s41467-019-08743-8 – volume: 144 start-page: 1575 year: 2019 end-page: 1583 ident: CR504 article-title: Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2019.08.004 – volume: 66 start-page: 100903 year: 2023 ident: CR326 article-title: A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44(+)CD24(-) enriched breast cancer stem-like cells publication-title: Drug Resist. Updat. doi: 10.1016/j.drup.2022.100903 – volume: 176 start-page: 1 year: 2014 end-page: 10 ident: CR551 article-title: Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases publication-title: Clin. Exp. Immunol. doi: 10.1111/cei.12248 – volume: 6 start-page: 90 year: 2013 ident: CR92 article-title: STAT inhibitors for cancer therapy publication-title: J. Hematol. Oncol. doi: 10.1186/1756-8722-6-90 – volume: 40 start-page: 1671 year: 2022 end-page: 1680 ident: CR422 article-title: Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase ii safety and efficacy publication-title: J. Clin. Oncol. doi: 10.1200/JCO.21.02188 – volume: 12 year: 2022 ident: CR164 article-title: The driver role of JAK-STAT signalling in cancer stemness capabilities leading to new therapeutic strategies for therapy- and castration-resistant prostate cancer publication-title: Clin. Transl. Med. doi: 10.1002/ctm2.978 – volume: 42 start-page: 1208 year: 2005 end-page: 1236 ident: CR295 article-title: Management of hepatocellular carcinoma publication-title: Hepatology doi: 10.1002/hep.20933 – volume: 86 start-page: 2516 year: 1995 end-page: 2525 ident: CR236 article-title: The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors publication-title: Blood doi: 10.1182/blood.V86.7.2516.2516 – volume: 43 start-page: 75 year: 2023 end-page: 86 ident: CR315 article-title: Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration? publication-title: Cancer Commun. (Lond.) doi: 10.1002/cac2.12393 – volume: 192 start-page: 114688 year: 2021 ident: CR384 article-title: TTI-101: a competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain publication-title: Biochem. Pharm. doi: 10.1016/j.bcp.2021.114688 – volume: 369 start-page: 197 year: 2013 end-page: 198 ident: CR433 article-title: Progressive multifocal leukoencephalopathy associated with ruxolitinib publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc1302135 – volume: 7 start-page: 6 year: 2021 ident: CR293 article-title: Hepatocellular carcinoma publication-title: Nat Rev Dis Primers. doi: 10.1038/s41572-020-00240-3 – volume: 79 start-page: 1719 year: 2019 end-page: 1725 ident: CR560 article-title: Fedratinib: first approval publication-title: Drugs doi: 10.1007/s40265-019-01205-x – volume: 15 start-page: 1 year: 2005 end-page: 5 ident: CR39 article-title: JAK/STAT signaling regulates tissue outgrowth and male germline stem cell fate in Drosophila publication-title: Cell Res. doi: 10.1038/sj.cr.7290255 – volume: 271 start-page: 13221 year: 1996 end-page: 13227 ident: CR371 article-title: STAT3beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription publication-title: J. Biol. Chem. doi: 10.1074/jbc.271.22.13221 – volume: 10 start-page: e2202956 year: 2023 ident: CR324 article-title: Tumor cell-intrinsic CD96 mediates chemoresistance and cancer stemness by regulating mitochondrial fatty acid β-oxidation publication-title: Adv. Sci. (Weinh.) – volume: 65 start-page: 149 year: 2006 end-page: 156 ident: CR184 article-title: Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis publication-title: Ann. Rheum. Dis. doi: 10.1136/ard.2005.037929 – volume: 20 start-page: 181 year: 2019 end-page: 192 ident: CR273 article-title: JAK inhibitors for atopic dermatitis: an update publication-title: Am. J. Clin. Dermatol. doi: 10.1007/s40257-018-0413-2 – volume: 23 start-page: 115 year: 2023 end-page: 134 ident: CR112 article-title: STAT proteins in cancer: orchestration of metabolism publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-022-00537-3 – volume: 367 start-page: 495 year: 2012 end-page: 507 ident: CR465 article-title: Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1109071 – volume: 108 start-page: 3472 year: 2006 end-page: 3476 ident: CR241 article-title: MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients publication-title: Blood doi: 10.1182/blood-2006-04-018879 – volume: 28 start-page: 4 year: 2001 end-page: 5 ident: CR124 article-title: Knocking the SOCS off a tumor suppressor publication-title: Nat. Genet. doi: 10.1038/ng0501-4 – volume: 35 start-page: 2616 year: 2021 end-page: 2620 ident: CR557 article-title: JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis publication-title: Leukemia doi: 10.1038/s41375-021-01266-6 – volume: 13 year: 2022 ident: CR71 article-title: Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm publication-title: Nat. Commun. doi: 10.1038/s41467-022-32927-4 – volume: 338 start-page: 28 year: 2010 end-page: 37 ident: CR163 article-title: JAK/STAT signaling coordinates stem cell proliferation and multilineage differentiation in the Drosophila intestinal stem cell lineage publication-title: Dev. Biol. doi: 10.1016/j.ydbio.2009.10.045 – volume: 13 start-page: 1068260 year: 2022 ident: CR248 article-title: JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review publication-title: Front. Immunol. doi: 10.3389/fimmu.2022.1068260 – volume: 18 start-page: jjaa162 year: 2020 ident: CR67 article-title: The JAK1/3 inhibitor tofacitinib suppresses T cell homing and activation in chronic intestinal inflammation publication-title: J. Crohns Colitis – volume: 80 start-page: 848 year: 2021 end-page: 858 ident: CR179 article-title: Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2020-219214 – volume: 74 start-page: 95 year: 2022 end-page: 104 ident: CR442 article-title: Randomized trial of ruxolitinib in antiretroviral-treated adults with human immunodeficiency virus publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciab212 – volume: 70 start-page: 338 year: 2014 end-page: 351 ident: CR245 article-title: Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2013.10.010 – volume: 84 start-page: 106497 year: 2020 ident: CR191 article-title: LncRNA LINC-PINT increases SOCS1 expression by sponging miR-155-5p to inhibit the activation of ERK signaling pathway in rheumatoid arthritis synovial fibroblasts induced by TNF-α publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2020.106497 – volume: 385 start-page: 228 year: 2021 end-page: 238 ident: CR428 article-title: Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2033122 – volume: 18 start-page: 88 year: 2017 end-page: 99 ident: CR421 article-title: Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30558-7 – volume: 7 start-page: 128 year: 2017 end-page: 130 ident: CR155 article-title: JAK mutations as escape mechanisms to anti-PD-1 therapy publication-title: Cancer Disco. doi: 10.1158/2159-8290.CD-16-1439 – volume: 145 start-page: 572 year: 2020 end-page: 582 ident: CR258 article-title: Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2019.08.042 – volume: 13 start-page: 67 year: 2010 end-page: 78 ident: CR29 article-title: Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches publication-title: Drug Resist. Updat. doi: 10.1016/j.drup.2010.04.001 – volume: 10 start-page: 888 year: 2022 end-page: 899 ident: CR488 article-title: Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(22)00088-1 – volume: 396 start-page: 345 year: 2020 end-page: 360 ident: CR242 article-title: Atopic dermatitis publication-title: Lancet doi: 10.1016/S0140-6736(20)31286-1 – volume: 36 start-page: 542 year: 2012 end-page: 550 ident: CR134 article-title: JAK and STAT signaling molecules in immunoregulation and immune-mediated disease publication-title: Immunity doi: 10.1016/j.immuni.2012.03.014 – volume: 17 start-page: 360 year: 2020 end-page: 371 ident: CR161 article-title: Lineage plasticity in cancer: a shared pathway of therapeutic resistance publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-020-0340-z – volume: 85 start-page: 854 year: 2021 end-page: 862 ident: CR503 article-title: Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2021.06.014 – volume: 150 start-page: 931 year: 2022 end-page: 946 ident: CR100 article-title: STAT5B restrains human B-cell differentiation to maintain humoral immune homeostasis publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2022.04.011 – volume: 204 start-page: 2383 year: 2007 end-page: 2396 ident: CR355 article-title: High basal STAT4 balanced by STAT1 induction to control type 1 interferon effects in natural killer cells publication-title: J. Exp. Med. doi: 10.1084/jem.20070401 – volume: 9 start-page: e14 year: 2022 end-page: e25 ident: CR519 article-title: Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial publication-title: Lancet Haematol. doi: 10.1016/S2352-3026(21)00367-7 – volume: 28 start-page: 1472 year: 2014 end-page: 1477 ident: CR230 article-title: CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons publication-title: Leukemia doi: 10.1038/leu.2014.3 – volume: 13 start-page: 105 year: 1997 end-page: 110 ident: CR3 article-title: The JAK-STAT pathway in drosophila publication-title: Trends Genet. doi: 10.1016/S0168-9525(97)01006-8 – volume: 38 start-page: 1006 year: 2020 end-page: 1018 ident: CR423 article-title: Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia publication-title: J. Clin. Oncol. doi: 10.1200/JCO.19.00895 – volume: 20 start-page: 116 year: 2022 end-page: 125.e115 ident: CR461 article-title: Maintenance of remission with tofacitinib therapy in patients with ulcerative colitis publication-title: Clin. Gastroenterol. Hepatol. doi: 10.1016/j.cgh.2020.10.004 – volume: 15 start-page: 7 year: 2022 ident: CR220 article-title: Momelotinib: an emerging treatment for myelofibrosis patients with anemia publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-021-01157-4 – volume: 290 start-page: F762 year: 2006 end-page: F768 ident: CR340 article-title: Role of the JAK/STAT signaling pathway in diabetic nephropathy publication-title: Am. J. Physiol. Ren. Physiol. doi: 10.1152/ajprenal.00181.2005 – volume: 30 start-page: 1701 year: 2016 end-page: 1707 ident: CR426 article-title: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis publication-title: Leukemia doi: 10.1038/leu.2016.148 – volume: 352 start-page: 1779 year: 2005 end-page: 1790 ident: CR226 article-title: A gain-of-function mutation of JAK2 in myeloproliferative disorders publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa051113 – volume: 2 start-page: 100269 year: 2021 ident: CR361 article-title: Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome publication-title: Cell Rep. Med. doi: 10.1016/j.xcrm.2021.100269 – volume: 396 start-page: 255 year: 2020 end-page: 266 ident: CR287 article-title: Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(20)30732-7 – volume: 384 start-page: 795 year: 2021 end-page: 807 ident: CR486 article-title: Baricitinib plus remdesivir for hospitalized adults with Covid-19 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2031994 – volume: 6 start-page: eaay3245 year: 2020 ident: CR95 article-title: IL-27 signaling activates skin cells to induce innate antiviral proteins and protects against Zika virus infection publication-title: Sci. Adv. doi: 10.1126/sciadv.aay3245 – volume: 81 start-page: 1504 year: 2022 end-page: 1514 ident: CR99 article-title: Age-associated B cells contribute to the pathogenesis of rheumatoid arthritis by inducing activation of fibroblast-like synoviocytes via TNF-α-mediated ERK1/2 and JAK-STAT1 pathways publication-title: Ann. Rheum. Dis. doi: 10.1136/ard-2022-222605 – volume: 10 start-page: 54 year: 2017 ident: CR239 article-title: Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-017-0425-z – volume: 28 start-page: 477 year: 2008 end-page: 487 ident: CR135 article-title: Cytokine signaling modules in inflammatory responses publication-title: Immunity doi: 10.1016/j.immuni.2008.03.002 – volume: 49 start-page: 19 year: 1996 end-page: 25 ident: CR47 article-title: PDGF stimulates tyrosine phosphorylation of JAK 1 protein tyrosine kinase in human mesangial cells publication-title: Kidney Int. doi: 10.1038/ki.1996.3 – volume: 138 start-page: 657 year: 2013 end-page: 664 ident: CR330 article-title: The role of intratumoral and systemic IL-6 in breast cancer publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-013-2488-z – volume: 20 start-page: 1574 year: 2019 end-page: 1583 ident: CR4 article-title: Interferon target-gene expression and epigenomic signatures in health and disease publication-title: Nat. Immunol. doi: 10.1038/s41590-019-0466-2 – volume: 381 start-page: 451 year: 2013 end-page: 460 ident: CR30 article-title: Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(12)61424-X – volume: 366 start-page: 787 year: 2012 end-page: 798 ident: CR424 article-title: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1110556 – volume: 79 start-page: 887 year: 2019 end-page: 891 ident: CR496 article-title: Peficitinib: first global approval publication-title: Drugs doi: 10.1007/s40265-019-01131-y – volume: 80 start-page: 727 year: 2021 end-page: 738 ident: CR198 article-title: Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2020-219213 – volume: 26 start-page: 1065 year: 2012 end-page: 1081 ident: CR235 article-title: Myeloproliferative neoplasm animal models publication-title: Hematol. Oncol. Clin. North Am. doi: 10.1016/j.hoc.2012.07.007 – ident: CR104 – volume: 397 start-page: 195 year: 2021 end-page: 196 ident: CR288 article-title: Abrocitinib for atopic dermatitis publication-title: Lancet doi: 10.1016/S0140-6736(21)00036-2 – volume: 13 start-page: 277 year: 2019 end-page: 292 ident: CR305 article-title: C1QTNF1-AS1 regulates the occurrence and development of hepatocellular carcinoma by regulating miR-221-3p/SOCS3 publication-title: Hepatol. Int. doi: 10.1007/s12072-019-09944-5 – volume: 855 start-page: 252 year: 2019 end-page: 261 ident: CR376 article-title: Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage publication-title: Eur. J. Pharm. doi: 10.1016/j.ejphar.2019.05.020 – volume: 80 start-page: 312 year: 2021 end-page: 320 ident: CR272 article-title: Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2020-218870 – volume: 353 start-page: 1253 year: 1999 end-page: 1257 ident: CR296 article-title: Hepatocellular carcinoma publication-title: Lancet doi: 10.1016/S0140-6736(98)09148-X – volume: 130 start-page: 1863 year: 2020 end-page: 1878 ident: CR149 article-title: TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis publication-title: J. Clin. Invest. doi: 10.1172/JCI126567 – volume: 10 start-page: e004384 year: 2022 ident: CR377 article-title: STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice publication-title: J. Immunother. Cancer doi: 10.1136/jitc-2021-004384 – volume: 12 start-page: 1847 year: 2022 end-page: 1859 ident: CR159 article-title: Mapping phenotypic plasticity upon the cancer cell state landscape using manifold learning publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-21-0282 – volume: 65 start-page: 8380 year: 2022 end-page: 8400 ident: CR70 article-title: Insights on JAK2 modulation by potent, selective, and cell-permeable pseudokinase-domain ligands publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.2c00283 – volume: 83 start-page: 71 year: 1998 end-page: 86 ident: CR212 article-title: Pathogenesis, etiology and epidemiology of myelodysplastic syndromes publication-title: Haematologica – volume: 81 start-page: e20 year: 2022 ident: CR430 article-title: Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: a case report publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2020-216983 – volume: 392 start-page: 222 year: 2018 end-page: 231 ident: CR480 article-title: Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial publication-title: Lancet doi: 10.1016/S0140-6736(18)31363-1 – volume: 353 start-page: 405 year: 2015 end-page: 414 ident: CR514 article-title: VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease publication-title: J. Pharm. Exp. Ther. doi: 10.1124/jpet.114.221176 – volume: 400 start-page: 369 year: 2022 end-page: 379 ident: CR524 article-title: Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(22)01212-0 – volume: 202 start-page: 139 year: 2004 end-page: 156 ident: CR143 article-title: Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4 publication-title: Immunol. Rev. doi: 10.1111/j.0105-2896.2004.00211.x – volume: 32 start-page: 854 year: 2022 end-page: 867 ident: CR156 article-title: Phenotypic plasticity during metastatic colonization publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2022.03.007 – volume: 11 start-page: 885 year: 2017 end-page: 893 ident: CR410 article-title: The future of janus kinase inhibitors in inflammatory bowel disease publication-title: J. Crohns Colitis doi: 10.1093/ecco-jcc/jjx003 – volume: 71 start-page: 405 year: 1999 end-page: 422 ident: CR106 article-title: The STAT family of proteins in cytokine signaling publication-title: Prog. Biophys. Mol. Biol. doi: 10.1016/S0079-6107(98)00051-0 – volume: 364 start-page: 2496 year: 2011 end-page: 2506 ident: CR214 article-title: Clinical effect of point mutations in myelodysplastic syndromes publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1013343 – volume: 148 start-page: 51 year: 2010 end-page: 59 ident: CR301 article-title: Hepatitis B virus overexpresses suppressor of cytokine signaling-3 (SOCS3) thereby contributing to severity of inflammation in the liver publication-title: Virus Res. doi: 10.1016/j.virusres.2009.12.003 – volume: 36 start-page: 1308 year: 2022 end-page: 1317 ident: CR527 article-title: High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents publication-title: J. Eur. Acad. Dermatol. Venereol. doi: 10.1111/jdv.18170 – volume: 13 year: 2022 ident: CR65 article-title: The influenza virus PB2 protein evades antiviral innate immunity by inhibiting JAK1/STAT signalling publication-title: Nat. Commun. doi: 10.1038/s41467-022-33909-2 – volume: 82 start-page: 823 year: 2020 end-page: 831 ident: CR502 article-title: Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2019.12.015 – volume: 197 start-page: 114940 year: 2022 ident: CR402 article-title: Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells publication-title: Biochem. Pharm. doi: 10.1016/j.bcp.2022.114940 – volume: 6 start-page: 402 year: 2021 ident: CR76 article-title: The JAK/STAT signaling pathway: from bench to clinic publication-title: Signal Transduct. Target Ther. doi: 10.1038/s41392-021-00791-1 – volume: 68 start-page: 1249 year: 2013 end-page: 1258 ident: CR152 article-title: STAT6 polymorphisms are associated with neonatal regulatory T cells and cytokines and atopic diseases at 3 years publication-title: Allergy doi: 10.1111/all.12220 – volume: 19 start-page: 2020 year: 2021 end-page: 2024 ident: CR297 article-title: Recent advances in hepatocellular carcinoma treatment publication-title: Clin. Gastroenterol. Hepatol. doi: 10.1016/j.cgh.2021.05.045 – volume: 28 start-page: 15 year: 2015 end-page: 28 ident: CR208 article-title: CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms publication-title: Cancer Cell doi: 10.1016/j.ccell.2015.06.006 – volume: 156 start-page: 863 year: 2020 end-page: 873 ident: CR528 article-title: Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial publication-title: JAMA Dermatol. doi: 10.1001/jamadermatol.2020.1406 – volume: 93 start-page: 397 year: 1998 end-page: 409 ident: CR73 article-title: Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis publication-title: Cell doi: 10.1016/S0092-8674(00)81168-X – volume: 15 start-page: 1135 year: 2021 end-page: 1147 ident: CR531 article-title: The efficacy and safety of abrocitinib as a treatment option for atopic dermatitis: a short report of the clinical data publication-title: Drug Des. Devel. Ther. doi: 10.2147/DDDT.S240866 – volume: 18 start-page: 374 year: 2017 end-page: 384 ident: CR43 article-title: Mechanisms and consequences of Jak-STAT signaling in the immune system publication-title: Nat. Immunol. doi: 10.1038/ni.3691 – volume: 4 start-page: e351 year: 2022 end-page: e361 ident: CR431 article-title: Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet Rheumatol. doi: 10.1016/S2665-9913(22)00044-3 – volume: 376 start-page: 1094 year: 2010 end-page: 1108 ident: CR171 article-title: Rheumatoid arthritis publication-title: Lancet doi: 10.1016/S0140-6736(10)60826-4 – volume: 20 start-page: 1821 year: 2022 end-page: 1830.e1823 ident: CR451 article-title: Efficacy and safety of extended induction with tofacitinib for the treatment of ulcerative colitis publication-title: Clin. Gastroenterol. Hepatol. doi: 10.1016/j.cgh.2020.10.038 – volume: 89 start-page: 12 year: 2017 end-page: 20 ident: CR24 article-title: The good and the bad faces of STAT1 in solid tumours publication-title: Cytokine doi: 10.1016/j.cyto.2015.11.011 – volume: 100 start-page: 184 year: 2008 end-page: 198 ident: CR562 article-title: Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/djm328 – volume: 123 start-page: 1833 year: 2014 end-page: 1835 ident: CR439 article-title: Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts publication-title: Blood doi: 10.1182/blood-2013-12-544411 – volume: 7 start-page: 41 year: 2007 end-page: 51 ident: CR372 article-title: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment publication-title: Nat. Rev. Immunol. doi: 10.1038/nri1995 – volume: 71 start-page: 1042 year: 2019 end-page: 1055 ident: CR495 article-title: Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis publication-title: Arthritis Rheumatol. doi: 10.1002/art.40841 – volume: 182 start-page: 1103 year: 2020 end-page: 1110 ident: CR500 article-title: Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study publication-title: Br. J. Dermatol. doi: 10.1111/bjd.18469 – volume: 72 start-page: ii111 year: 2013 end-page: ii115 ident: CR140 article-title: Janus kinase inhibitors in autoimmune diseases publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2012-202576 – volume: 11 start-page: 415 year: 2015 end-page: 429 ident: CR176 article-title: The IL-23-IL-17 axis in inflammatory arthritis publication-title: Nat. Rev. Rheumatol. doi: 10.1038/nrrheum.2015.53 – volume: 397 start-page: 2169 year: 2021 end-page: 2181 ident: CR259 article-title: Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(21)00589-4 – volume: 35 start-page: 533 year: 2017 end-page: 550 ident: CR44 article-title: Disorders of the JAK/STAT pathway in T cell lymphoma pathogenesis: implications for immunotherapy publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev-immunol-110416-120628 – volume: 8 start-page: e11782 year: 2022 ident: CR436 article-title: Severe ARDS due to ruxolitinib discontinuation syndrome: case presentation and literature review publication-title: Heliyon doi: 10.1016/j.heliyon.2022.e11782 – volume: 114 start-page: 476 year: 2004 end-page: 489 ident: CR13 article-title: Khurana Hershey, G. K. Turning off signal transducer and activator of transcription (STAT): the negative regulation of STAT signaling publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2004.06.042 – volume: 33 start-page: 1978 year: 2019 end-page: 1995 ident: CR432 article-title: Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling publication-title: Leukemia doi: 10.1038/s41375-019-0379-y – volume: 19 year: 2020 ident: CR319 article-title: Targeting STAT3 in cancer immunotherapy publication-title: Mol. Cancer doi: 10.1186/s12943-020-01258-7 – volume: 13 start-page: 369 year: 1995 end-page: 398 ident: CR80 article-title: Signaling through the hematopoietic cytokine receptors publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev.iy.13.040195.002101 – volume: 22 start-page: 2169 year: 2008 end-page: 2175 ident: CR216 article-title: SOCS2: inhibitor of JAK2V617F-mediated signal transduction publication-title: Leukemia doi: 10.1038/leu.2008.226 – volume: 24 start-page: 1387 year: 2014 end-page: 1402 ident: CR390 article-title: STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation publication-title: Cell Res. doi: 10.1038/cr.2014.154 – volume: 75 start-page: 1979 year: 2016 end-page: 1983 ident: CR517 article-title: Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2015-208901 – volume: 187 start-page: 42 year: 2022 end-page: 51 ident: CR499 article-title: The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial publication-title: Br. J. Dermatol. doi: 10.1111/bjd.21037 – volume: 163 start-page: 1555 year: 2022 end-page: 1568 ident: CR539 article-title: Efficacy and safety of ivarmacitinib in patients with moderate-to-severe, active, ulcerative colitis: a phase II study publication-title: Gastroenterology doi: 10.1053/j.gastro.2022.08.007 – volume: 155 start-page: 1079 year: 1995 end-page: 1090 ident: CR64 article-title: IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes publication-title: J. Immunol. doi: 10.4049/jimmunol.155.3.1079 – volume: 11 start-page: 6333 year: 2005 end-page: 6341 ident: CR310 article-title: Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-05-0148 – volume: 74 start-page: 1311 year: 2015 end-page: 1316 ident: CR32 article-title: The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2014-206028 – volume: 64 start-page: 617 year: 2012 end-page: 629 ident: CR201 article-title: Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs publication-title: Arthritis Rheum. doi: 10.1002/art.33383 – volume: 386 start-page: 1687 year: 2022 end-page: 1699 ident: CR487 article-title: Two phase 3 trials of baricitinib for alopecia areata publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2110343 – volume: 115 start-page: 1692 year: 2009 end-page: 1700 ident: CR68 article-title: Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations publication-title: Cancer doi: 10.1002/cncr.24183 – volume: 119 start-page: 3997 year: 2012 end-page: 4008 ident: CR148 article-title: Functional STAT3 deficiency compromises the generation of human T follicular helper cells publication-title: Blood doi: 10.1182/blood-2011-11-392985 – volume: 81 start-page: 2149 year: 2021 end-page: 2157 ident: CR283 article-title: Abrocitinib: first approval publication-title: Drugs doi: 10.1007/s40265-021-01638-3 – volume: 365 start-page: 2205 year: 2011 end-page: 2219 ident: CR173 article-title: The pathogenesis of rheumatoid arthritis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra1004965 – volume: 61 start-page: e202205231 year: 2022 ident: CR549 article-title: Small Molecule Inhibitors of Interferon-Induced JAK-STAT Signalling publication-title: Angew. Chem. Int. Ed. Engl. – volume: 55 start-page: 1547 year: 2016 end-page: 1558 ident: CR274 article-title: Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis publication-title: Clin. Pharmacokinet. doi: 10.1007/s40262-016-0419-y – volume: 20 start-page: 102750 year: 2021 ident: CR352 article-title: Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart? publication-title: Autoimmun. Rev. doi: 10.1016/j.autrev.2021.102750 – volume: 118 start-page: 20 year: 2015 end-page: 28 ident: CR303 article-title: Down-regulation of suppressor of cytokine signaling 3 by miR-122 enhances interferon-mediated suppression of hepatitis B virus publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2015.03.001 – volume: 11 start-page: 69 year: 1995 end-page: 74 ident: CR17 article-title: Jaks and Stats in signaling by the cytokine receptor superfamily publication-title: Trends Genet. doi: 10.1016/S0168-9525(00)89000-9 – volume: 27 start-page: 4660 year: 2022 ident: CR252 article-title: Potential natural biomolecules targeting JAK/STAT/SOCS signaling in the management of atopic dermatitis publication-title: Molecules doi: 10.3390/molecules27144660 – volume: 95 start-page: 594 year: 2020 end-page: 603 ident: CR509 article-title: Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure publication-title: Am. J. Hematol. doi: 10.1002/ajh.25777 – volume: 24 start-page: 5948 year: 2018 end-page: 5962 ident: CR394 article-title: STAT3 inhibition combined with CpG immunostimulation activates antitumor immunity to eradicate genetically distinct castration-resistant prostate cancers publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-1277 – volume: 270 start-page: 3327 year: 1995 end-page: 3334 ident: CR86 article-title: Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alpha/beta and for signal transduction publication-title: J. Biol. Chem. doi: 10.1074/jbc.270.7.3327 – volume: 119 start-page: e2114324119 year: 2022 ident: CR169 article-title: H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.2114324119 – ident: CR249 – volume: 63 start-page: 192 year: 2023 end-page: 223 ident: CR395 article-title: Guava (Psidium guajava L.): a glorious plant with cancer preventive and therapeutic potential publication-title: Crit. Rev. Food Sci. Nutr. doi: 10.1080/10408398.2021.1945531 – volume: 80 start-page: 304 year: 2021 end-page: 311 ident: CR261 article-title: Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2020-218510 – volume: 24 start-page: 3391 year: 2023 ident: CR83 article-title: Tyk2 targeting in immune-mediated inflammatory diseases publication-title: Int J. Mol. Sci. doi: 10.3390/ijms24043391 – volume: 80 start-page: 106210 year: 2020 ident: CR109 article-title: The role of JAK/STAT signaling pathway and its inhibitors in diseases publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2020.106210 – volume: 157 start-page: 1165 year: 2021 end-page: 1173 ident: CR529 article-title: Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial publication-title: JAMA Dermatol. doi: 10.1001/jamadermatol.2021.2830 – volume: 111 start-page: 784 year: 2016 end-page: 803 ident: CR45 article-title: Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases publication-title: Pharm. Res. doi: 10.1016/j.phrs.2016.07.038 – volume: 73 start-page: 5288 year: 2013 end-page: 5298 ident: CR359 article-title: JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-13-0874 – volume: 66 start-page: 588 year: 1999 end-page: 592 ident: CR123 article-title: Suppressors of cytokine signaling (SOCS): negative regulators of signal transduction publication-title: J. Leukoc. Biol. doi: 10.1002/jlb.66.4.588 – volume: 363 start-page: 1117 year: 2010 end-page: 1127 ident: CR411 article-title: Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1002028 – volume: 30 start-page: 9636897211033778 year: 2021 ident: CR541 article-title: Preventive and therapeutic effects of a novel JAK inhibitor SHR0302 in acute graft-versus-host disease publication-title: Cell Transpl. doi: 10.1177/09636897211033778 – volume: 12 start-page: 25 year: 2016 end-page: 36 ident: CR137 article-title: Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases publication-title: Nat. Rev. Rheumatol. doi: 10.1038/nrrheum.2015.167 – volume: 124 start-page: 3092 year: 2014 end-page: 3100 ident: CR54 article-title: JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model publication-title: Blood doi: 10.1182/blood-2014-04-566687 – volume: 12 year: 2021 ident: CR116 article-title: Discovery of an exosite on the SOCS2-SH2 domain that enhances SH2 binding to phosphorylated ligands publication-title: Nat. Commun. doi: 10.1038/s41467-021-26983-5 – volume: 7 start-page: R424 year: 1997 end-page: R426 ident: CR78 article-title: Cytokines: shared receptors, distinct functions publication-title: Curr. Biol. doi: 10.1016/S0960-9822(06)00208-9 – volume: 374 start-page: 1243 year: 2016 end-page: 1252 ident: CR475 article-title: Baricitinib in patients with refractory rheumatoid arthritis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1507247 – volume: 87 start-page: 351 year: 2022 end-page: 358 ident: CR530 article-title: Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND) publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2022.04.009 – volume: 74 start-page: 1648 year: 2022 end-page: 1659 ident: CR471 article-title: Tofacitinib and risk of malignancy: results from the safety of tofacitinib in routine care patients with rheumatoid arthritis (STAR-RA) study publication-title: Arthritis Rheumatol. doi: 10.1002/art.42250 – volume: 11 start-page: 7020 year: 2022 ident: CR389 article-title: Genetic and small-molecule modulation of stat3 in a mouse model of Crohn’s disease publication-title: J. Clin. Med. doi: 10.3390/jcm11237020 – volume: 34 start-page: 487 year: 2022 end-page: 501.e488 ident: CR404 article-title: Itaconate and itaconate derivatives target JAK1 to suppress alternative activation of macrophages publication-title: Cell Metab. doi: 10.1016/j.cmet.2022.02.002 – volume: 382 start-page: 1800 year: 2020 end-page: 1810 ident: CR413 article-title: Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1917635 – volume: 123 start-page: e123 year: 2014 end-page: e133 ident: CR223 article-title: Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis publication-title: Blood doi: 10.1182/blood-2014-02-554634 – volume: 10 start-page: tkac023 year: 2022 ident: CR160 article-title: WNT5A drives interleukin-6-dependent epithelial-mesenchymal transition via the JAK/STAT pathway in keloid pathogenesis publication-title: Burns Trauma doi: 10.1093/burnst/tkac023 – ident: CR41 – volume: 159 start-page: 253 year: 2013 end-page: 261 ident: CR203 article-title: Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial publication-title: Ann. Intern. Med. doi: 10.7326/0003-4819-159-4-201308200-00006 – volume: 187 start-page: 338 year: 2022 end-page: 352 ident: CR484 article-title: Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4) publication-title: Br. J. Dermatol. doi: 10.1111/bjd.21630 – volume: 14 start-page: 1421 year: 1995 end-page: 1429 ident: CR63 article-title: A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6 publication-title: EMBO J. doi: 10.1002/j.1460-2075.1995.tb07128.x – volume: 270 start-page: 12286 year: 1995 end-page: 12296 ident: CR89 article-title: Interleukin-13 signal transduction in lymphohemopoietic cells. Similarities and differences in signal transduction with interleukin-4 and insulin publication-title: J. Biol. Chem. doi: 10.1074/jbc.270.20.12286 – volume: 20 start-page: 1033 year: 2022 end-page: 1062 ident: CR512 article-title: Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology publication-title: J. Natl. Compr. Cancer Netw. doi: 10.6004/jnccn.2022.0046 – volume: 383 start-page: 1511 year: 2020 end-page: 1521 ident: CR260 article-title: Trial of upadacitinib or abatacept in rheumatoid arthritis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2008250 – volume: 23 start-page: 101822 year: 2020 ident: CR380 article-title: STAT3 inhibitor OPB-51602 is cytotoxic to tumor cells through inhibition of complex I and ROS induction publication-title: iScience doi: 10.1016/j.isci.2020.101822 – volume: 107 start-page: 798 year: 2003 end-page: 802 ident: CR353 article-title: Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy publication-title: Circulation doi: 10.1161/01.CIR.0000057545.82749.FF – volume: 7 start-page: 1347 year: 1992 end-page: 1353 ident: CR7 article-title: JAK2, a third member of the JAK family of protein tyrosine kinases publication-title: Oncogene – volume: 3 start-page: e270 year: 2006 ident: CR231 article-title: MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia publication-title: PLoS Med. doi: 10.1371/journal.pmed.0030270 – volume: 74 start-page: 70 year: 2022 end-page: 80 ident: CR264 article-title: Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: one-year results of a double-blind, placebo-controlled study and open-label extension publication-title: Arthritis Rheumatol. doi: 10.1002/art.41911 – volume: 4 start-page: e317 year: 2017 end-page: e324 ident: CR417 article-title: Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study publication-title: Lancet Haematol. doi: 10.1016/S2352-3026(17)30088-1 – volume: 11 start-page: 1763 year: 2021 end-page: 1776 ident: CR534 article-title: Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with janus kinase 1/2/3 inhibitors publication-title: Dermatol. Ther. doi: 10.1007/s13555-021-00596-8 – volume: 377 start-page: 1537 year: 2017 end-page: 1550 ident: CR466 article-title: Tofacitinib or adalimumab versus placebo for psoriatic arthritis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1615975 – volume: 76 start-page: 694 year: 2017 end-page: 700 ident: CR478 article-title: Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON) publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2016-209821 – volume: 82 start-page: 4624 year: 2022 end-page: 4640 ident: CR110 article-title: PRC2-mediated epigenetic suppression of Type I IFN-STAT2 signaling impairs antitumor immunity in luminal breast cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-22-0736 – volume: 106 start-page: 2162 year: 2005 end-page: 2168 ident: CR224 article-title: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders publication-title: Blood doi: 10.1182/blood-2005-03-1320 – volume: 189 start-page: 106703 year: 2023 ident: CR405 article-title: Dual inhibition of MYC and SLC39A10 by a novel natural product STAT3 inhibitor derived from Chaetomium globosum suppresses tumor growth and metastasis in gastric cancer publication-title: Pharm. Res. doi: 10.1016/j.phrs.2023.106703 – volume: 17 start-page: 431 year: 2006 end-page: 439 ident: CR119 article-title: Suppressor of cytokine signaling (SOCS) 2, a protein with multiple functions publication-title: Cytokine Growth Factor Rev. doi: 10.1016/j.cytogfr.2006.09.008 – volume: 15 start-page: 973 year: 2020 end-page: 982 ident: CR338 article-title: JAK-STAT activity in peripheral blood cells and kidney tissue in IgA nephropathy publication-title: Clin. J. Am. Soc. Nephrol. doi: 10.2215/CJN.11010919 – volume: 86 start-page: 84 year: 2022 end-page: 106 ident: CR318 article-title: STAT family of transcription factors in breast cancer: Pathogenesis and therapeutic opportunities and challenges publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2022.08.003 – volume: 9 year: 2019 ident: CR346 article-title: Renal expression of JAK2 is high in polycystic kidney disease and its inhibition reduces cystogenesis publication-title: Sci. Rep. doi: 10.1038/s41598-019-41106-3 – volume: 35 start-page: 1 year: 2021 end-page: 17 ident: CR561 article-title: Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis publication-title: Leukemia doi: 10.1038/s41375-020-0954-2 – volume: 270 start-page: 794 year: 1995 end-page: 797 ident: CR81 article-title: Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3 publication-title: Science doi: 10.1126/science.270.5237.794 – volume: 19 start-page: 222 year: 1994 end-page: 227 ident: CR18 article-title: Signaling by the cytokine receptor superfamily: JAKs and STATs publication-title: Trends Biochem. Sci. doi: 10.1016/0968-0004(94)90026-4 – volume: 65 start-page: 559 year: 2013 end-page: 570 ident: CR204 article-title: Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study publication-title: Arthritis Rheum. doi: 10.1002/art.37816 – volume: 22 start-page: 877 year: 2021 end-page: 889 ident: CR542 article-title: Efficacy and safety of SHR0302, a highly selective janus kinase 1 inhibitor, in patients with moderate to severe atopic dermatitis: a phase II randomized clinical trial publication-title: Am. J. Clin. Dermatol. doi: 10.1007/s40257-021-00627-2 – volume: 29 start-page: 55 year: 2018 end-page: 65 ident: CR77 article-title: JAK/STAT - emerging players in metabolism publication-title: Trends Endocrinol. Metab. doi: 10.1016/j.tem.2017.11.001 – volume: 69 start-page: 1949 year: 2017 end-page: 1959 ident: CR197 article-title: Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective JAK-1 inhibitor, after short-term treatment of rheumatoid arthritis: results of two randomized phase IIa trials publication-title: Arthritis Rheumatol. doi: 10.1002/art.40186 – volume: 64 start-page: 621 year: 1995 end-page: 651 ident: CR79 article-title: Transcriptional responses to polypeptide ligands: the JAK-STAT pathway publication-title: Annu. Rev. Biochem. doi: 10.1146/annurev.bi.64.070195.003201 – volume: 13 year: 2022 ident: CR325 article-title: Natural product preferentially targets redox and metabolic adaptations and aberrantly active STAT3 to inhibit breast tumor growth in vivo publication-title: Cell Death Dis. doi: 10.1038/s41419-022-05477-2 – volume: 39 start-page: 365 year: 2017 end-page: 383 ident: CR174 article-title: Selected cytokine pathways in rheumatoid arthritis publication-title: Semin. Immunopathol. doi: 10.1007/s00281-017-0619-z – volume: 31 start-page: 1 year: 2016 end-page: 15 ident: CR373 article-title: STAT3 signaling in immunity publication-title: Cytokine Growth Factor Rev. doi: 10.1016/j.cytogfr.2016.05.001 – volume: 79 start-page: 1321 year: 2019 end-page: 1335 ident: CR460 article-title: Innovations in oral therapies for inflammatory bowel disease publication-title: Drugs doi: 10.1007/s40265-019-01169-y – volume: 147 start-page: 436 year: 2011 end-page: 446 ident: CR103 article-title: Activation of STAT6 by STING is critical for antiviral innate immunity publication-title: Cell doi: 10.1016/j.cell.2011.09.022 – volume: 34 start-page: 1 year: 2019 end-page: 15 ident: CR211 article-title: Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it publication-title: Blood Rev. doi: 10.1016/j.blre.2018.09.001 – volume: 71 start-page: 1788 year: 2019 end-page: 1800 ident: CR266 article-title: Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase iii, double-blind, randomized controlled trial publication-title: Arthritis Rheumatol. doi: 10.1002/art.41032 – volume: 101 start-page: 1743 year: 2004 end-page: 1747 ident: CR302 article-title: Signal transduction pathways that inhibit hepatitis B virus replication publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0308340100 – volume: 106 start-page: 219 year: 2013 end-page: 228 ident: CR175 article-title: What is causing my arthritis, doctor? A glimpse beyond the usual suspects in the pathogenesis of rheumatoid arthritis publication-title: QJM doi: 10.1093/qjmed/hcs205 – volume: 112 start-page: 1402 year: 2008 end-page: 1412 ident: CR217 article-title: JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders publication-title: Blood doi: 10.1182/blood-2008-01-134114 – volume: 179 start-page: 54 year: 2018 end-page: 62 ident: CR289 article-title: Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study publication-title: Br. J. Dermatol. doi: 10.1111/bjd.16004 – volume: 60 start-page: 887 year: 2020 end-page: 939 ident: CR400 article-title: Cellular and molecular mechanisms of curcumin in prevention and treatment of disease publication-title: Crit. Rev. Food Sci. Nutr. doi: 10.1080/10408398.2018.1552244 – volume: 450 start-page: 110 year: 2019 end-page: 122 ident: CR393 article-title: STAT3 inhibition enhances CDN-induced STING signaling and antitumor immunity publication-title: Cancer Lett. doi: 10.1016/j.canlet.2019.02.029 – volume: 52 start-page: 164 year: 2017 end-page: 181 ident: CR146 article-title: The role of STAT signaling pathways in the pathogenesis of systemic lupus erythematosus publication-title: Clin. Rev. Allergy Immunol. doi: 10.1007/s12016-016-8550-y – volume: 149 start-page: 977 year: 2022 end-page: 987.e914 ident: CR267 article-title: Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD Up study results publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2021.07.036 – volume: 66 start-page: 1049 year: 2017 end-page: 1059 ident: CR467 article-title: Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials publication-title: Gut doi: 10.1136/gutjnl-2016-312735 – volume: 66 start-page: 918 year: 2014 end-page: 929 ident: CR147 article-title: STA-21, a promising STAT-3 inhibitor that reciprocally regulates Th17 and Treg cells, inhibits osteoclastogenesis in mice and humans and alleviates autoimmune inflammation in an experimental model of rheumatoid arthritis publication-title: Arthritis Rheumatol. doi: 10.1002/art.38305 – volume: 230 start-page: 107969 year: 2022 ident: CR114 article-title: Signal transducer and activator of transcription 3 signaling in tumor immune evasion publication-title: Pharm. Ther. doi: 10.1016/j.pharmthera.2021.107969 – volume: 10 start-page: 327 year: 2022 end-page: 336 ident: CR489 article-title: Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(22)00006-6 – volume: 158 start-page: 2123 year: 2020 end-page: 2138.e2128 ident: CR271 article-title: Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease publication-title: Gastroenterology doi: 10.1053/j.gastro.2020.01.047 – volume: 398 start-page: 803 year: 2021 end-page: 816 ident: CR408 article-title: Current and future status of JAK inhibitors publication-title: Lancet doi: 10.1016/S0140-6736(21)00438-4 – volume: 283 start-page: 33569 year: 2008 end-page: 33577 ident: CR53 article-title: Ligand-independent homomeric and heteromeric complexes between interleukin-2 or -9 receptor subunits and the gamma chain publication-title: J. Biol. Chem. doi: 10.1074/jbc.M803125200 – volume: 76 start-page: 1009 year: 2017 end-page: 1019 ident: CR178 article-title: Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2) publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2016-210105 – volume: 5 start-page: e73 year: 2018 end-page: e81 ident: CR209 article-title: Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial publication-title: Lancet Haematol. doi: 10.1016/S2352-3026(17)30237-5 – volume: 8 start-page: 615 year: 1998 end-page: 623 ident: CR362 article-title: Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis publication-title: Immunity doi: 10.1016/S1074-7613(00)80566-X – volume: 367 start-page: 616 year: 2012 end-page: 624 ident: CR447 article-title: Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1112168 – ident: CR543 – volume: 66 start-page: 1008 year: 2007 end-page: 1014 ident: CR189 article-title: Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients publication-title: Ann. Rheum. Dis. doi: 10.1136/ard.2006.063412 – volume: 23 start-page: 3418 year: 2008 end-page: 3426 ident: CR347 article-title: Activation of signal transducer and activator of transcription 3 correlates with cell proliferation and renal injury in human glomerulonephritis publication-title: Nephrol. Dial. Transpl. doi: 10.1093/ndt/gfn314 – volume: 98 start-page: 166 year: 2023 end-page: 179 ident: CR219 article-title: The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms publication-title: Am. J. Hematol. doi: 10.1002/ajh.26751 – volume: 8 start-page: 71 year: 2017 ident: CR57 article-title: The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK-Receptor Interactions publication-title: Front. Endocrinol. (Lausanne) doi: 10.3389/fendo.2017.00071 – volume: 69 start-page: 932 year: 2017 end-page: 942 ident: CR188 article-title: Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis publication-title: Arthritis Rheumatol. doi: 10.1002/art.40054 – volume: 30 start-page: 764 year: 2020 ident: 1468_CR158 publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2020.07.003 – volume: 124 start-page: 3529 year: 2014 ident: 1468_CR222 publication-title: Blood doi: 10.1182/blood-2014-05-577635 – volume: 18 start-page: 88 year: 2017 ident: 1468_CR421 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30558-7 – volume: 80 start-page: 913 year: 2019 ident: 1468_CR483 publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2018.01.018 – volume: 365 start-page: 1455 year: 2011 ident: 1468_CR425 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc1109555 – volume: 4 start-page: e351 year: 2022 ident: 1468_CR431 publication-title: Lancet Rheumatol. doi: 10.1016/S2665-9913(22)00044-3 – volume: 7 start-page: 454 year: 2007 ident: 1468_CR120 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri2093 – ident: 1468_CR468 doi: 10.1093/ecco-jcc/jjac141 – volume: 18 start-page: 374 year: 2017 ident: 1468_CR43 publication-title: Nat. Immunol. doi: 10.1038/ni.3691 – volume: 7 year: 2016 ident: 1468_CR332 publication-title: Nat. Commun. doi: 10.1038/ncomms12258 – volume: 145 start-page: 1406 year: 2020 ident: 1468_CR247 publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2019.11.047 – volume: 10 start-page: 156 year: 2017 ident: 1468_CR440 publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-017-0527-7 – volume: 363 start-page: 1117 year: 2010 ident: 1468_CR411 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1002028 – volume: 13 start-page: 369 year: 1995 ident: 1468_CR80 publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev.iy.13.040195.002101 – volume: 82 start-page: 292 year: 2022 ident: 1468_CR351 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-20-2426 – volume: 11 start-page: 69 year: 1995 ident: 1468_CR17 publication-title: Trends Genet. doi: 10.1016/S0168-9525(00)89000-9 – volume: 83 start-page: 71 year: 1998 ident: 1468_CR212 publication-title: Haematologica – volume: 10 start-page: e2202956 year: 2023 ident: 1468_CR324 publication-title: Adv. Sci. (Weinh.) – volume: 66 start-page: 100903 year: 2023 ident: 1468_CR326 publication-title: Drug Resist. Updat. doi: 10.1016/j.drup.2022.100903 – volume: 5 year: 2004 ident: 1468_CR6 publication-title: Genome Biol. doi: 10.1186/gb-2004-5-12-253 – volume: 19 year: 2020 ident: 1468_CR319 publication-title: Mol. Cancer doi: 10.1186/s12943-020-01258-7 – volume: 118 start-page: 20 year: 2015 ident: 1468_CR303 publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2015.03.001 – volume: 87 start-page: 4544 year: 1996 ident: 1468_CR238 publication-title: Blood doi: 10.1182/blood.V87.11.4544.bloodjournal87114544 – volume: 271 start-page: 13221 year: 1996 ident: 1468_CR371 publication-title: J. Biol. Chem. doi: 10.1074/jbc.271.22.13221 – volume: 79 start-page: 791 year: 2005 ident: 1468_CR349 publication-title: Transplantation doi: 10.1097/01.TP.0000157117.30290.6F – volume: 138 start-page: 657 year: 2013 ident: 1468_CR330 publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-013-2488-z – volume: 383 start-page: 1358 year: 2020 ident: 1468_CR213 publication-title: N. Engl. J. Med doi: 10.1056/NEJMra1904794 – volume: 78 start-page: S53 year: 2018 ident: 1468_CR250 publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2017.12.019 – volume: 21 start-page: 1015 year: 2019 ident: 1468_CR167 publication-title: Nat. Cell Biol. doi: 10.1038/s41556-019-0359-5 – volume: 22 start-page: 2169 year: 2008 ident: 1468_CR216 publication-title: Leukemia doi: 10.1038/leu.2008.226 – volume: 397 start-page: 2151 year: 2021 ident: 1468_CR279 publication-title: Lancet doi: 10.1016/S0140-6736(21)00588-2 – volume: 99 start-page: 8043 year: 2002 ident: 1468_CR139 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.122236099 – volume: 41 start-page: 837 year: 2014 ident: 1468_CR449 publication-title: J. Rheumatol. doi: 10.3899/jrheum.130683 – volume: 15 start-page: 234 year: 2018 ident: 1468_CR322 publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2018.8 – volume: 234 start-page: 108118 year: 2022 ident: 1468_CR113 publication-title: Pharm. Ther. doi: 10.1016/j.pharmthera.2022.108118 – volume: 76 start-page: 1009 year: 2017 ident: 1468_CR178 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2016-210105 – volume: 30 start-page: 846 year: 2019 ident: 1468_CR387 publication-title: Anticancer Drugs doi: 10.1097/CAD.0000000000000783 – volume: 67 start-page: 334 year: 2015 ident: 1468_CR515 publication-title: Arthritis Rheumatol. doi: 10.1002/art.38949 – volume: 184 start-page: 106419 year: 2022 ident: 1468_CR396 publication-title: Pharm. Res. doi: 10.1016/j.phrs.2022.106419 – volume: 13 start-page: 549 year: 2000 ident: 1468_CR82 publication-title: Immunity doi: 10.1016/S1074-7613(00)00054-6 – volume: 76 start-page: 694 year: 2017 ident: 1468_CR478 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2016-209821 – volume: 11 start-page: 604314 year: 2020 ident: 1468_CR545 publication-title: Front. Pharm. doi: 10.3389/fphar.2020.604314 – volume: 8 start-page: e11782 year: 2022 ident: 1468_CR436 publication-title: Heliyon doi: 10.1016/j.heliyon.2022.e11782 – volume: 377 start-page: 1537 year: 2017 ident: 1468_CR466 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1615975 – volume: 114 start-page: E4924 year: 2017 ident: 1468_CR382 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1615730114 – volume: 385 start-page: 228 year: 2021 ident: 1468_CR428 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2033122 – volume: 62 start-page: 6659 year: 2002 ident: 1468_CR309 publication-title: Cancer Res. – volume: 10 start-page: 888 year: 2022 ident: 1468_CR488 publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(22)00088-1 – volume: 855 start-page: 252 year: 2019 ident: 1468_CR376 publication-title: Eur. J. Pharm. doi: 10.1016/j.ejphar.2019.05.020 – volume: 69 start-page: 932 year: 2017 ident: 1468_CR188 publication-title: Arthritis Rheumatol. doi: 10.1002/art.40054 – volume: 81 start-page: 1515 year: 2022 ident: 1468_CR275 publication-title: Ann. Rheum. Dis. doi: 10.1136/ard-2022-222608 – volume: 19 start-page: 754 year: 2012 ident: 1468_CR61 publication-title: Nat. Struct. Mol. Biol. doi: 10.1038/nsmb.2348 – volume: 302 start-page: 875 year: 2003 ident: 1468_CR350 publication-title: Science doi: 10.1126/science.1087061 – volume: 79 start-page: 1719 year: 2019 ident: 1468_CR560 publication-title: Drugs doi: 10.1007/s40265-019-01205-x – volume: 77 start-page: 521 year: 2017 ident: 1468_CR42 publication-title: Drugs doi: 10.1007/s40265-017-0701-9 – volume: 290 start-page: F762 year: 2006 ident: 1468_CR340 publication-title: Am. J. Physiol. Ren. Physiol. doi: 10.1152/ajprenal.00181.2005 – volume: 18 start-page: 545 year: 2008 ident: 1468_CR107 publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2008.08.008 – volume: 48 start-page: 1230 year: 2021 ident: 1468_CR522 publication-title: J. Rheumatol. doi: 10.3899/jrheum.201183 – volume: 377 start-page: 1180 year: 2022 ident: 1468_CR31 publication-title: Science doi: 10.1126/science.abn0478 – volume: 106 start-page: 2162 year: 2005 ident: 1468_CR224 publication-title: Blood doi: 10.1182/blood-2005-03-1320 – volume: 71 start-page: 209 year: 2021 ident: 1468_CR291 publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21660 – volume: 20 start-page: 1033 year: 2022 ident: 1468_CR512 publication-title: J. Natl. Compr. Cancer Netw. doi: 10.6004/jnccn.2022.0046 – volume: 14 start-page: S713 year: 2020 ident: 1468_CR505 publication-title: J. Crohns Colitis doi: 10.1093/ecco-jcc/jjz206 – volume: 119 start-page: e2114324119 year: 2022 ident: 1468_CR169 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.2114324119 – volume: 2 start-page: 86 year: 2000 ident: 1468_CR320 publication-title: Breast Cancer Res. doi: 10.1186/bcr38 – ident: 1468_CR257 doi: 10.1016/j.jaad.2022.09.060 – volume: 14 start-page: 1421 year: 1995 ident: 1468_CR63 publication-title: EMBO J. doi: 10.1002/j.1460-2075.1995.tb07128.x – volume: 36 start-page: 2261 year: 2022 ident: 1468_CR207 publication-title: Leukemia doi: 10.1038/s41375-022-01637-7 – volume: 74 start-page: 1311 year: 2015 ident: 1468_CR32 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2014-206028 – volume: 57 start-page: 1838 year: 2018 ident: 1468_CR388 publication-title: Rheumatology doi: 10.1093/rheumatology/kex347 – volume: 181 start-page: 399 year: 1995 ident: 1468_CR88 publication-title: J. Exp. Med. doi: 10.1084/jem.181.1.399 – volume: 4 start-page: e317 year: 2017 ident: 1468_CR417 publication-title: Lancet Haematol. doi: 10.1016/S2352-3026(17)30088-1 – volume: 18 start-page: 971 year: 2011 ident: 1468_CR225 publication-title: Nat. Struct. Mol. Biol. doi: 10.1038/nsmb.2099 – volume: 60 start-page: 2472 year: 2021 ident: 1468_CR470 publication-title: Rheumatology doi: 10.1093/rheumatology/keaa613 – volume: 382 start-page: 1800 year: 2020 ident: 1468_CR413 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1917635 – volume: 11 start-page: 1701 year: 2019 ident: 1468_CR84 publication-title: Cancers (Basel) doi: 10.3390/cancers11111701 – volume: 36 start-page: 1308 year: 2022 ident: 1468_CR527 publication-title: J. Eur. Acad. Dermatol. Venereol. doi: 10.1111/jdv.18170 – volume: 42 start-page: 1208 year: 2005 ident: 1468_CR295 publication-title: Hepatology doi: 10.1002/hep.20933 – volume: 15 start-page: 973 year: 2020 ident: 1468_CR338 publication-title: Clin. J. Am. Soc. Nephrol. doi: 10.2215/CJN.11010919 – volume: 23 start-page: 701 year: 2011 ident: 1468_CR181 publication-title: Int. Immunol. doi: 10.1093/intimm/dxr077 – volume: 376 start-page: 163 year: 2022 ident: 1468_CR56 publication-title: Science doi: 10.1126/science.abn8933 – volume: 71 start-page: 2497 year: 2011 ident: 1468_CR144 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-10-3025 – volume: 282 start-page: 20059 year: 2007 ident: 1468_CR102 publication-title: J. Biol. Chem. doi: 10.1074/jbc.R700016200 – volume: 461 start-page: 819 year: 2009 ident: 1468_CR218 publication-title: Nature doi: 10.1038/nature08448 – volume: 11 start-page: 7020 year: 2022 ident: 1468_CR389 publication-title: J. Clin. Med. doi: 10.3390/jcm11237020 – volume: 19 start-page: 2566 year: 2000 ident: 1468_CR364 publication-title: Oncogene doi: 10.1038/sj.onc.1203523 – volume: 26 start-page: 998 year: 2015 ident: 1468_CR383 publication-title: Ann. Oncol. doi: 10.1093/annonc/mdv026 – volume: 93 start-page: 397 year: 1998 ident: 1468_CR73 publication-title: Cell doi: 10.1016/S0092-8674(00)81168-X – volume: 11 start-page: 42 year: 2018 ident: 1468_CR427 publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-018-0585-5 – volume: 20 start-page: 116 year: 2022 ident: 1468_CR461 publication-title: Clin. Gastroenterol. Hepatol. doi: 10.1016/j.cgh.2020.10.004 – volume: 99 start-page: 1 year: 2019 ident: 1468_CR131 publication-title: J. Autoimmun. doi: 10.1016/j.jaut.2019.01.013 – volume: 176 start-page: 1 year: 2014 ident: 1468_CR551 publication-title: Clin. Exp. Immunol. doi: 10.1111/cei.12248 – volume: 11 start-page: 179 year: 1997 ident: 1468_CR363 publication-title: Genes Dev. doi: 10.1101/gad.11.2.179 – volume: 34 start-page: 1 year: 2019 ident: 1468_CR211 publication-title: Blood Rev. doi: 10.1016/j.blre.2018.09.001 – volume: 59 start-page: 229 year: 2020 ident: 1468_CR472 publication-title: Intern. Med. doi: 10.2169/internalmedicine.3528-19 – ident: 1468_CR374 doi: 10.1172/JCI153247 – volume: 108 start-page: 3472 year: 2006 ident: 1468_CR241 publication-title: Blood doi: 10.1182/blood-2006-04-018879 – volume: 208 start-page: 356 year: 2022 ident: 1468_CR399 publication-title: Int. J. Biol. Macromol. doi: 10.1016/j.ijbiomac.2022.03.137 – volume: 123 start-page: e123 year: 2014 ident: 1468_CR223 publication-title: Blood doi: 10.1182/blood-2014-02-554634 – volume: 123 start-page: 2157 year: 2014 ident: 1468_CR438 publication-title: Blood doi: 10.1182/blood-2013-11-536557 – volume: 107 start-page: 798 year: 2003 ident: 1468_CR353 publication-title: Circulation doi: 10.1161/01.CIR.0000057545.82749.FF – volume: 13 year: 2022 ident: 1468_CR325 publication-title: Cell Death Dis. doi: 10.1038/s41419-022-05477-2 – volume: 81 start-page: 318 year: 2020 ident: 1468_CR493 publication-title: J. Infect. doi: 10.1016/j.jinf.2020.04.017 – volume: 16 start-page: 293 year: 1998 ident: 1468_CR1 publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev.immunol.16.1.293 – volume: 74 start-page: 1395 year: 2021 ident: 1468_CR385 publication-title: Hepatology doi: 10.1002/hep.31812 – volume: 35 start-page: 1 year: 2021 ident: 1468_CR561 publication-title: Leukemia doi: 10.1038/s41375-020-0954-2 – volume: 391 start-page: 2503 year: 2018 ident: 1468_CR520 publication-title: Lancet doi: 10.1016/S0140-6736(18)31115-2 – volume: 147 start-page: 436 year: 2011 ident: 1468_CR103 publication-title: Cell doi: 10.1016/j.cell.2011.09.022 – volume: 197 start-page: 114940 year: 2022 ident: 1468_CR402 publication-title: Biochem. Pharm. doi: 10.1016/j.bcp.2022.114940 – volume: 73 start-page: 2166 year: 2021 ident: 1468_CR409 publication-title: Arthritis Rheumatol. doi: 10.1002/art.41906 – volume: 47 start-page: 114 year: 2020 ident: 1468_CR501 publication-title: J. Dermatol. doi: 10.1111/1346-8138.15173 – volume: 368 start-page: 161 year: 2013 ident: 1468_CR138 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra1202117 – volume: 78 start-page: 257 year: 2010 ident: 1468_CR335 publication-title: Kidney Int. doi: 10.1038/ki.2010.154 – volume: 7 start-page: 6 year: 2021 ident: 1468_CR293 publication-title: Nat Rev Dis Primers. doi: 10.1038/s41572-020-00240-3 – volume: 81 start-page: 335 year: 2022 ident: 1468_CR476 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2021-221276 – volume: 73 start-page: 5288 year: 2013 ident: 1468_CR359 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-13-0874 – volume: 28 start-page: 248 year: 2014 ident: 1468_CR93 publication-title: Leukemia doi: 10.1038/leu.2013.192 – volume: 6 start-page: 368 year: 2016 ident: 1468_CR234 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-15-1434 – volume: 902 start-page: 174121 year: 2021 ident: 1468_CR342 publication-title: Eur. J. Pharm. doi: 10.1016/j.ejphar.2021.174121 – volume: 85 start-page: 863 year: 2021 ident: 1468_CR256 publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2021.04.085 – volume: 25 start-page: 695 year: 2006 ident: 1468_CR90 publication-title: Immunity doi: 10.1016/j.immuni.2006.10.007 – volume: 450 start-page: 110 year: 2019 ident: 1468_CR393 publication-title: Cancer Lett. doi: 10.1016/j.canlet.2019.02.029 – volume: 74 start-page: 70 year: 2022 ident: 1468_CR264 publication-title: Arthritis Rheumatol. doi: 10.1002/art.41911 – volume: 51 start-page: 3505 year: 2002 ident: 1468_CR339 publication-title: Diabetes doi: 10.2337/diabetes.51.12.3505 – volume: 13 year: 2022 ident: 1468_CR469 publication-title: Nat. Commun. doi: 10.1038/s41467-022-30615-x – volume: 34 start-page: 555 year: 2019 ident: 1468_CR157 publication-title: Trends Ecol. Evol. doi: 10.1016/j.tree.2019.02.010 – ident: 1468_CR281 doi: 10.1016/j.anai.2023.01.020 – volume: 12 year: 2021 ident: 1468_CR116 publication-title: Nat. Commun. doi: 10.1038/s41467-021-26983-5 – volume: 144 start-page: 1575 year: 2019 ident: 1468_CR504 publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2019.08.004 – volume: 114 start-page: 476 year: 2004 ident: 1468_CR13 publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2004.06.042 – volume: 82 start-page: 843 year: 2022 ident: 1468_CR246 publication-title: Drugs doi: 10.1007/s40265-022-01722-2 – volume: 66 start-page: 3029 year: 2009 ident: 1468_CR128 publication-title: Cell Mol. Life Sci. doi: 10.1007/s00018-009-0061-z – volume: 353 start-page: 405 year: 2015 ident: 1468_CR514 publication-title: J. Pharm. Exp. Ther. doi: 10.1124/jpet.114.221176 – volume: 82 start-page: 823 year: 2020 ident: 1468_CR502 publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2019.12.015 – volume: 10 year: 2019 ident: 1468_CR141 publication-title: Nat. Commun. doi: 10.1038/s41467-019-08743-8 – volume: 75 start-page: 1057 year: 2016 ident: 1468_CR187 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2015-208279 – volume: 31 start-page: 1 year: 2016 ident: 1468_CR373 publication-title: Cytokine Growth Factor Rev. doi: 10.1016/j.cytogfr.2016.05.001 – volume: 397 start-page: 195 year: 2021 ident: 1468_CR288 publication-title: Lancet doi: 10.1016/S0140-6736(21)00036-2 – volume: 65 start-page: 559 year: 2013 ident: 1468_CR204 publication-title: Arthritis Rheum. doi: 10.1002/art.37816 – volume: 185 start-page: 3857 year: 2022 ident: 1468_CR548 publication-title: Cell doi: 10.1016/j.cell.2022.09.023 – volume: 48 start-page: 2132 year: 2003 ident: 1468_CR183 publication-title: Arthritis Rheum. doi: 10.1002/art.11096 – volume: 10 start-page: 54 year: 2017 ident: 1468_CR239 publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-017-0425-z – volume: 55 start-page: 1547 year: 2016 ident: 1468_CR274 publication-title: Clin. Pharmacokinet. doi: 10.1007/s40262-016-0419-y – volume: 397 start-page: 2169 year: 2021 ident: 1468_CR259 publication-title: Lancet doi: 10.1016/S0140-6736(21)00589-4 – volume: 19 start-page: 222 year: 1994 ident: 1468_CR18 publication-title: Trends Biochem. Sci. doi: 10.1016/0968-0004(94)90026-4 – volume: 7 start-page: R424 year: 1997 ident: 1468_CR78 publication-title: Curr. Biol. doi: 10.1016/S0960-9822(06)00208-9 – volume: 366 start-page: 799 year: 2012 ident: 1468_CR420 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1110557 – volume: 423 start-page: 356 year: 2003 ident: 1468_CR170 publication-title: Nature doi: 10.1038/nature01661 – volume: 120 start-page: 3048 year: 2012 ident: 1468_CR20 publication-title: Blood doi: 10.1182/blood-2012-06-435297 – volume: 43 start-page: 424 year: 2022 ident: 1468_CR506 publication-title: Trends Pharm. Sci. doi: 10.1016/j.tips.2022.02.008 – volume: 296 start-page: 115507 year: 2022 ident: 1468_CR74 publication-title: J. Ethnopharmacol. doi: 10.1016/j.jep.2022.115507 – volume: 19 start-page: 2240 year: 2013 ident: 1468_CR162 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-2246 – volume: 135 start-page: 683 year: 2006 ident: 1468_CR240 publication-title: Br. J. Haematol. doi: 10.1111/j.1365-2141.2006.06348.x – volume: 37 start-page: 67 year: 2017 ident: 1468_CR406 publication-title: Cytokine Growth Factor Rev. doi: 10.1016/j.cytogfr.2017.07.005 – volume: 80 start-page: 304 year: 2021 ident: 1468_CR261 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2020-218510 – volume: 13 start-page: 23 year: 2023 ident: 1468_CR313 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-22-0475 – volume: 145 start-page: 572 year: 2020 ident: 1468_CR258 publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2019.08.042 – volume: 73 start-page: 857 year: 2013 ident: 1468_CR443 publication-title: Drugs doi: 10.1007/s40265-013-0065-8 – volume: 6 start-page: 90 year: 2013 ident: 1468_CR92 publication-title: J. Hematol. Oncol. doi: 10.1186/1756-8722-6-90 – volume: 12 start-page: 1847 year: 2022 ident: 1468_CR159 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-21-0282 – volume: 26 start-page: 1065 year: 2012 ident: 1468_CR235 publication-title: Hematol. Oncol. Clin. North Am. doi: 10.1016/j.hoc.2012.07.007 – volume: 192 start-page: 114688 year: 2021 ident: 1468_CR384 publication-title: Biochem. Pharm. doi: 10.1016/j.bcp.2021.114688 – volume: 29 start-page: 679 year: 2008 ident: 1468_CR356 publication-title: Immunity doi: 10.1016/j.immuni.2008.08.017 – volume: 5 year: 2015 ident: 1468_CR510 publication-title: Blood Cancer J. doi: 10.1038/bcj.2015.63 – volume: 189 start-page: 4 year: 2018 ident: 1468_CR132 publication-title: Clin. Immunol. doi: 10.1016/j.clim.2016.09.014 – volume: 353 start-page: 1253 year: 1999 ident: 1468_CR296 publication-title: Lancet doi: 10.1016/S0140-6736(98)09148-X – volume: 369 start-page: 197 year: 2013 ident: 1468_CR433 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc1302135 – volume: 270 start-page: 794 year: 1995 ident: 1468_CR81 publication-title: Science doi: 10.1126/science.270.5237.794 – volume: 384 start-page: 1101 year: 2021 ident: 1468_CR284 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2019380 – volume: 95 start-page: 594 year: 2020 ident: 1468_CR509 publication-title: Am. J. Hematol. doi: 10.1002/ajh.25777 – volume: 35 start-page: 533 year: 2017 ident: 1468_CR44 publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev-immunol-110416-120628 – volume: 66 start-page: 588 year: 1999 ident: 1468_CR123 publication-title: J. Leukoc. Biol. doi: 10.1002/jlb.66.4.588 – volume: 8 start-page: 959 year: 2001 ident: 1468_CR58 publication-title: Mol. Cell doi: 10.1016/S1097-2765(01)00398-7 – ident: 1468_CR316 doi: 10.1016/j.annonc.2023.01.009 – volume: 80 start-page: 106210 year: 2020 ident: 1468_CR109 publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2020.106210 – volume: 7 start-page: e226 year: 2020 ident: 1468_CR416 publication-title: Lancet Haematol. doi: 10.1016/S2352-3026(19)30207-8 – volume: 71 start-page: 1788 year: 2019 ident: 1468_CR266 publication-title: Arthritis Rheumatol. doi: 10.1002/art.41032 – volume: 158 start-page: 2123 year: 2020 ident: 1468_CR271 publication-title: Gastroenterology doi: 10.1053/j.gastro.2020.01.047 – volume: 150 start-page: 78 year: 2014 ident: 1468_CR336 publication-title: Clin. Immunol. doi: 10.1016/j.clim.2013.11.003 – volume: 10 start-page: e004384 year: 2022 ident: 1468_CR377 publication-title: J. Immunother. Cancer doi: 10.1136/jitc-2021-004384 – volume: 367 start-page: 495 year: 2012 ident: 1468_CR465 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1109071 – volume: 71 start-page: 405 year: 1999 ident: 1468_CR106 publication-title: Prog. Biophys. Mol. Biol. doi: 10.1016/S0079-6107(98)00051-0 – volume: 42 start-page: 186 year: 2000 ident: 1468_CR25 publication-title: Prostate doi: 10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E – volume: 86 start-page: 2516 year: 1995 ident: 1468_CR236 publication-title: Blood doi: 10.1182/blood.V86.7.2516.2516 – volume: 14 start-page: 1402 year: 1995 ident: 1468_CR367 publication-title: EMBO J. doi: 10.1002/j.1460-2075.1995.tb07126.x – volume: 167 start-page: 61 year: 2016 ident: 1468_CR133 publication-title: Transl. Res. doi: 10.1016/j.trsl.2015.08.013 – volume: 11 start-page: 1763 year: 2021 ident: 1468_CR534 publication-title: Dermatol. Ther. doi: 10.1007/s13555-021-00596-8 – volume: 70 start-page: 2029 year: 2011 ident: 1468_CR190 publication-title: Ann. Rheum. Dis. doi: 10.1136/ard.2011.150326 – volume: 80 start-page: 727 year: 2021 ident: 1468_CR198 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2020-219213 – volume: 5 start-page: 475 year: 2004 ident: 1468_CR298 publication-title: Curr. Protein Pept. Sci. doi: 10.2174/1389203043379378 – volume: 385 start-page: 406 year: 2021 ident: 1468_CR445 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2101643 – volume: 377 start-page: 1525 year: 2017 ident: 1468_CR454 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1615977 – volume: 24 start-page: 3391 year: 2023 ident: 1468_CR83 publication-title: Int J. Mol. Sci. doi: 10.3390/ijms24043391 – volume: 9 start-page: 2415 year: 1994 ident: 1468_CR8 publication-title: Oncogene – ident: 1468_CR543 doi: 10.1021/acs.jmedchem.9b01392 – volume: 283 start-page: 33569 year: 2008 ident: 1468_CR53 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M803125200 – volume: 155 start-page: 1079 year: 1995 ident: 1468_CR64 publication-title: J. Immunol. doi: 10.4049/jimmunol.155.3.1079 – volume: 17 start-page: 431 year: 2006 ident: 1468_CR119 publication-title: Cytokine Growth Factor Rev. doi: 10.1016/j.cytogfr.2006.09.008 – volume: 386 start-page: 1687 year: 2022 ident: 1468_CR487 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2110343 – volume: 263 start-page: 92 year: 1994 ident: 1468_CR87 publication-title: Science doi: 10.1126/science.8272873 – volume: 383 start-page: 1511 year: 2020 ident: 1468_CR260 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2008250 – volume: 8 start-page: 71 year: 2017 ident: 1468_CR57 publication-title: Front. Endocrinol. (Lausanne) doi: 10.3389/fendo.2017.00071 – volume: 28 start-page: 477 year: 2008 ident: 1468_CR135 publication-title: Immunity doi: 10.1016/j.immuni.2008.03.002 – volume: 39 start-page: 365 year: 2017 ident: 1468_CR174 publication-title: Semin. Immunopathol. doi: 10.1007/s00281-017-0619-z – volume: 98 start-page: 166 year: 2023 ident: 1468_CR219 publication-title: Am. J. Hematol. doi: 10.1002/ajh.26751 – volume: 140 start-page: 2076 year: 2022 ident: 1468_CR98 publication-title: Blood doi: 10.1182/blood.2022015677 – volume: 33 start-page: 1978 year: 2019 ident: 1468_CR432 publication-title: Leukemia doi: 10.1038/s41375-019-0379-y – volume: 11 start-page: 415 year: 2015 ident: 1468_CR176 publication-title: Nat. Rev. Rheumatol. doi: 10.1038/nrrheum.2015.53 – volume: 75 start-page: 1293 year: 2016 ident: 1468_CR200 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2014-207178 – volume: 72 start-page: ii111 year: 2013 ident: 1468_CR140 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2012-202576 – volume: 9 start-page: 997 year: 2015 ident: 1468_CR554 publication-title: Mol. Oncol. doi: 10.1016/j.molonc.2014.07.025 – volume: 63 start-page: 233 year: 2004 ident: 1468_CR182 publication-title: Ann. Rheum. Dis. doi: 10.1136/ard.2003.013276 – volume: 23 start-page: 115 year: 2023 ident: 1468_CR112 publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-022-00537-3 – volume: 27 start-page: 1485 year: 2009 ident: 1468_CR292 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2008.20.7753 – volume: 36 start-page: 157 year: 2012 ident: 1468_CR115 publication-title: Immunity doi: 10.1016/j.immuni.2012.01.010 – volume: 87 start-page: 784 year: 2022 ident: 1468_CR263 publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2022.06.012 – volume: 18 start-page: 706 year: 2019 ident: 1468_CR513 publication-title: Autoimmun. Rev. doi: 10.1016/j.autrev.2019.05.007 – volume: 15 start-page: 2022 year: 2021 ident: 1468_CR278 publication-title: J. Crohns Colitis doi: 10.1093/ecco-jcc/jjab099 – volume: 20 start-page: 1574 year: 2019 ident: 1468_CR4 publication-title: Nat. Immunol. doi: 10.1038/s41590-019-0466-2 – volume: 60 start-page: 303 year: 2004 ident: 1468_CR27 publication-title: Prostate doi: 10.1002/pros.20072 – volume: 18 start-page: jjaa162 year: 2020 ident: 1468_CR67 publication-title: J. Crohns Colitis – volume: 376 start-page: 652 year: 2017 ident: 1468_CR485 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1608345 – volume: 30 start-page: 2345 year: 2011 ident: 1468_CR26 publication-title: Oncogene doi: 10.1038/onc.2010.605 – volume: 85 start-page: 854 year: 2021 ident: 1468_CR503 publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2021.06.014 – volume: 75 start-page: 242 year: 2023 ident: 1468_CR538 publication-title: Arthritis Rheumatol. doi: 10.1002/art.42391 – volume: 175 start-page: Jc113 year: 2022 ident: 1468_CR269 publication-title: Ann. Intern. Med. doi: 10.7326/J22-0073 – volume: 81 start-page: 647 year: 2020 ident: 1468_CR494 publication-title: J. Infect. doi: 10.1016/j.jinf.2020.06.052 – volume: 137 start-page: 1079 year: 2016 ident: 1468_CR457 publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2015.12.1318 – volume: 366 start-page: 787 year: 2012 ident: 1468_CR424 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1110556 – volume: 42 start-page: 112061 year: 2023 ident: 1468_CR165 publication-title: Cell Rep. doi: 10.1016/j.celrep.2023.112061 – ident: 1468_CR282 doi: 10.2174/0929867330666230216123419 – volume: 72 start-page: 865 year: 2020 ident: 1468_CR299 publication-title: J. Hepatol. doi: 10.1016/j.jhep.2019.12.009 – volume: 10 start-page: 327 year: 2022 ident: 1468_CR489 publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(22)00006-6 – volume: 156 start-page: 863 year: 2020 ident: 1468_CR528 publication-title: JAMA Dermatol. doi: 10.1001/jamadermatol.2020.1406 – volume: 38 start-page: 1006 year: 2020 ident: 1468_CR423 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.19.00895 – volume: 374 start-page: 1243 year: 2016 ident: 1468_CR475 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1507247 – volume: 215 start-page: 337 year: 2018 ident: 1468_CR357 publication-title: J. Exp. Med. doi: 10.1084/jem.20170457 – volume: 92 start-page: 833 year: 2017 ident: 1468_CR434 publication-title: Am. J. Hematol. doi: 10.1002/ajh.24775 – volume: 273 start-page: 12567 year: 1998 ident: 1468_CR62 publication-title: J. Biol. Chem. doi: 10.1074/jbc.273.20.12567 – volume: 84 start-page: 106497 year: 2020 ident: 1468_CR191 publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2020.106497 – volume: 85 start-page: 3101 year: 1995 ident: 1468_CR46 publication-title: Blood doi: 10.1182/blood.V85.11.3101.bloodjournal85113101 – volume: 6 start-page: 183 year: 2015 ident: 1468_CR407 publication-title: Front. Immunol. doi: 10.3389/fimmu.2015.00183 – volume: 31 start-page: 1285 year: 2013 ident: 1468_CR415 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2012.44.4489 – volume: 60 start-page: 41 year: 2020 ident: 1468_CR91 publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2019.10.002 – volume: 193 start-page: 114760 year: 2021 ident: 1468_CR28 publication-title: Biochem. Pharm. doi: 10.1016/j.bcp.2021.114760 – volume: 29 start-page: 2163 year: 2022 ident: 1468_CR51 publication-title: Cell Death Differ. doi: 10.1038/s41418-022-01005-z – ident: 1468_CR464 doi: 10.1136/ard-2022-223356corr1 – volume: 173 start-page: 767 year: 2015 ident: 1468_CR193 publication-title: Br. J. Dermatol. doi: 10.1111/bjd.13745 – volume: 29 start-page: 1631 year: 2015 ident: 1468_CR331 publication-title: Genes Dev. doi: 10.1101/gad.262642.115 – volume: 149 start-page: 977 year: 2022 ident: 1468_CR267 publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2021.07.036 – volume: 8 start-page: 945 year: 2002 ident: 1468_CR368 publication-title: Clin. Cancer Res. – volume: 185 start-page: 351 year: 1997 ident: 1468_CR50 publication-title: J. Exp. Med. doi: 10.1084/jem.185.2.351 – volume: 119 start-page: 3997 year: 2012 ident: 1468_CR148 publication-title: Blood doi: 10.1182/blood-2011-11-392985 – volume: 66 start-page: 918 year: 2014 ident: 1468_CR147 publication-title: Arthritis Rheumatol. doi: 10.1002/art.38305 – volume: 112 start-page: 1402 year: 2008 ident: 1468_CR217 publication-title: Blood doi: 10.1182/blood-2008-01-134114 – volume: 27 start-page: 136 year: 2018 ident: 1468_CR323 publication-title: Cell Metab. doi: 10.1016/j.cmet.2017.11.001 – volume: 384 start-page: 1227 year: 2021 ident: 1468_CR277 publication-title: N. Engl. J. Med doi: 10.1056/NEJMoa2022516 – volume: 352 start-page: 1779 year: 2005 ident: 1468_CR226 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa051113 – volume: 64 start-page: 617 year: 2012 ident: 1468_CR201 publication-title: Arthritis Rheum. doi: 10.1002/art.33383 – volume: 270 start-page: 12286 year: 1995 ident: 1468_CR89 publication-title: J. Biol. Chem. doi: 10.1074/jbc.270.20.12286 – volume: 20 start-page: 181 year: 2019 ident: 1468_CR273 publication-title: Am. J. Clin. Dermatol. doi: 10.1007/s40257-018-0413-2 – volume: 79 start-page: 887 year: 2019 ident: 1468_CR496 publication-title: Drugs doi: 10.1007/s40265-019-01131-y – volume: 12 start-page: 738481 year: 2021 ident: 1468_CR33 publication-title: Front. Immunol. doi: 10.3389/fimmu.2021.738481 – volume: 20 start-page: 400 year: 2020 ident: 1468_CR491 publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(20)30132-8 – volume: 115 start-page: 1692 year: 2009 ident: 1468_CR68 publication-title: Cancer doi: 10.1002/cncr.24183 – volume: 24 start-page: 279 year: 2017 ident: 1468_CR12 publication-title: Nat. Struct. Mol. Biol. doi: 10.1038/nsmb.3378 – volume: 29 start-page: 789 year: 2011 ident: 1468_CR507 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.32.8021 – volume: 94 start-page: 11839 year: 1997 ident: 1468_CR85 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.94.22.11839 – volume: 2 start-page: 100269 year: 2021 ident: 1468_CR361 publication-title: Cell Rep. Med. doi: 10.1016/j.xcrm.2021.100269 – volume: 20 start-page: 7132 year: 2000 ident: 1468_CR94 publication-title: Mol. Cell Biol. doi: 10.1128/MCB.20.19.7132-7139.2000 – volume: 12 year: 2022 ident: 1468_CR164 publication-title: Clin. Transl. Med. doi: 10.1002/ctm2.978 – volume: 2 start-page: 740 year: 2002 ident: 1468_CR14 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc906 – volume: 42 start-page: 4389 year: 2021 ident: 1468_CR108 publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehab447 – volume: 15 year: 2017 ident: 1468_CR126 publication-title: Cell Commun. Signal. doi: 10.1186/s12964-017-0177-y – volume: 392 start-page: 222 year: 2018 ident: 1468_CR480 publication-title: Lancet doi: 10.1016/S0140-6736(18)31363-1 – volume: 3 start-page: 651 year: 2002 ident: 1468_CR10 publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/nrm909 – volume: 400 start-page: 369 year: 2022 ident: 1468_CR524 publication-title: Lancet doi: 10.1016/S0140-6736(22)01212-0 – volume: 365 start-page: 2205 year: 2011 ident: 1468_CR173 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra1004965 – volume: 71 start-page: 892 year: 2019 ident: 1468_CR37 publication-title: Arthritis Rheumatol. doi: 10.1002/art.40798 – volume: 35 start-page: 2616 year: 2021 ident: 1468_CR557 publication-title: Leukemia doi: 10.1038/s41375-021-01266-6 – volume: 40 start-page: 1671 year: 2022 ident: 1468_CR422 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.21.02188 – volume: 12 start-page: 1158 year: 2018 ident: 1468_CR194 publication-title: J. Crohns Colitis doi: 10.1093/ecco-jcc/jjy085 – volume: 183 start-page: 242 year: 2020 ident: 1468_CR255 publication-title: Br. J. Dermatol. doi: 10.1111/bjd.18898 – volume: 155 start-page: 1371 year: 2019 ident: 1468_CR526 publication-title: JAMA Dermatol. doi: 10.1001/jamadermatol.2019.2855 – volume: 92 start-page: 3234 year: 1995 ident: 1468_CR237 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.92.8.3234 – volume: 65 start-page: 149 year: 2006 ident: 1468_CR184 publication-title: Ann. Rheum. Dis. doi: 10.1136/ard.2005.037929 – volume: 266 start-page: 1042 year: 1994 ident: 1468_CR49 publication-title: Science doi: 10.1126/science.7973658 – volume: 75 start-page: 1341 year: 2015 ident: 1468_CR311 publication-title: Prostate doi: 10.1002/pros.23015 – volume: 176 start-page: 105964 year: 2023 ident: 1468_CR75 publication-title: Neurobiol. Dis. doi: 10.1016/j.nbd.2022.105964 – volume: 29 start-page: 55 year: 2018 ident: 1468_CR77 publication-title: Trends Endocrinol. Metab. doi: 10.1016/j.tem.2017.11.001 – volume: 27 start-page: 4660 year: 2022 ident: 1468_CR252 publication-title: Molecules doi: 10.3390/molecules27144660 – volume: 4 start-page: e8100 year: 2009 ident: 1468_CR341 publication-title: PLoS One doi: 10.1371/journal.pone.0008100 – ident: 1468_CR294 doi: 10.1016/j.jhep.2011.12.001 – volume: 83 start-page: 525 year: 2016 ident: 1468_CR540 publication-title: Jt. Bone Spine doi: 10.1016/j.jbspin.2015.09.002 – volume: 7 start-page: 1 year: 1997 ident: 1468_CR2 publication-title: Immunity doi: 10.1016/S1074-7613(00)80505-1 – volume: 45 start-page: 1585 year: 2022 ident: 1468_CR308 publication-title: Inflammation doi: 10.1007/s10753-022-01644-x – volume: 90 start-page: 636 year: 2012 ident: 1468_CR151 publication-title: Am. J. Hum. Genet. doi: 10.1016/j.ajhg.2012.02.020 – volume: 124 start-page: 3092 year: 2014 ident: 1468_CR54 publication-title: Blood doi: 10.1182/blood-2014-04-566687 – volume: 14 start-page: 1026 year: 2020 ident: 1468_CR462 publication-title: J. Crohns Colitis doi: 10.1093/ecco-jcc/jjaa018 – volume: 7 start-page: 1958 year: 2019 ident: 1468_CR153 publication-title: J. Allergy Clin. Immunol. Pr. doi: 10.1016/j.jaip.2019.02.018 – volume: 44 start-page: 1265 year: 2014 ident: 1468_CR122 publication-title: Eur. J. Immunol. doi: 10.1002/eji.201344369 – volume: 88 start-page: 29 year: 2023 ident: 1468_CR536 publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2022.07.002 – volume: 99 start-page: 1331 year: 2021 ident: 1468_CR479 publication-title: Kidney Int. doi: 10.1016/j.kint.2021.01.024 – volume: 69 start-page: 7 year: 2019 ident: 1468_CR314 publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21551 – volume: 366 start-page: 1905 year: 2012 ident: 1468_CR19 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1114885 – volume: 46 start-page: 220 year: 2017 ident: 1468_CR180 publication-title: Immunity doi: 10.1016/j.immuni.2017.01.004 – volume: 38 start-page: 533 year: 2019 ident: 1468_CR392 publication-title: Oncogene doi: 10.1038/s41388-018-0449-z – volume: 24 start-page: 1387 year: 2014 ident: 1468_CR390 publication-title: Cell Res. doi: 10.1038/cr.2014.154 – volume: 10 start-page: tkac023 year: 2022 ident: 1468_CR160 publication-title: Burns Trauma doi: 10.1093/burnst/tkac023 – volume: 79 start-page: 1819 year: 2019 ident: 1468_CR521 publication-title: Drugs doi: 10.1007/s40265-019-01211-z – volume: 13 start-page: 67 year: 2010 ident: 1468_CR29 publication-title: Drug Resist. Updat. doi: 10.1016/j.drup.2010.04.001 – volume: 66 start-page: 311 year: 2015 ident: 1468_CR38 publication-title: Annu. Rev. Med. doi: 10.1146/annurev-med-051113-024537 – volume: 58 start-page: 953 year: 2019 ident: 1468_CR552 publication-title: Rheumatology doi: 10.1093/rheumatology/key339 – volume: 322 start-page: 315 year: 2019 ident: 1468_CR177 publication-title: Jama doi: 10.1001/jama.2019.9055 – volume: 24 start-page: 1128 year: 2010 ident: 1468_CR215 publication-title: Leukemia doi: 10.1038/leu.2010.69 – volume: 396 start-page: 110 year: 2020 ident: 1468_CR412 publication-title: Lancet doi: 10.1016/S0140-6736(20)30609-7 – volume: 100 start-page: 184 year: 2008 ident: 1468_CR562 publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/djm328 – volume: 183 start-page: 106359 year: 2022 ident: 1468_CR36 publication-title: Pharm. Res. doi: 10.1016/j.phrs.2022.106359 – volume: 23 start-page: 101822 year: 2020 ident: 1468_CR380 publication-title: iScience doi: 10.1016/j.isci.2020.101822 – volume: 13 year: 2022 ident: 1468_CR65 publication-title: Nat. Commun. doi: 10.1038/s41467-022-33909-2 – volume: 187 start-page: 338 year: 2022 ident: 1468_CR484 publication-title: Br. J. Dermatol. doi: 10.1111/bjd.21630 – volume: 10 start-page: 1742 year: 2020 ident: 1468_CR559 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-20-0026 – volume: 9 start-page: 2504 year: 2018 ident: 1468_CR130 publication-title: Front. Immunol. doi: 10.3389/fimmu.2018.02504 – volume: 84 start-page: 431 year: 1996 ident: 1468_CR5 publication-title: Cell doi: 10.1016/S0092-8674(00)81288-X – volume: 33 start-page: 122 year: 2008 ident: 1468_CR21 publication-title: Trends Biochem. Sci. doi: 10.1016/j.tibs.2007.12.002 – volume: 33 start-page: 4039 year: 2015 ident: 1468_CR414 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2015.61.4578 – volume: 97 start-page: 1507 year: 2022 ident: 1468_CR544 publication-title: Am. J. Hematol. doi: 10.1002/ajh.26712 – volume: 14 start-page: 1166 year: 1995 ident: 1468_CR365 publication-title: EMBO J. doi: 10.1002/j.1460-2075.1995.tb07100.x – volume: 22 start-page: 871 year: 2020 ident: 1468_CR337 publication-title: Mol. Ther. Nucleic Acids doi: 10.1016/j.omtn.2020.10.008 – volume: 88 start-page: 40 year: 2023 ident: 1468_CR537 publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2022.08.061 – volume: 80 start-page: 848 year: 2021 ident: 1468_CR179 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2020-219214 – volume: 13 start-page: 105 year: 1997 ident: 1468_CR3 publication-title: Trends Genet. doi: 10.1016/S0168-9525(97)01006-8 – volume: 39 start-page: 259 year: 2020 ident: 1468_CR307 publication-title: J. Exp. Clin. Cancer Res. doi: 10.1186/s13046-020-01769-7 – volume: 182 start-page: 106357 year: 2022 ident: 1468_CR398 publication-title: Pharm. Res. doi: 10.1016/j.phrs.2022.106357 – volume: 20 start-page: 1408 year: 2022 ident: 1468_CR429 publication-title: Clin. Gastroenterol. Hepatol. doi: 10.1016/j.cgh.2021.07.040 – volume: 79 start-page: 1321 year: 2019 ident: 1468_CR460 publication-title: Drugs doi: 10.1007/s40265-019-01169-y – volume: 97 start-page: E433 year: 2022 ident: 1468_CR221 publication-title: Am. J. Hematol. doi: 10.1002/ajh.26714 – volume: 158 start-page: 2139 year: 2020 ident: 1468_CR270 publication-title: Gastroenterology doi: 10.1053/j.gastro.2020.02.030 – volume: 74 start-page: 1648 year: 2022 ident: 1468_CR471 publication-title: Arthritis Rheumatol. doi: 10.1002/art.42250 – ident: 1468_CR280 – volume: 81 start-page: 2149 year: 2021 ident: 1468_CR283 publication-title: Drugs doi: 10.1007/s40265-021-01638-3 – volume: 2022 start-page: 7838583 year: 2022 ident: 1468_CR40 publication-title: Oxid. Med Cell Longev. doi: 10.1155/2022/7838583 – volume: 338 start-page: 28 year: 2010 ident: 1468_CR163 publication-title: Dev. Biol. doi: 10.1016/j.ydbio.2009.10.045 – volume: 202 start-page: 139 year: 2004 ident: 1468_CR143 publication-title: Immunol. Rev. doi: 10.1111/j.0105-2896.2004.00211.x – volume: 49 start-page: 19 year: 1996 ident: 1468_CR47 publication-title: Kidney Int. doi: 10.1038/ki.1996.3 – volume: 291 start-page: 279 year: 2016 ident: 1468_CR127 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M115.691170 – volume: 63 start-page: 192 year: 2023 ident: 1468_CR395 publication-title: Crit. Rev. Food Sci. Nutr. doi: 10.1080/10408398.2021.1945531 – volume: 3 start-page: e270 year: 2006 ident: 1468_CR231 publication-title: PLoS Med. doi: 10.1371/journal.pmed.0030270 – volume: 81 start-page: e20 year: 2022 ident: 1468_CR430 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2020-216983 – volume: 384 start-page: 795 year: 2021 ident: 1468_CR486 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2031994 – volume: 13 start-page: 932240 year: 2022 ident: 1468_CR34 publication-title: Front. Immunol. doi: 10.3389/fimmu.2022.932240 – volume: 182 start-page: 106347 year: 2022 ident: 1468_CR550 publication-title: Pharm. Res. doi: 10.1016/j.phrs.2022.106347 – volume: 23 start-page: 3418 year: 2008 ident: 1468_CR347 publication-title: Nephrol. Dial. Transpl. doi: 10.1093/ndt/gfn314 – volume: 15 start-page: 1135 year: 2021 ident: 1468_CR531 publication-title: Drug Des. Devel. Ther. doi: 10.2147/DDDT.S240866 – volume: 80 start-page: 432 year: 2021 ident: 1468_CR276 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2020-218412 – ident: 1468_CR104 doi: 10.1111/imm.13614 – volume: 188 start-page: 106630 year: 2023 ident: 1468_CR397 publication-title: Pharm. Res. doi: 10.1016/j.phrs.2022.106630 – volume: 8 start-page: 615 year: 1998 ident: 1468_CR362 publication-title: Immunity doi: 10.1016/S1074-7613(00)80566-X – ident: 1468_CR97 doi: 10.1172/JCI125986 – volume: 13 start-page: 277 year: 2019 ident: 1468_CR305 publication-title: Hepatol. Int. doi: 10.1007/s12072-019-09944-5 – volume: 19 start-page: 1130 year: 2022 ident: 1468_CR66 publication-title: Cell Mol. Immunol. doi: 10.1038/s41423-022-00904-y – volume: 123 start-page: 1833 year: 2014 ident: 1468_CR439 publication-title: Blood doi: 10.1182/blood-2013-12-544411 – volume: 65 start-page: 8380 year: 2022 ident: 1468_CR70 publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.2c00283 – volume: 367 start-page: 616 year: 2012 ident: 1468_CR447 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1112168 – volume: 1 start-page: 643 year: 2015 ident: 1468_CR508 publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2015.1590 – volume: 163 start-page: 1555 year: 2022 ident: 1468_CR539 publication-title: Gastroenterology doi: 10.1053/j.gastro.2022.08.007 – volume: 4 start-page: eaat3834 year: 2018 ident: 1468_CR435 publication-title: Sci. Adv. doi: 10.1126/sciadv.aat3834 – volume: 130 start-page: 1863 year: 2020 ident: 1468_CR149 publication-title: J. Clin. Invest. doi: 10.1172/JCI126567 – volume: 109 start-page: S121 year: 2002 ident: 1468_CR16 publication-title: Cell doi: 10.1016/S0092-8674(02)00701-8 – volume: 4 start-page: 437 year: 2013 ident: 1468_CR142 publication-title: Cell Rep. doi: 10.1016/j.celrep.2013.07.012 – volume: 234 start-page: 21126 year: 2019 ident: 1468_CR401 publication-title: J. Cell Physiol. doi: 10.1002/jcp.28715 – volume: 32 start-page: 854 year: 2022 ident: 1468_CR156 publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2022.03.007 – volume: 17 start-page: 1541 year: 2019 ident: 1468_CR453 publication-title: Clin. Gastroenterol. Hepatol. doi: 10.1016/j.cgh.2018.11.035 – volume: 77 start-page: 5701 year: 2017 ident: 1468_CR129 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-1510 – volume: 13 year: 2022 ident: 1468_CR71 publication-title: Nat. Commun. doi: 10.1038/s41467-022-32927-4 – volume: 42 start-page: 629 year: 2022 ident: 1468_CR344 publication-title: Med. Res. Rev. doi: 10.1002/med.21850 – volume: 23 start-page: 5537 year: 2017 ident: 1468_CR386 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-2253 – volume: 36 start-page: 542 year: 2012 ident: 1468_CR134 publication-title: Immunity doi: 10.1016/j.immuni.2012.03.014 – volume: 277 start-page: 1630 year: 1997 ident: 1468_CR11 publication-title: Science doi: 10.1126/science.277.5332.1630 – volume: 78 start-page: 1305 year: 2019 ident: 1468_CR186 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2019-215164 – volume: 14 start-page: S711 year: 2020 ident: 1468_CR354 publication-title: J. Crohns Colitis doi: 10.1093/ecco-jcc/jjaa109 – volume: 12 start-page: 31 year: 2022 ident: 1468_CR168 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-21-1059 – volume: 44 start-page: 310 year: 2013 ident: 1468_CR22 publication-title: Hum. Pathol. doi: 10.1016/j.humpath.2012.06.001 – volume: 9 year: 2018 ident: 1468_CR118 publication-title: Nat. Commun. doi: 10.1038/s41467-018-04013-1 – volume: 182 start-page: 1103 year: 2020 ident: 1468_CR500 publication-title: Br. J. Dermatol. doi: 10.1111/bjd.18469 – volume: 135 start-page: 1739 year: 2020 ident: 1468_CR437 publication-title: Blood doi: 10.1182/blood.2020004823 – volume: 25 start-page: 5901 year: 2019 ident: 1468_CR227 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-4089 – volume: 22 start-page: 693 year: 2021 ident: 1468_CR533 publication-title: Am. J. Clin. Dermatol. doi: 10.1007/s40257-021-00618-3 – volume: 12 start-page: 25 year: 2016 ident: 1468_CR137 publication-title: Nat. Rev. Rheumatol. doi: 10.1038/nrrheum.2015.167 – volume: 81 start-page: 1358 year: 2022 ident: 1468_CR195 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2022-222586 – volume: 10 start-page: 55 year: 2017 ident: 1468_CR441 publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-017-0417-z – volume: 89 start-page: 12 year: 2017 ident: 1468_CR24 publication-title: Cytokine doi: 10.1016/j.cyto.2015.11.011 – volume: 64 start-page: 621 year: 1995 ident: 1468_CR79 publication-title: Annu. Rev. Biochem. doi: 10.1146/annurev.bi.64.070195.003201 – ident: 1468_CR41 doi: 10.1016/j.blre.2022.100992 – volume: 12 start-page: 651415 year: 2021 ident: 1468_CR564 publication-title: Front. Pharm. doi: 10.3389/fphar.2021.651415 – volume: 24 start-page: 5948 year: 2018 ident: 1468_CR394 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-1277 – volume: 4 start-page: 406 year: 2021 ident: 1468_CR55 publication-title: Commun. Biol. doi: 10.1038/s42003-021-01846-3 – volume: 75 start-page: 1979 year: 2016 ident: 1468_CR517 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2015-208901 – volume: 28 start-page: 4 year: 2001 ident: 1468_CR124 publication-title: Nat. Genet. doi: 10.1038/ng0501-4 – volume: 7 start-page: 1347 year: 1992 ident: 1468_CR7 publication-title: Oncogene – volume: 11 start-page: 6333 year: 2005 ident: 1468_CR310 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-05-0148 – volume: 175 start-page: 902 year: 2016 ident: 1468_CR459 publication-title: Br. J. Dermatol. doi: 10.1111/bjd.14871 – volume: 29 start-page: 1069 year: 2010 ident: 1468_CR59 publication-title: EMBO J. doi: 10.1038/emboj.2010.4 – volume: 28 start-page: 1472 year: 2014 ident: 1468_CR230 publication-title: Leukemia doi: 10.1038/leu.2014.3 – volume: 3 start-page: 1071 year: 2022 ident: 1468_CR166 publication-title: Nat. Cancer doi: 10.1038/s43018-022-00431-9 – volume: 70 start-page: 338 year: 2014 ident: 1468_CR245 publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2013.10.010 – volume: 42 start-page: 35 year: 2022 ident: 1468_CR463 publication-title: Inflamm. Regen. doi: 10.1186/s41232-022-00221-x – volume: 9 year: 2019 ident: 1468_CR346 publication-title: Sci. Rep. doi: 10.1038/s41598-019-41106-3 – volume: 80 start-page: 609 year: 2020 ident: 1468_CR498 publication-title: Drugs doi: 10.1007/s40265-020-01291-2 – volume: 198 start-page: 317 year: 2022 ident: 1468_CR511 publication-title: Br. J. Haematol. doi: 10.1111/bjh.18207 – volume: 5 start-page: e73 year: 2018 ident: 1468_CR209 publication-title: Lancet Haematol. doi: 10.1016/S2352-3026(17)30237-5 – volume: 428 start-page: 117 year: 2018 ident: 1468_CR375 publication-title: Cancer Lett. doi: 10.1016/j.canlet.2018.04.008 – volume: 17 start-page: 360 year: 2020 ident: 1468_CR161 publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-020-0340-z – volume: 369 start-page: 2391 year: 2013 ident: 1468_CR232 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1312542 – volume: 21 start-page: 1754 year: 2002 ident: 1468_CR15 publication-title: EMBO J. doi: 10.1093/emboj/21.7.1754 – volume: 111 start-page: 784 year: 2016 ident: 1468_CR45 publication-title: Pharm. Res. doi: 10.1016/j.phrs.2016.07.038 – volume: 71 start-page: 40 year: 2022 ident: 1468_CR251 publication-title: Allergol. Int. doi: 10.1016/j.alit.2021.10.004 – volume: 91 start-page: 575 year: 2017 ident: 1468_CR345 publication-title: Kidney Int doi: 10.1016/j.kint.2016.10.039 – volume: 86 start-page: 104 year: 2022 ident: 1468_CR285 publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2021.05.075 – volume: 81 start-page: 798 year: 2022 ident: 1468_CR455 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2021-221915 – ident: 1468_CR249 doi: 10.3390/ijms24010781 – volume: 81 start-page: 1504 year: 2022 ident: 1468_CR99 publication-title: Ann. Rheum. Dis. doi: 10.1136/ard-2022-222605 – volume: 97 start-page: 1510 year: 2022 ident: 1468_CR546 publication-title: Am. J. Hematol. doi: 10.1002/ajh.26709 – volume: 7 year: 2017 ident: 1468_CR370 publication-title: Sci. Rep. doi: 10.1038/s41598-017-17600-x – volume: 399 start-page: 2113 year: 2022 ident: 1468_CR525 publication-title: Lancet doi: 10.1016/S0140-6736(22)00581-5 – volume: 20 year: 2020 ident: 1468_CR304 publication-title: BMC Cancer doi: 10.1186/s12885-020-07285-3 – ident: 1468_CR23 doi: 10.3390/cancers11122002 – volume: 69 start-page: 4184 year: 2009 ident: 1468_CR329 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-08-2989 – volume: 20 start-page: 1821 year: 2022 ident: 1468_CR451 publication-title: Clin. Gastroenterol. Hepatol. doi: 10.1016/j.cgh.2020.10.038 – volume: 9 start-page: e14 year: 2022 ident: 1468_CR519 publication-title: Lancet Haematol. doi: 10.1016/S2352-3026(21)00367-7 – volume: 127 start-page: 2391 year: 2016 ident: 1468_CR228 publication-title: Blood doi: 10.1182/blood-2016-03-643544 – volume: 31 start-page: 393 year: 2017 ident: 1468_CR35 publication-title: Leukemia doi: 10.1038/leu.2016.215 – volume: 40 start-page: 298 year: 2019 ident: 1468_CR117 publication-title: Trends Pharm. Sci. doi: 10.1016/j.tips.2019.03.001 – volume: 387 start-page: 917 year: 1997 ident: 1468_CR121 publication-title: Nature doi: 10.1038/43206 – volume: 23 start-page: 15646 year: 2022 ident: 1468_CR473 publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms232415646 – volume: 12 year: 2022 ident: 1468_CR474 publication-title: Sci. Rep. doi: 10.1038/s41598-022-10777-w – volume: 28 start-page: 15 year: 2015 ident: 1468_CR208 publication-title: Cancer Cell doi: 10.1016/j.ccell.2015.06.006 – volume: 150 start-page: 931 year: 2022 ident: 1468_CR100 publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2022.04.011 – volume: 33 start-page: 29 year: 2018 ident: 1468_CR558 publication-title: Cancer Cell doi: 10.1016/j.ccell.2017.11.009 – volume: 110 start-page: 102400 year: 2020 ident: 1468_CR172 publication-title: J. Autoimmun. doi: 10.1016/j.jaut.2019.102400 – volume: 25 start-page: 745 year: 2006 ident: 1468_CR9 publication-title: Immunity doi: 10.1016/j.immuni.2006.09.009 – volume: 30 start-page: 963689721103377 year: 2021 ident: 1468_CR541 publication-title: Cell Transpl. doi: 10.1177/09636897211033778 – volume: 43 start-page: 75 year: 2023 ident: 1468_CR315 publication-title: Cancer Commun. (Lond.) doi: 10.1002/cac2.12393 – volume: 367 start-page: 508 year: 2012 ident: 1468_CR202 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1112072 – volume: 9 start-page: 1407 year: 2021 ident: 1468_CR490 publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(21)00331-3 – volume: 75 start-page: 572 year: 2021 ident: 1468_CR145 publication-title: J. Hepatol. doi: 10.1016/j.jhep.2021.04.055 – volume: 76 start-page: 528 year: 2005 ident: 1468_CR150 publication-title: Am. J. Hum. Genet. doi: 10.1086/428480 – volume: 147 start-page: 2202 year: 2021 ident: 1468_CR253 publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2020.11.041 – volume: 111 start-page: 3508 year: 2014 ident: 1468_CR52 publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1301138111 – volume: 10 start-page: 212 year: 2019 ident: 1468_CR555 publication-title: Front. Pharm. doi: 10.3389/fphar.2019.00212 – volume: 74 start-page: 95 year: 2022 ident: 1468_CR442 publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciab212 – volume: 78 start-page: 1320 year: 2019 ident: 1468_CR185 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2019-215163 – volume: 25 start-page: 101076 year: 2019 ident: 1468_CR381 publication-title: Redox Biol. doi: 10.1016/j.redox.2018.101076 – volume: 80 start-page: 312 year: 2021 ident: 1468_CR272 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2020-218870 – volume: 87 start-page: 351 year: 2022 ident: 1468_CR530 publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2022.04.009 – volume: 21 year: 2022 ident: 1468_CR327 publication-title: Mol. Cancer doi: 10.1186/s12943-022-01679-6 – volume: 13 start-page: 1068260 year: 2022 ident: 1468_CR248 publication-title: Front. Immunol. doi: 10.3389/fimmu.2022.1068260 – volume: 6 start-page: eaay3245 year: 2020 ident: 1468_CR95 publication-title: Sci. Adv. doi: 10.1126/sciadv.aay3245 – volume: 396 start-page: 255 year: 2020 ident: 1468_CR287 publication-title: Lancet doi: 10.1016/S0140-6736(20)30732-7 – volume: 20 year: 2021 ident: 1468_CR306 publication-title: Mol. Cancer doi: 10.1186/s12943-021-01377-9 – volume: 82 start-page: 1671 year: 2022 ident: 1468_CR535 publication-title: Drugs doi: 10.1007/s40265-022-01796-y – volume: 78 start-page: 1454 year: 2019 ident: 1468_CR262 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2019-215764 – volume: 157 start-page: 1165 year: 2021 ident: 1468_CR529 publication-title: JAMA Dermatol. doi: 10.1001/jamadermatol.2021.2830 – volume: 309 start-page: 120996 year: 2022 ident: 1468_CR328 publication-title: Life Sci. doi: 10.1016/j.lfs.2022.120996 – volume: 80 start-page: 1004 year: 2021 ident: 1468_CR456 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2020-219601 – volume: 68 start-page: 1249 year: 2013 ident: 1468_CR152 publication-title: Allergy doi: 10.1111/all.12220 – volume: 9 start-page: 510 year: 2010 ident: 1468_CR358 publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-09-0461 – volume: 8 start-page: eabo4363 year: 2022 ident: 1468_CR199 publication-title: Sci. Adv. doi: 10.1126/sciadv.abo4363 – volume: 131 start-page: 1838 year: 2011 ident: 1468_CR563 publication-title: J. Invest. Dermatol. doi: 10.1038/jid.2011.140 – volume: 8 start-page: 582 year: 1998 ident: 1468_CR105 publication-title: Curr. Opin. Genet. Dev. doi: 10.1016/S0959-437X(98)80015-4 – volume: 69 start-page: 1949 year: 2017 ident: 1468_CR197 publication-title: Arthritis Rheumatol. doi: 10.1002/art.40186 – volume: 40 start-page: 65 year: 2020 ident: 1468_CR497 publication-title: Clin. Drug Investig. doi: 10.1007/s40261-019-00863-9 – volume: 187 start-page: 42 year: 2022 ident: 1468_CR499 publication-title: Br. J. Dermatol. doi: 10.1111/bjd.21037 – volume: 381 start-page: 451 year: 2013 ident: 1468_CR30 publication-title: Lancet doi: 10.1016/S0140-6736(12)61424-X – volume: 369 start-page: 2379 year: 2013 ident: 1468_CR233 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1311347 – volume: 101 start-page: 1743 year: 2004 ident: 1468_CR302 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0308340100 – volume: 335 start-page: 145 year: 2013 ident: 1468_CR379 publication-title: Cancer Lett. doi: 10.1016/j.canlet.2013.02.010 – volume: 34 start-page: 487 year: 2022 ident: 1468_CR404 publication-title: Cell Metab. doi: 10.1016/j.cmet.2022.02.002 – volume: 183 start-page: 106362 year: 2022 ident: 1468_CR69 publication-title: Pharm. Res. doi: 10.1016/j.phrs.2022.106362 – volume: 113 start-page: 365 year: 2015 ident: 1468_CR125 publication-title: Br. J. Cancer doi: 10.1038/bjc.2015.233 – volume: 35 start-page: 3844 year: 2017 ident: 1468_CR206 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2017.73.4418 – volume: 145 start-page: 877 year: 2020 ident: 1468_CR268 publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2019.11.025 – volume: 179 start-page: 54 year: 2018 ident: 1468_CR289 publication-title: Br. J. Dermatol. doi: 10.1111/bjd.16004 – volume: 386 start-page: 316 year: 2022 ident: 1468_CR448 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2109927 – volume: 13 year: 2022 ident: 1468_CR72 publication-title: Nat. Commun. doi: 10.1038/s41467-022-32928-3 – volume: 370 start-page: 2377 year: 2014 ident: 1468_CR205 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1310476 – volume: 66 start-page: 1049 year: 2017 ident: 1468_CR467 publication-title: Gut doi: 10.1136/gutjnl-2016-312735 – volume: 189 start-page: 106703 year: 2023 ident: 1468_CR405 publication-title: Pharm. Res. doi: 10.1016/j.phrs.2023.106703 – volume: 393 start-page: 2303 year: 2019 ident: 1468_CR523 publication-title: Lancet doi: 10.1016/S0140-6736(19)30419-2 – volume: 152 start-page: 873 year: 2016 ident: 1468_CR244 publication-title: JAMA Dermatol. doi: 10.1001/jamadermatol.2016.1978 – volume: 230 start-page: 107969 year: 2022 ident: 1468_CR114 publication-title: Pharm. Ther. doi: 10.1016/j.pharmthera.2021.107969 – volume: 72 start-page: 1607 year: 2020 ident: 1468_CR265 publication-title: Arthritis Rheumatol. doi: 10.1002/art.41384 – volume: 69 start-page: 709 year: 2017 ident: 1468_CR192 publication-title: Arthritis Rheumatol. doi: 10.1002/art.39955 – volume: 86 start-page: 84 year: 2022 ident: 1468_CR318 publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2022.08.003 – volume: 15 start-page: 7 year: 2022 ident: 1468_CR220 publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-021-01157-4 – volume: 60 start-page: 1895 year: 2009 ident: 1468_CR450 publication-title: Arthritis Rheum. doi: 10.1002/art.24567 – volume: 395 start-page: e30 year: 2020 ident: 1468_CR492 publication-title: Lancet doi: 10.1016/S0140-6736(20)30304-4 – volume: 15 start-page: 1 year: 2005 ident: 1468_CR39 publication-title: Cell Res. doi: 10.1038/sj.cr.7290255 – volume: 78 start-page: 890 year: 2019 ident: 1468_CR477 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2018-214529 – volume: 361 start-page: 1872 year: 2009 ident: 1468_CR210 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra0902908 – volume: 398 start-page: 803 year: 2021 ident: 1468_CR408 publication-title: Lancet doi: 10.1016/S0140-6736(21)00438-4 – volume: 14 start-page: 736 year: 2014 ident: 1468_CR321 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3818 – volume: 7 start-page: 128 year: 2017 ident: 1468_CR155 publication-title: Cancer Disco. doi: 10.1158/2159-8290.CD-16-1439 – volume: 159 start-page: 253 year: 2013 ident: 1468_CR203 publication-title: Ann. Intern. Med. doi: 10.7326/0003-4819-159-4-201308200-00006 – volume: 150 start-page: 955 year: 2022 ident: 1468_CR111 publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2022.01.026 – volume: 396 start-page: 215 year: 2020 ident: 1468_CR286 publication-title: Lancet doi: 10.1016/S0140-6736(20)31284-8 – volume: 30 start-page: 1701 year: 2016 ident: 1468_CR426 publication-title: Leukemia doi: 10.1038/leu.2016.148 – volume: 380 start-page: 1450 year: 2019 ident: 1468_CR290 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra1713263 – volume: 14 start-page: 854 year: 1995 ident: 1468_CR366 publication-title: EMBO J. doi: 10.1002/j.1460-2075.1995.tb07064.x – volume: 55 start-page: 1047 year: 2012 ident: 1468_CR369 publication-title: J. Med Chem. doi: 10.1021/jm200720n – volume: 7 start-page: 41 year: 2007 ident: 1468_CR372 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri1995 – volume: 154 start-page: 113618 year: 2022 ident: 1468_CR403 publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2022.113618 – volume: 204 start-page: 2383 year: 2007 ident: 1468_CR355 publication-title: J. Exp. Med. doi: 10.1084/jem.20070401 – volume: 266 start-page: 1045 year: 1994 ident: 1468_CR48 publication-title: Science doi: 10.1126/science.7973659 – volume: 82 start-page: 4624 year: 2022 ident: 1468_CR110 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-22-0736 – volume: 7 start-page: 245 year: 2019 ident: 1468_CR391 publication-title: J. Immunother. Cancer doi: 10.1186/s40425-019-0733-7 – volume: 6 start-page: 402 year: 2021 ident: 1468_CR76 publication-title: Signal Transduct. Target Ther. doi: 10.1038/s41392-021-00791-1 – volume: 141 start-page: 481 year: 2023 ident: 1468_CR518 publication-title: Blood doi: 10.1182/blood.2022017442 – volume: 11 start-page: 613 year: 2002 ident: 1468_CR101 publication-title: Hum. Mol. Genet. doi: 10.1093/hmg/11.6.613 – volume: 270 start-page: 3327 year: 1995 ident: 1468_CR86 publication-title: J. Biol. Chem. doi: 10.1074/jbc.270.7.3327 – volume: 35 start-page: 1365 year: 2021 ident: 1468_CR154 publication-title: Leukemia doi: 10.1038/s41375-021-01231-3 – volume: 76 start-page: 998 year: 2017 ident: 1468_CR196 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2016-210104 – volume: 78 start-page: 54 year: 2018 ident: 1468_CR243 publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2017.08.002 – volume: 61 start-page: e202205231 year: 2022 ident: 1468_CR549 publication-title: Angew. Chem. Int. Ed. Engl. doi: 10.1002/anie.202205231 – volume: 22 start-page: 877 year: 2021 ident: 1468_CR542 publication-title: Am. J. Clin. Dermatol. doi: 10.1007/s40257-021-00627-2 – volume: 68 start-page: 46 year: 2016 ident: 1468_CR516 publication-title: Arthritis Rheumatol. doi: 10.1002/art.39473 – volume: 376 start-page: 1094 year: 2010 ident: 1468_CR171 publication-title: Lancet doi: 10.1016/S0140-6736(10)60826-4 – volume: 31 start-page: 100 year: 2020 ident: 1468_CR553 publication-title: Mediterr. J. Rheumatol. doi: 10.31138/mjr.31.1.100 – volume: 147 start-page: 75 year: 2017 ident: 1468_CR300 publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2017.10.003 – volume: 116 start-page: 12442 year: 2019 ident: 1468_CR333 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1816410116 – volume: 442 start-page: 130083 year: 2023 ident: 1468_CR96 publication-title: J. Hazard Mater. doi: 10.1016/j.jhazmat.2022.130083 – volume: 60 start-page: 887 year: 2020 ident: 1468_CR400 publication-title: Crit. Rev. Food Sci. Nutr. doi: 10.1080/10408398.2018.1552244 – volume: 12 start-page: 1485 year: 2014 ident: 1468_CR458 publication-title: Clin. Gastroenterol. Hepatol. doi: 10.1016/j.cgh.2014.01.029 – volume: 11 start-page: 885 year: 2017 ident: 1468_CR410 publication-title: J. Crohns Colitis doi: 10.1093/ecco-jcc/jjx003 – volume: 74 start-page: 201 year: 2014 ident: 1468_CR312 publication-title: Prostate doi: 10.1002/pros.22741 – volume: 71 start-page: 1042 year: 2019 ident: 1468_CR495 publication-title: Arthritis Rheumatol. doi: 10.1002/art.40841 – volume: 52 start-page: 164 year: 2017 ident: 1468_CR146 publication-title: Clin. Rev. Allergy Immunol. doi: 10.1007/s12016-016-8550-y – volume: 364 start-page: 2496 year: 2011 ident: 1468_CR214 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1013343 – volume: 10 start-page: e3222 year: 2022 ident: 1468_CR532 publication-title: J. Allergy Clin. Immunol. Pract. doi: 10.1016/j.jaip.2022.08.042 – volume: 20 start-page: 591 year: 2022 ident: 1468_CR452 publication-title: Clin. Gastroenterol. Hepatol. doi: 10.1016/j.cgh.2021.02.043 – volume: 111 start-page: 8025 year: 2014 ident: 1468_CR60 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1401180111 – volume: 12 start-page: 175628481985320 year: 2019 ident: 1468_CR556 publication-title: Ther. Adv. Gastroenterol. doi: 10.1177/1756284819853208 – volume: 106 start-page: 219 year: 2013 ident: 1468_CR175 publication-title: QJM doi: 10.1093/qjmed/hcs205 – volume: 376 start-page: 1723 year: 2017 ident: 1468_CR446 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1606910 – volume: 156 start-page: 1333 year: 2020 ident: 1468_CR254 publication-title: JAMA Dermatol. doi: 10.1001/jamadermatol.2020.3260 – volume: 152 start-page: 104609 year: 2020 ident: 1468_CR418 publication-title: Pharm. Res. doi: 10.1016/j.phrs.2019.104609 – volume: 94 start-page: 795 year: 2018 ident: 1468_CR334 publication-title: Kidney Int. doi: 10.1016/j.kint.2018.05.022 – volume: 85 start-page: 847 year: 2021 ident: 1468_CR481 publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2021.05.050 – volume: 66 start-page: 1008 year: 2007 ident: 1468_CR189 publication-title: Ann. Rheum. Dis. doi: 10.1136/ard.2006.063412 – volume: 92 start-page: 909 year: 2017 ident: 1468_CR343 publication-title: Kidney Int. doi: 10.1016/j.kint.2017.03.027 – volume: 148 start-page: 51 year: 2010 ident: 1468_CR301 publication-title: Virus Res. doi: 10.1016/j.virusres.2009.12.003 – volume: 26 start-page: 88 year: 2014 ident: 1468_CR360 publication-title: Semin. Immunol. doi: 10.1016/j.smim.2014.01.009 – volume: 264 start-page: 1415 year: 1994 ident: 1468_CR136 publication-title: Science doi: 10.1126/science.8197455 – volume: 372 start-page: 426 year: 2015 ident: 1468_CR419 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1409002 – volume: 77 start-page: 1987 year: 2017 ident: 1468_CR444 publication-title: Drugs doi: 10.1007/s40265-017-0835-9 – volume: 85 start-page: 62 year: 2021 ident: 1468_CR482 publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2021.02.028 – volume: 19 start-page: 2020 year: 2021 ident: 1468_CR297 publication-title: Clin. Gastroenterol. Hepatol. doi: 10.1016/j.cgh.2021.05.045 – volume: 31 start-page: 934 year: 2017 ident: 1468_CR229 publication-title: Leukemia doi: 10.1038/leu.2016.280 – volume: 97 start-page: 439 year: 2005 ident: 1468_CR317 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/dji064 – volume: 20 start-page: 102750 year: 2021 ident: 1468_CR352 publication-title: Autoimmun. Rev. doi: 10.1016/j.autrev.2021.102750 – volume: 14 start-page: 161 year: 2020 ident: 1468_CR547 publication-title: Biosci. Trends doi: 10.5582/bst.2020.03106 – volume: 396 start-page: 345 year: 2020 ident: 1468_CR242 publication-title: Lancet doi: 10.1016/S0140-6736(20)31286-1 – volume: 3 start-page: 263 year: 2018 ident: 1468_CR378 publication-title: Lancet Gastroenterol. Hepatol. doi: 10.1016/S2468-1253(18)30009-8 – volume: 80 start-page: 1756 year: 2005 ident: 1468_CR348 publication-title: Transplantation doi: 10.1097/01.tp.0000184634.25042.ea |
| SSID | ssj0001637754 ssib046561479 ssib044760960 |
| Score | 2.6560473 |
| SecondaryResourceType | review_article |
| Snippet | The Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway is an evolutionarily conserved mechanism of transmembrane signal... Abstract The Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway is an evolutionarily conserved mechanism of transmembrane... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 204 |
| SubjectTerms | 631/250/580 692/53 Autoimmune diseases Autoimmune Diseases - drug therapy Autoimmune Diseases - genetics Cancer Research Cell Biology Clinical trials Cognition Cytokines - metabolism Drug development Growth factors Humans Immune response Immunosuppressive agents Internal Medicine Janus kinase Janus Kinase Inhibitors Janus Kinases - metabolism Kinases Malignancy Medicine Medicine & Public Health Neoplasms - drug therapy Neoplasms - genetics Neoplasms - metabolism Oncology Pathology Review Review Article Signal transduction Signal Transduction - genetics STAT Transcription Factors - genetics STAT Transcription Factors - metabolism |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYq1EMviJYC29LKlSouEBEnk9jpbVuBqlZCSCwSN8vxQ6wESbUPEP--M052y7YULhxySexoNA97xp75hrHPBiBUNkfPTRQSAxRvEwMhJADWxTZ2rjSx2YQ8OVEXF9XpvVZflBPWwQN3jDt0uIEYU7pQF_gTl9ahchKjKgiqrmVqafVNZXUvmIqnK2VO0G59lUyaq8MprtaUaJlR-hCVG8mVnSgC9j_kZf6bLPnXjWnciI432HrvQfJhR_lr9sI3b9jmsMHo-fqO7_GY0xkPyzfZ-RGuPnRkwPs0obbhbeDo9PEfw5_J2Wg44pTBYagonVN34ltz94Wb-awdU-GI565H55xy0zhuSUcmb9n58dHo2_ekb6SQ2DKVs6SorFAWXR3vDcjagsGorgQHToFA3sqQO-88oPOWeokBn8hsAF_gkzoIIt9ia03b-B3GJRghrbPgjMW5xiiPJl2XNivqWoAcMLFgqrY9yjg1u7jS8bY7V7oThEZB6CgIjXP2l3N-dRgbj47-SrJajiR87PgCtUb3WqOf0poB211IWvdGO9WZEoUifP58wD4tP6O50R2KaXw7j2NKSTU1SMd2pxhLSqjhD9WwDZhaUZkVUle_NOPLCOktCKYop58eLLTrD13_58W75-DFe_Yqi2ZRJKLaZWuzydx_YC_tzWw8nXyMdvUbX9knJQ priority: 102 providerName: Directory of Open Access Journals |
| Title | Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer |
| URI | https://link.springer.com/article/10.1038/s41392-023-01468-7 https://www.ncbi.nlm.nih.gov/pubmed/37208335 https://www.proquest.com/docview/2815862043 https://www.proquest.com/docview/2816762427 https://pubmed.ncbi.nlm.nih.gov/PMC10196327 https://doaj.org/article/d661aa6dfb5a4fd0bf9d78374f8bb70c |
| Volume | 8 |
| WOSCitedRecordID | wos000992776400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2059-3635 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001637754 issn: 2059-3635 databaseCode: DOA dateStart: 20160101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2059-3635 dateEnd: 99991231 omitProxy: false ssIdentifier: ssib044760960 issn: 2059-3635 databaseCode: M~E dateStart: 20160101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2059-3635 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001637754 issn: 2059-3635 databaseCode: M7P dateStart: 20210101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2059-3635 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001637754 issn: 2059-3635 databaseCode: 7X7 dateStart: 20210101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2059-3635 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001637754 issn: 2059-3635 databaseCode: BENPR dateStart: 20210101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2059-3635 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001637754 issn: 2059-3635 databaseCode: PIMPY dateStart: 20210101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZoy4ELr0JZKCsjIS4QNU6c2OGCtmgrHmIVwVZaTpHjB6wESdkHqBd-OzNeJ9Xy6IVDImVtR_bOeDIznvmGkMeKc1foFDQ3lgkwUKyOFHcu4lwbX8bO5MoXmxCTiZzNijI43JYhrLKTiV5Qm1ajj_wokSyTCJ6evjj7FmHVKDxdDSU0dsgeoiQkPnSv7PiJc5Gjht4_5wh7GU6lvA8mTxEADuvPxViyEAzFkFcTp_JoCfIdQzMTDDjCBCWx9e3yEP9_00v_DK_87YzVf7pObvzvom-S60FppaMNl90iV2xzm-yPGjDYv57TJ9SHkXr__D45HYPAQy8FDZFJbUNbR0HPpG9Gb6MP09GUYtCIwjx4igWRf6jz51StV-0cc1UsNQEQdElVY6hGtlzcIacn4-nLV1Go3RDpPBarKCs0kxq0K2sVF7XmCgzJnBtuJGcqN8KlxhrLQV-MrQAbkyXacZvBFRvuWHqX7DZtY-8RKrhiQhvNjdIwVilpQYrUuU6yugZ6DgjrqFLpAGyO9TW-VP6APZXVhpIVULLylKxgzNN-zNkG1uPS3sdI7L4nQnL7H9rFpyrs8MqApqNgZa7OgNtNXLvCCDD_uZN1LWI9IIcdjasgJ5bVBYEH5FHfDDscj21UY9u175MLTOOBeRxsOKufCdYYwrS5AZFbPLc11e2WZv7Zo4gzREZK8aXPOva8mNe__4v7ly_jAbmW-B2TRaw4JLurxdo-JFf199V8uRiSHTET_i6HZO94PCnfD70XZOg3Lt5_jqGlfP2u_PgLLddD5A |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxEB6VFAkuvMojUMBIwIWuug_v2kFCKECrhrRRJVKpnIzX9kIk2C15UOVP8RuZcXZThUdvPXDYQ3btlb35Zjxjz8wH8FRzXnRMgpZblAp0UJwJNC-KgHNjPY2dzbQnmxCDgTw-7hyuwc8mF4bCKhud6BW1rQztkW_HMkolFU9PXp98D4g1ik5XGwqNBSz6bn6KLtvkVe8d_r_P4nh3Z_h2L6hZBQKThWIapB0TSYPrvnOai9xwjS5Oxi23kkc6s6JIrLOOoyUTOoHeTxSbgrsUr9DyIkrwvZdgnRPYW7B-2Ds4_NggmHORkU-w_J1Roc36HMzv-mQJlZwjxruQSBLRNa0zecJEbk9wRaFg0JhCnCglSqyslp5U4G-W8J8Bnb-d6vrFcvf6__aZb8C12ixn3YUc3YQ1V96CjW6pp9W3OXvOfKCsP4HYgKMdVOm0D8Pq2KuqZFXB0JJm77v94MOwO2QUFqMp058R5fOpnr9kejatRpSN45itS55OmC4tMyR449twdCETvAOtsirdPWCC60gYa7jVBvtqLR3qyTwzcZrniJ82RA0KlKlLtxODyFflQwgSqRbIUYgc5ZGjsM-LZZ-TReGSc1u_IXAtW1LRcX-jGn9WtQ5TFm05jTMr8hTl2YZ50bFCJoIXMs9FaNqw2WBK1Zpwos4A1YYny8eow-hgSpeumvk2maBEJRzH3QWSlyMhFiVKDGyDXMH4ylBXn5SjL75OekS1nxJ66VYjDmfj-ve3uH_-NB7Dlb3hwb7a7w36D-Bq7KU1DaLOJrSm45l7CJfNj-loMn5UKwcGny5aUH4B-sObTg |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lj9MwELaWLkJceC2PwgJGAi5s1Dyc2EVCqLBbUQpVJbrScjKOH1AJkqVpWfWv8euYcZOuymNve-CQQxM7stNvxjP2zHyEPFaMua5OwHKLUg4OitWBYs4FjGnjaexMpjzZBB-NxNFRd7xFfja5MBhW2ehEr6hNqXGPvBOLKBVYPD3puDosYrzff3n8PUAGKTxpbeg0VhAZ2uUJuG_Vi8E-_NdP4rh_MHn9JqgZBgKdhXwepF0dCQ02gLWK8VwzBe5OxgwzgkUqM9wlxhrLwKoJLQdPKIq1YzaFKzTMRQm89wLZBpOcxS2yPR68H39s0MwYz9A_WP_OsOhmfSbmd4CyBMvPIftdiISJ4KbWWT1hIjoVrC4YGBpjuBOmR_GNldMTDPzNKv4zuPO3E16_cPav_s-f_Bq5UpvrtLeSr-tkyxY3yE6vUPPy25I-pT6A1p9M7JDDA1D1uD9D65issqClo2Bh07e9YfBh0ptQDJdRWAGAIhX0iVo-p2oxL6eYpWOpqUuhVlQVhmoUyNlNcnguE7xFWkVZ2DuEcqYiro1mRmnoq5SwoD_zTMdpngOW2iRqECF1XdIdmUW-Sh9akAi5QpEEFEmPIgl9nq37HK8KmpzZ-hUCbd0Si5H7G-Xss6x1mzRg4ymYmctTkHMT5q5ruEg4cyLPeajbZLfBl6w1ZCVPwdUmj9aPQbfhgZUqbLnwbTKOCUwwjtsrVK9HguxKmDDYJmID7xtD3XxSTL_4-ukR1oRK8KV7jWicjuvf3-Lu2dN4SC6BdMh3g9HwHrkce8FNg6i7S1rz2cLeJxf1j_m0mj2o9QQln85bTn4BuO2kDg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evolving+cognition+of+the+JAK-STAT+signaling+pathway%3A+autoimmune+disorders+and+cancer&rft.jtitle=Signal+transduction+and+targeted+therapy&rft.au=Xue%2C+Chen&rft.au=Yao%2C+Qinfan&rft.au=Gu%2C+Xinyu&rft.au=Shi%2C+Qingmiao&rft.date=2023-05-19&rft.issn=2059-3635&rft.eissn=2059-3635&rft.volume=8&rft.issue=1&rft_id=info:doi/10.1038%2Fs41392-023-01468-7&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41392_023_01468_7 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2059-3635&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2059-3635&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2059-3635&client=summon |